BioMedLib Search Engine
[ goto HOMEPAGE ]
Search the biomedical literature, for the most relevant articles.
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
benign neoplasm of the breast 2005:2010[pubdate] *count=100
722 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
benign neoplasm of the breast
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 722
1.
Gogo-Abite M, Seleye-Fubara D, Jamabo RS:
Fibroadenoma coexisting with infiltrating ductal carcinoma--a case report.
Niger J Med
; 2005 Apr-Jun;14(2):221-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Fibroadenomas are
benign breast
tumours
that are commonly diagnosed in young women in their 20's and early 30's.
Occurrence of malignancy in the
breasts
of these women is very rare.
METHOD AND RESULT: We report a case of an infiltrating ductal carcinoma within an otherwise
benign
fibroadenoma in a 23-year-old woman.
She presented with a lump, approximately 7cm in diameter, in her right
breast
.
CONCLUSION: Fibroadenomas are commonly diagnosed in patients in their 20's when the risk of developing
breast
cancer is extremely rare.
Despite this rarity all excised
breast
lumps should be subjected to histopathological evaluation in order to avoid a diagnostic pitfall.
[MeSH-major]
Breast
Neoplasms
/
diagnosis
. Carcinoma, Ductal,
Breast
/
diagnosis
. Fibroadenoma /
diagnosis
[MeSH-minor]
Adult.
Diagnosis
, Differential. Female. Humans
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16083250.001).
[ISSN]
1115-2613
[Journal-full-title]
Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
[ISO-abbreviation]
Niger J Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Nigeria
2.
Sisci D, Morelli C, Garofalo C, Romeo F, Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Andò S, Surmacz E:
Expression of nuclear insulin receptor substrate 1 in breast cancer.
J Clin Pathol
; 2007 Jun;60(6):633-41
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of nuclear insulin receptor substrate 1 in
breast
cancer.
BACKGROUND: Insulin receptor substrate 1 (IRS-1), a cytoplasmic protein transmitting signals from the insulin and insulin-like growth factor 1 receptors, has been implicated in
breast
cancer.
However, the expression of nuclear IRS-1 in
breast
cancer biopsy specimens has never been examined.
AIMS: To assess whether nuclear IRS-1 is present in
breast
cancer and non-cancer mammary epithelium, and whether it correlates with other markers, especially ERalpha.
RESULTS: Median nuclear IRS-1 expression was found to be low in normal mammary epithelial cells (1.6%) and high in
benign
tumours
(20.5%), ductal grade 2 carcinoma (11.0%) and lobular carcinoma (approximately 30%).
Median ERalpha expression in normal epithelium,
benign
tumours
, ductal cancer grade 2 and 3, and lobular cancer grade 2 and 3 were 10.5, 20.5, 65.0, 0.0, 80 and 15%, respectively.
Nuclear IRS-1 and ERalpha positively correlated in ductal cancer (p<0.001) and
benign
tumours
(p<0.01), but were not associated in lobular cancer and normal mammary epithelium.
In ductal carcinoma, both nuclear IRS-1 and ERalpha negatively correlated with
tumour
grade, size, mitotic index and lymph node involvement.
CONCLUSIONS: A positive association between nuclear IRS-1 and ERalpha is a characteristic for ductal
breast
cancer and marks a more differentiated, non-metastatic phenotype.
[MeSH-major]
Biomarkers,
Tumor
/ metabolism.
Breast
Neoplasms
/ metabolism. Cell Nucleus / metabolism. Phosphoproteins / metabolism
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Carcinoma, Ductal,
Breast
/ metabolism. Carcinoma, Ductal,
Breast
/ pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Cytoplasm / metabolism. Estrogen Receptor alpha / metabolism. Female. Humans. Immunoenzyme Techniques. Insulin Receptor Substrate Proteins. Mammary Glands, Human / metabolism. Microscopy, Confocal. Middle Aged.
Neoplasm
Invasiveness.
Neoplasm
Proteins / metabolism
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 2001 Mar 30;276(13):9817-24
[
11139588.001
]
[Cites]
J Cell Physiol. 2006 Jan;206(1):35-46
[
15965906.001
]
[Cites]
Cancer Res. 2001 Sep 15;61(18):6747-54
[
11559546.001
]
[Cites]
Endocr Relat Cancer. 2001 Sep;8(3):197-209
[
11566611.001
]
[Cites]
Biochem Biophys Res Commun. 2001 Nov 2;288(3):685-9
[
11676497.001
]
[Cites]
J Biol Chem. 2002 May 10;277(19):17231-8
[
11877394.001
]
[Cites]
J Biol Chem. 2002 Aug 30;277(35):32078-85
[
12063262.001
]
[Cites]
J Cell Physiol. 2003 Feb;194(2):108-16
[
12494449.001
]
[Cites]
Oncogene. 2003 Jun 26;22(26):4007-16
[
12821935.001
]
[Cites]
Oncogene. 2003 Sep 29;22(42):6589-97
[
14528284.001
]
[Cites]
Int J Cancer. 2003 Dec 20;107(6):873-7
[
14601044.001
]
[Cites]
Metabolism. 2003 Dec;52(12):1606-11
[
14669164.001
]
[Cites]
Horm Metab Res. 2003 Nov-Dec;35(11-12):794-801
[
14710360.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9272-6
[
15197263.001
]
[Cites]
Oncogene. 2004 Sep 30;23(45):7517-26
[
15318176.001
]
[Cites]
J Clin Invest. 1973 Jan;52(1):73-7
[
4345203.001
]
[Cites]
Monogr Pathol. 1984;(25):149-74
[
6377047.001
]
[Cites]
Bull Cancer. 1989;76(3):311-9
[
2544239.001
]
[Cites]
Clin Chem. 1993 Jun;39(6):1345-6
[
7684958.001
]
[Cites]
Cancer Res. 1993 Aug 15;53(16):3736-40
[
8339284.001
]
[Cites]
Eur J Cancer. 1994;30A(3):307-11
[
8204350.001
]
[Cites]
Cancer. 1994 Jul 1;74(1 Suppl):381-400
[
8004612.001
]
[Cites]
Trends Biochem Sci. 1994 Jul;19(7):289-93
[
8048169.001
]
[Cites]
J Cell Biochem. 2000 Jan;76(4):605-14
[
10653980.001
]
[Cites]
J Biol Chem. 2000 Apr 28;275(17):12565-71
[
10777546.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):95-105
[
10791772.001
]
[Cites]
Prev Vet Med. 2000 May 30;45(1-2):23-41
[
10802332.001
]
[Cites]
Heart. 2000 Jul;84(1):71-8
[
10862595.001
]
[Cites]
Int J Cancer. 2000 Nov 20;89(6):506-13
[
11102895.001
]
[Cites]
Oncogene. 2000 Nov 20;19(49):5574-81
[
11114737.001
]
[Cites]
Breast Cancer Res Treat. 1994;32(1):85-95
[
7529598.001
]
[Cites]
Science. 1995 Dec 1;270(5241):1491-4
[
7491495.001
]
[Cites]
Endocrinology. 1996 May;137(5):1735-44
[
8612509.001
]
[Cites]
EMBO J. 1996 Mar 15;15(6):1292-300
[
8635462.001
]
[Cites]
Ann N Y Acad Sci. 1996 Apr 30;784:189-201
[
8651569.001
]
[Cites]
Annu Rev Pharmacol Toxicol. 1996;36:615-58
[
8725404.001
]
[Cites]
Cancer Res. 1997 Jul 1;57(13):2606-10
[
9205064.001
]
[Cites]
Cancer Res. 1997 Aug 1;57(15):3079-83
[
9242428.001
]
[Cites]
Diabetologia. 1997 Jul;40 Suppl 2:S2-17
[
9248696.001
]
[Cites]
Int J Cancer. 1997 Sep 4;72(5):828-34
[
9311601.001
]
[Cites]
J Pathol. 1997 Dec;183(4):412-7
[
9496257.001
]
[Cites]
Breast Cancer Res Treat. 1998 Feb;47(3):295-302
[
9516083.001
]
[Cites]
Recent Prog Horm Res. 1998;53:119-38
[
9769706.001
]
[Cites]
Clin Cancer Res. 1995 Nov;1(11):1429-36
[
9815941.001
]
[Cites]
Clin Cancer Res. 1996 Dec;2(12):2037-42
[
9816164.001
]
[Cites]
Clin Cancer Res. 1997 Jan;3(1):103-9
[
9815544.001
]
[Cites]
Biochem Biophys Res Commun. 1998 Dec 18;253(2):315-9
[
9878535.001
]
[Cites]
Recent Results Cancer Res. 1998;152:63-70
[
9928547.001
]
[Cites]
Int J Cancer. 1999 Apr 12;81(2):299-304
[
10188734.001
]
[Cites]
Mol Endocrinol. 1999 May;13(5):787-96
[
10319328.001
]
[Cites]
J Exp Clin Cancer Res. 2004 Sep;23(3):385-94
[
15595626.001
]
[Cites]
J Clin Pathol. 2005 Jun;58(6):645-9
[
15917419.001
]
[Cites]
J Biol Chem. 2005 Aug 19;280(33):29912-20
[
15967802.001
]
[Cites]
Clin Cancer Res. 2001 Aug;7(8):2545-54
[
11489838.001
]
(PMID = 16882697.001).
[ISSN]
0021-9746
[Journal-full-title]
Journal of clinical pathology
[ISO-abbreviation]
J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Neoplasm Proteins; 0 / Phosphoproteins
[Other-IDs]
NLM/ PMC1955087
3.
Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N:
Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer.
BMC Mol Biol
; 2008;9:76
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of suitable endogenous control genes for microRNA gene expression analysis in human
breast
cancer.
While ECs have been validated for quantification of mRNA expression in various experimental settings, to date there is no report of the validation of miRNA ECs for expression profiling in
breast
tissue.
In this study, the expression of five miRNA genes (let-7a, miR-10b, miR-16, miR-21 and miR-26b) and three small nucleolar RNA genes (RNU19, RNU48 and Z30) was examined across malignant,
benign
and normal
breast
tissues to determine the most appropriate normalisation strategy.
This is the first study to identify reliable ECs for analysis of miRNA by RQ-PCR in human
breast
tissue.
[MeSH-major]
Breast
Neoplasms
/ genetics. Gene Expression Profiling / standards. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics
[MeSH-minor]
Female. Gene Silencing. Genes,
Neoplasm
. Humans. Polymerase Chain Reaction / standards. RNA, Small Nuclear / genetics. Reference Standards
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hum Mol Genet. 2005 Dec 15;14(24):3813-21
[
16239240.001
]
[Cites]
Nucleic Acids Res. 2005;33(20):e179
[
16314309.001
]
[Cites]
Nucleic Acids Res. 2006;34(2):e9
[
16434699.001
]
[Cites]
Nat Rev Cancer. 2006 Apr;6(4):259-69
[
16557279.001
]
[Cites]
Biochem Biophys Res Commun. 2006 Apr 28;343(1):85-9
[
16529715.001
]
[Cites]
J Urol. 2006 May;175(5):1915-20
[
16600798.001
]
[Cites]
Mol Cancer. 2006;5:24
[
16784538.001
]
[Cites]
Oncogene. 2006 Oct 9;25(46):6188-96
[
17028598.001
]
[Cites]
Cell. 2006 Nov 17;127(4):679-95
[
17110329.001
]
[Cites]
Mol Cell Biol. 2007 Mar;27(5):1859-67
[
17194750.001
]
[Cites]
Am J Obstet Gynecol. 2007 Mar;196(3):261.e1-6
[
17346547.001
]
[Cites]
Nat Protoc. 2006;1(3):1559-82
[
17406449.001
]
[Cites]
BMC Genomics. 2007;8:166
[
17565689.001
]
[Cites]
Biochem Biophys Res Commun. 2007 Nov 23;363(3):542-6
[
17889832.001
]
[Cites]
Nature. 2007 Oct 11;449(7163):682-8
[
17898713.001
]
[Cites]
Nature. 2008 Jan 10;451(7175):147-52
[
18185580.001
]
[Cites]
BMC Mol Biol. 2007;8:107
[
18042273.001
]
[Cites]
Nat Cell Biol. 2008 Feb;10(2):202-10
[
18193036.001
]
[Cites]
Breast Cancer Res. 2007;9(6):R76
[
17980029.001
]
[Cites]
Hepatology. 2008 Mar;47(3):897-907
[
18176954.001
]
[Cites]
RNA. 2008 May;14(5):844-52
[
18375788.001
]
[Cites]
J Biol Chem. 2000 May 5;275(18):13967-73
[
10788523.001
]
[Cites]
J Mol Endocrinol. 2000 Oct;25(2):169-93
[
11013345.001
]
[Cites]
J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81
[
11086195.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14311-6
[
11106375.001
]
[Cites]
EMBO Rep. 2001 Nov;2(11):986-91
[
11713189.001
]
[Cites]
Hum Mol Genet. 2001 Nov 1;10(23):2687-700
[
11726556.001
]
[Cites]
Nucleic Acids Res. 2002 Feb 15;30(4):894-902
[
11842100.001
]
[Cites]
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
[
12184808.001
]
[Cites]
Mol Cell Biol. 2002 Oct;22(19):6663-8
[
12215523.001
]
[Cites]
Anal Biochem. 2002 Oct 15;309(2):293-300
[
12413463.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
[
12434020.001
]
[Cites]
Cancer Lett. 2003 Mar 20;192(1):1-17
[
12637148.001
]
[Cites]
Nat Rev Cancer. 2003 Jun;3(6):453-8
[
12778135.001
]
[Cites]
Bioessays. 2003 Oct;25(10):930-9
[
14505360.001
]
[Cites]
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11
[
14681370.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
[
14973191.001
]
[Cites]
Genome Biol. 2004;5(3):R13
[
15003116.001
]
[Cites]
Cancer Res. 2004 Jun 1;64(11):3753-6
[
15172979.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4
[
15210942.001
]
[Cites]
Cancer Res. 2004 Aug 1;64(15):5245-50
[
15289330.001
]
[Cites]
J Biomol Tech. 2004 Sep;15(3):155-66
[
15331581.001
]
[Cites]
Genome Biol. 2004;5(9):R68
[
15345052.001
]
[Cites]
In Vitro Cell Dev Biol. 1987 Aug;23(8):585-90
[
3114226.001
]
[Cites]
Cancer Res. 1987 Nov 1;47(21):5616-9
[
3664468.001
]
[Cites]
Cell. 1993 Dec 3;75(5):843-54
[
8252621.001
]
[Cites]
Mol Cell Biol. 1996 Apr;16(4):1391-400
[
8657112.001
]
[Cites]
BMC Dev Biol. 2005;5:27
[
16324220.001
]
[Cites]
Cell. 1997 May 30;89(5):799-809
[
9182768.001
]
[Cites]
Nucleic Acids Res. 1998 Apr 1;26(7):1576-87
[
9512526.001
]
[Cites]
RNA. 1998 Apr;4(4):445-54
[
9630250.001
]
[Cites]
Mol Cell Biol. 1999 Oct;19(10):6906-17
[
10490628.001
]
[Cites]
Anal Biochem. 2004 Dec 1;335(1):1-9
[
15519565.001
]
[Cites]
Cell. 2005 Mar 11;120(5):635-47
[
15766527.001
]
[Cites]
Nature. 2005 Jun 9;435(7043):834-8
[
15944708.001
]
[Cites]
Nature. 2005 Jun 9;435(7043):839-43
[
15944709.001
]
[Cites]
Cancer Res. 2005 Jul 15;65(14):6029-33
[
16024602.001
]
[Cites]
Biotechniques. 2005 Jul;39(1):75-85
[
16060372.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
[
16166262.001
]
[Cites]
Clin Cancer Res. 2005 Oct 15;11(20):7376-83
[
16243810.001
]
[Cites]
RNA. 2005 Nov;11(11):1737-44
[
16244135.001
]
[Cites]
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4
[
16381832.001
]
(PMID = 18718003.001).
[ISSN]
1471-2199
[Journal-full-title]
BMC molecular biology
[ISO-abbreviation]
BMC Mol. Biol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / MicroRNAs; 0 / RNA, Small Nuclear
[Other-IDs]
NLM/ PMC2533012
Advertisement
4.
Buch A, Rout P, Makhija P:
Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump.
Indian J Pathol Microbiol
; 2006 Apr;49(2):259-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adenomyoepithelioma with phyllodes
tumor
--a rare combination in a solitary
breast
lump.
An unusual combination of two
benign breast
neoplasms
adenomyoepithelioma and phyllodes
tumor
presenting as a solitary
breast
lump have been described.
Both these
tumors
have tendencies to recur and have malignant potential.
This patient also presented with a recurrent
breast neoplasm
.
[MeSH-major]
Adenomyoma / pathology.
Breast
Neoplasms
/ pathology. Myoepithelioma / pathology.
Neoplasms
, Multiple Primary / pathology. Phyllodes
Tumor
/ pathology
[MeSH-minor]
Female. Humans. Middle Aged.
Neoplasm
Recurrence, Local / pathology
Genetic Alliance.
consumer health - Phyllodes Tumor
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Indian J Pathol Microbiol. 2006 Jul;49(3):476
(PMID = 16933731.001).
[ISSN]
0377-4929
[Journal-full-title]
Indian journal of pathology & microbiology
[ISO-abbreviation]
Indian J Pathol Microbiol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
India
5.
Giorgi Rossi P, Federici A, Farchi S, Chini F, Barca A, Guasticchi G, Borgia P:
The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy.
J Med Screen
; 2006;13(3):123-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The effect of screening programmes on the treatment
of benign breast
neoplasms
: observations from current practice in Italy.
In this study, we compare the incidences of treatments for
benign
and malignant
neoplasms
in the two groups.
We linked all incident cases of surgery for
benign
and malignant
breast
neoplasms
, from the Hospital Information System (1999-2003) to the Mammographic Screening Information System (1999-2001).
We calculated incidence, adjusted for age and standardized
breast
cancer mortality ratio in each area of residence, for
benign
and malignant
neoplasms
surgery in non-yet-contacted and contacted woman.
RESULTS: The target population in Lazio is 681,000; 116,000 women were contacted during the study period and 3252 malignant and 1566
benign
neoplasms
were surgically treated.
Annual incidence was, respectively, 2.0/1000 and 1.1/1000 for malignant and
benign
neoplasms
in women not contacted, and, respectively, 2.9/1000 and 1.1/1000 in the contacted population.
About one-half of the surgeries for
benign
neoplasms
in compliant women were treated against the recommendation of the screening programme.
CONCLUSIONS: The implementation of the screening programme did not increase the incidence of treatment for
benign
neoplasms
, and detected 50% more malignant
neoplasms
.
[MeSH-major]
Breast
Neoplasms
/ epidemiology. Mammography. Mass Screening. Patient Compliance / statistics & numerical data
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Mammography
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17007652.001).
[ISSN]
0969-1413
[Journal-full-title]
Journal of medical screening
[ISO-abbreviation]
J Med Screen
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
6.
Yang J, Hu A, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T:
NOEY2 mutations in primary breast cancers and breast hyperplasia.
Breast
; 2009 Jun;18(3):197-203
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
NOEY2 mutations in primary
breast
cancers and
breast
hyperplasia.
PURPOSE: The NOEY2 gene mutations and protein expression in human
breast
cancers, adjacent
breast
tissues and
breast benign
lesions were analysed to explore the potential correlation between the mutation spectrum and
breast
cancer development and progression.
EXPERIMENTAL DESIGN: The promoter, exon and intron regions of NOEY2 gene were amplified by polymerase chain reaction (PCR) with DNA extracted from 50 human
breast
cancer and corresponding adjacent
breast
tissues as well as 50
breast benign
lesions, respectively.
RESULTS: Twenty-one of 50 (42%)
breast
cancer mutations were identified in promoter (11 cases) and exon 2 (seven cases on untranslation region and three on coding region) and 17 of 50 (34%) adjacent
breast
tissues (all were atypical hyperplasia lesions) occurred mutations, including six promoter mutations and 11 exon 2 changes (10 cases on untranslation region and one on coding region).
Interestingly, the mutations were identified in both
breast
cancers and the corresponding adjacent
breast
tissues collected from the same patient in seven of them.
No mutation was identified in all
benign breast
tissues.
Immunohistochemical analysis showed that two of 17 mutational adjacent
breast
tissue samples were NOEY2 immunoreaction negative, and in all 21 mutations
of breast
cancers five cases were of loss of NOEY2 expression.
NOEY2 gene mutations were not correlated with patient ages, histological types,
tumour
sizes, histological grades, clinical stages, axillary lymph node metastases or with the condition of hormone receptor (ER, PR) expression and HER2 amplification.
CONCLUSIONS: The mutations of human NOEY2 were identified in human
breast
cancers and the corresponding adjacent
breast
tissues.
The presence of NOEY2 mutations in human
breast
cancer and early-stage lesions indicates that NOEY2 mutations may be partly associated with
breast
tumourigenesis.
[MeSH-major]
Breast
Neoplasms
/ genetics.
Breast
Neoplasms
/ pathology. rho GTP-Binding Proteins / metabolism
[MeSH-minor]
Adult. Aged. DNA Mutational Analysis / methods. Female. Gene Expression Regulation, Neoplastic. Humans. Hyperplasia / genetics. Hyperplasia / pathology. Immunohistochemistry. Middle Aged. Mutation.
Neoplasm
Invasiveness / genetics.
Neoplasm
Invasiveness / pathology. Polymerase Chain Reaction / methods
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19482475.001).
[ISSN]
1532-3080
[Journal-full-title]
Breast (Edinburgh, Scotland)
[ISO-abbreviation]
Breast
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / DIRAS3 protein, human; EC 3.6.5.2 / rho GTP-Binding Proteins
7.
Tafuri LS, Rocha GF, Gobbi H:
Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer.
BMC Cell Biol
; 2006;7:29
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cell cycle related proteins in hyperplasia of usual type in
breast
specimens of patients with and without
breast
cancer.
BACKGROUND: Hyperplasia of usual type (HUT) is a common proliferative lesion associated with a slight elevated risk for subsequent development
of breast
cancer.
The aim of this study was to analyze the expression of cell cycle related proteins in HUT
of breast
specimens of patients with and without
breast
cancer, and compare this expression with areas of invasive carcinomas.
RESULTS: Immunohistochemical evaluation was performed using antibodies against cell cycle related proteins ER, PR, p53, p21, p63, and Ki-67 in hyperplasia of usual type (HUT) in specimens of aesthetic reduction mammaplasty (ARM), in specimens of mammaplasty contralateral to
breast
cancer (MCC), and in specimens of invasive mammary carcinomas (IMC) presenting HUT in the adjacent parenchyma.
We also found cytoplasmic expression of p21 in
benign
hyperplastic lesions and in neoplastic cells of IMC.
CONCLUSION: Our data failed to demonstrate different expression of cell cycle related proteins in HUT from patients with and without
breast
cancer.
[MeSH-major]
Breast
Neoplasms
/ metabolism.
Breast
Neoplasms
/ pathology. Cell Cycle Proteins / physiology. Hyperplasia / metabolism
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans. Ki-67 Antigen / metabolism. Membrane Proteins / metabolism. Menopause / physiology. Middle Aged.
Neoplasm
Invasiveness / pathology. Proto-Oncogene Proteins p21(ras) / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism.
Tumor
Suppressor Protein p53 / metabolism
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
JAMA. 1992 Feb 19;267(7):941-4
[
1734106.001
]
[Cites]
Histopathology. 2005 Nov;47(5):458-66
[
16241993.001
]
[Cites]
Br J Cancer. 1993 Sep;68(3):540-8
[
8102535.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5545-9
[
7777546.001
]
[Cites]
J Clin Pathol. 1995 Jul;48(7):611-5
[
7560165.001
]
[Cites]
Eur J Cancer. 1995 Nov;31A(12):2049-52
[
8562164.001
]
[Cites]
Br J Cancer. 1996 Jul;74(2):208-15
[
8688323.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301
[
9149887.001
]
[Cites]
Am J Pathol. 1999 Dec;155(6):1811-5
[
10595909.001
]
[Cites]
Arch Pathol Lab Med. 2000 Jul;124(7):966-78
[
10888772.001
]
[Cites]
Pathol Res Pract. 2000;196(7):489-501
[
10926327.001
]
[Cites]
Breast Cancer Res Treat. 2000 May;61(1):33-43
[
10930088.001
]
[Cites]
Exp Cell Res. 2000 Nov 25;261(1):104-10
[
11082280.001
]
[Cites]
J Pathol. 2001 Mar;193(3):333-8
[
11241412.001
]
[Cites]
Am J Surg Pathol. 2001 Aug;25(8):1054-60
[
11474290.001
]
[Cites]
J Clin Pathol. 2001 Nov;54(11):866-70
[
11684722.001
]
[Cites]
Trends Genet. 2002 Feb;18(2):90-5
[
11818141.001
]
[Cites]
Clin Cancer Res. 2002 Feb;8(2):494-501
[
11839669.001
]
[Cites]
Adv Anat Pathol. 2002 May;9(3):185-97
[
11981114.001
]
[Cites]
Breast Cancer. 2002;9(3):216-9
[
12185332.001
]
[Cites]
Adv Anat Pathol. 2002 Sep;9(5):280-9
[
12195217.001
]
[Cites]
J Clin Pathol. 2003 Mar;56(3):214-20
[
12610102.001
]
[Cites]
Am J Surg Pathol. 2003 Jun;27(6):836-41
[
12766590.001
]
[Cites]
Breast Cancer Res. 2003;5(6):R242-9
[
14580260.001
]
[Cites]
Oncol Rep. 2004 Nov;12(5):1143-50
[
15492807.001
]
[Cites]
N Engl J Med. 1985 Jan 17;312(3):146-51
[
3965932.001
]
[Cites]
Cancer. 1990 Feb 1;65(3):518-29
[
2297643.001
]
[Cites]
Histopathology. 1991 Nov;19(5):403-10
[
1757079.001
]
[Cites]
Cancer Res. 1997 Nov 15;57(22):4987-91
[
9371488.001
]
[Cites]
J Natl Cancer Inst. 1998 Jan 7;90(1):37-42
[
9428781.001
]
[Cites]
Mod Pathol. 1998 Feb;11(2):155-68
[
9504686.001
]
[Cites]
J Pathol. 1998 Mar;184(3):265-71
[
9614378.001
]
[Cites]
Int J Cancer. 1998 Jun 10;76(6):891-6
[
9626358.001
]
[Cites]
Clin Cancer Res. 1996 Sep;2(9):1591-9
[
9816338.001
]
[Cites]
Hum Pathol. 1998 Dec;29(12):1539-45
[
9865845.001
]
[Cites]
EMBO J. 1999 Mar 1;18(5):1223-34
[
10064589.001
]
[Cites]
Int J Cancer. 2005 Feb 20;113(5):857-9
[
15499614.001
]
[Cites]
J Pathol. 2005 Jan;205(2):248-54
[
15641021.001
]
[Cites]
Clin Cancer Res. 2005 Jul 15;11(14):5175-80
[
16033833.001
]
[Cites]
N Engl J Med. 2005 Jul 21;353(3):229-37
[
16034008.001
]
[Cites]
Cancer Res. 1992 Dec 15;52(24):6949-52
[
1458485.001
]
(PMID = 16869981.001).
[ISSN]
1471-2121
[Journal-full-title]
BMC cell biology
[ISO-abbreviation]
BMC Cell Biol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / CKAP4 protein, human; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
[Other-IDs]
NLM/ PMC1563460
8.
Nadelman CM, Leslie KO, Fishbein MC:
"Benign," metastasizing adenomyoepithelioma of the breast: a report of 2 cases.
Arch Pathol Lab Med
; 2006 Sep;130(9):1349-53
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
"
Benign
," metastasizing adenomyoepithelioma of the
breast
: a report of 2 cases.
Adenomyoepitheliomas of the
breast
are rare
tumors
composed of a proliferation of 2 cell populations.
For the most part, they are considered to be
benign
, but they locally recur.
Those
neoplasms
that metastasize are deemed to have come from a histologically malignant primary
tumor
.
Herein, we describe 2 cases of metastases of histologically "
benign
" adenomyoepitheliomas of the
breast
to the lung.
In both cases, the primary
neoplasms
and the metastases did not show histologic features of malignancy.
These unique cases represent another example of
neoplasms
that can metastasize in the absence of histologic features that would suggest malignant behavior.
Establishing the
diagnosis
, determining optimal therapy, and predicting outcome are problematic because of the rarity of this entity.
Perhaps, classification of adenomyoepitheliomas should be changed to recognize those
neoplasms
with malignant behavior.
[MeSH-major]
Adenomyoma / pathology.
Breast
Neoplasms
/ pathology. Myoepithelioma / pathology
[MeSH-minor]
Aged. Female. Humans. Lung
Neoplasms
/ radiography. Middle Aged.
Neoplasm
Metastasis. Tomography, X-Ray Computed
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16948523.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
9.
Turnbull LW:
Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer.
NMR Biomed
; 2009 Jan;22(1):28-39
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Dynamic contrast-enhanced MRI in the
diagnosis
and management
of breast
cancer.
Dynamic contrast-enhanced MRI (DCE-MRI) is an evolving tool for determining
breast
disease, which benefits from the move to imaging at 3 T.
It has major capabilities for the
diagnosis
, detection and monitoring of malignancy.
However, there are also a number of limitations, including the overlap in enhancement patterns between malignant and
benign
disease, the failure to resolve microscopic disease particularly in the neoadjuvant setting, and the inconsistent predictive value of the enhancement pattern for clinical outcome.
[MeSH-major]
Breast
Neoplasms
/
diagnosis
.
Breast
Neoplasms
/ therapy. Contrast Media. Magnetic Resonance Imaging / methods
[MeSH-minor]
Carcinoma, Ductal,
Breast
/
diagnosis
. Female. Humans. Mass Screening.
Neoplasm
, Residual /
diagnosis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18654999.001).
[ISSN]
0952-3480
[Journal-full-title]
NMR in biomedicine
[ISO-abbreviation]
NMR Biomed
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Contrast Media
[Number-of-references]
71
10.
Durai R, Ruhomauly SN, Wilson E, Hoque H:
Metastatic renal cell carcinoma presenting as a breast lump in a treated breast cancer patient.
Singapore Med J
; 2009 Aug;50(8):e277-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metastatic renal cell carcinoma presenting as a
breast
lump in a treated
breast
cancer patient.
Metastatic malignancy in
the breast
is uncommon.
A 68-year-old woman with a past medical history
of breast
cancer presented with a lump in the opposite
breast
.
A mammogram suggested a possible
benign
lump.
The histology on
the breast
core biopsy showed it to be a metastatic renal cell carcinoma.
Subsequent computed tomography of the abdomen confirmed a renal primary
tumour
.
[MeSH-major]
Breast
Neoplasms
/ complications.
Breast
Neoplasms
/
diagnosis
. Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell /
diagnosis
. Kidney
Neoplasms
/ complications. Kidney
Neoplasms
/
diagnosis
[MeSH-minor]
Aged. Biopsy. Biopsy, Needle / methods.
Breast
/ pathology.
Diagnosis
, Differential. False Negative Reactions. Female. Humans. Mammography / methods.
Neoplasm
Metastasis. Tomography, X-Ray Computed / methods. Ultrasonography / methods
Genetic Alliance.
consumer health - Kidney cancer
.
Genetic Alliance.
consumer health - Breast Cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19710958.001).
[ISSN]
0037-5675
[Journal-full-title]
Singapore medical journal
[ISO-abbreviation]
Singapore Med J
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Singapore
11.
De Vries J, Van der Steeg AF, Roukema JA:
Determinants of fatigue 6 and 12 months after surgery in women with early-stage breast cancer: a comparison with women with benign breast problems.
J Psychosom Res
; 2009 Jun;66(6):495-502
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Determinants of fatigue 6 and 12 months after surgery in women with early-stage
breast
cancer: a comparison with women with
benign breast
problems.
OBJECTIVE: The objective of this study was to examine the predictors of fatigue 6 and 12 months after surgical treatment in women with early-stage
breast
cancer (BC group) and in women with
benign breast
problems (BBP group) in a prospective follow-up study.
METHODS: Women entered the study prior to
diagnosis
and completed questionnaires on personality factors, psychological factors, and social support.
Fatigue was assessed 6 and 12 months after
diagnosis
(BBP group) or surgical treatment (BC group).
CONCLUSION: Many patients who are already fatigued before
diagnosis
remain tired regardless of
diagnosis
.
[MeSH-major]
Breast
Diseases / epidemiology.
Breast
Neoplasms
. Fatigue /
diagnosis
. Fatigue / epidemiology.
Neoplasm
Staging
[MeSH-minor]
Adult. Aged. Anxiety Disorders /
diagnosis
. Anxiety Disorders / epidemiology. Anxiety Disorders / psychology. Cognition. Demography. Female. Humans. Middle Aged. Personality Disorders /
diagnosis
. Personality Disorders / epidemiology. Postoperative Period. Predictive Value of Tests. Prospective Studies. Severity of Illness Index. Social Support. Surveys and Questionnaires. Time Factors
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
MedlinePlus Health Information.
consumer health - Fatigue
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19446708.001).
[ISSN]
1879-1360
[Journal-full-title]
Journal of psychosomatic research
[ISO-abbreviation]
J Psychosom Res
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
12.
Tse GM, Tan PH, Lui PC, Gilks CB, Poon CS, Ma TK, Law BK, Lam WW:
The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
J Clin Pathol
; 2007 Mar;60(3):315-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential
diagnosis
of papillary lesions of the
breast
.
The evaluation of myoepithelial cells can be helpful, with
benign
papilloma showing a continuous myoepithelial cell layer, which becomes attenuated or absent in malignant papillary lesions.
METHODS: A large series of 100 papillomas (28 papillomas with florid epithelial hyperplasia) and 68 papillary carcinomas (9 invasive, 44 in situ, and 15 ductal carcinomas in situ (DCIS) involving papillomas) of the
breast
were stained for myoepithelial cells by immunohistochemistry using antibodies to smooth-muscle actin (SMA), p63, CD10 and cytokeratin (CK) 14.
CK14 and p63 may be used as an adjunct in assessing difficult papillary lesions of the
breast
.
[MeSH-major]
Biomarkers,
Tumor
/ metabolism.
Breast
Neoplasms
/ metabolism
[MeSH-minor]
Actins / metabolism. Adult. Aged. Aged, 80 and over. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. DNA-Binding Proteins / metabolism.
Diagnosis
, Differential. Female. Humans. Keratin-14 / metabolism. Middle Aged.
Neoplasm
Proteins / metabolism. Neprilysin / metabolism. Papilloma / metabolism. Papilloma / pathology. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology. Trans-Activators / metabolism. Transcription Factors.
Tumor
Suppressor Proteins / metabolism
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Pathol. 1999 Nov;52(11):862-4
[
10690183.001
]
[Cites]
Pathology. 2006 Feb;38(1):16-20
[
16484002.001
]
[Cites]
Diagn Cytopathol. 2000 Sep;23(3):151-5
[
10945900.001
]
[Cites]
Histopathology. 2000 Sep;37(3):232-40
[
10971699.001
]
[Cites]
Mod Pathol. 2001 May;14(5):465-71
[
11353058.001
]
[Cites]
Am J Surg Pathol. 2001 Aug;25(8):1054-60
[
11474290.001
]
[Cites]
Histopathology. 2001 Sep;39(3):273-8
[
11532038.001
]
[Cites]
Am J Clin Pathol. 2001 Dec;116(6):823-30
[
11764070.001
]
[Cites]
Clin Cancer Res. 2002 Feb;8(2):494-501
[
11839669.001
]
[Cites]
Mod Pathol. 2002 Apr;15(4):397-405
[
11950913.001
]
[Cites]
Am J Clin Pathol. 2002 Jul;118(1):101-8
[
12109843.001
]
[Cites]
J Clin Pathol. 2002 Dec;55(12):936-9
[
12461063.001
]
[Cites]
Arch Pathol Lab Med. 2003 Mar;127(3):336-40
[
12653579.001
]
[Cites]
Pathol Oncol Res. 2003;9(1):20-3
[
12704442.001
]
[Cites]
Cancer. 2003 Jun 25;99(3):172-9
[
12811858.001
]
[Cites]
Mod Pathol. 2004 Feb;17(2):165-71
[
14631369.001
]
[Cites]
Histol Histopathol. 2004 Apr;19(2):465-71
[
15024707.001
]
[Cites]
Semin Diagn Pathol. 2004 Feb;21(1):32-41
[
15074557.001
]
[Cites]
J Pathol. 2004 Jun;203(2):661-71
[
15141381.001
]
[Cites]
Am J Clin Pathol. 2004 Aug;122(2):217-21
[
15323138.001
]
[Cites]
Am J Clin Pathol. 2004 Sep;122(3):440-3
[
15362376.001
]
[Cites]
Am J Surg Pathol. 2004 Nov;28(11):1506-12
[
15489655.001
]
[Cites]
Clin Immunol Immunopathol. 1975 May;4(1):67-84
[
1092499.001
]
[Cites]
Cancer. 1981 Jul 1;48(1):122-33
[
7195300.001
]
[Cites]
Am J Surg Pathol. 1983 Jul;7(5):451-61
[
6351647.001
]
[Cites]
Mod Pathol. 1989 Nov;2(6):569-76
[
2479944.001
]
[Cites]
Am J Pathol. 1991 Mar;138(3):751-63
[
1705754.001
]
[Cites]
Histopathology. 1991 Jun;18(6):517-22
[
1715306.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1992;421(4):315-22
[
1384226.001
]
[Cites]
Nature. 1999 Apr 22;398(6729):708-13
[
10227293.001
]
[Cites]
Nature. 1999 Apr 22;398(6729):714-8
[
10227294.001
]
[Cites]
Ann Surg. 1951 Jan;133(1):18-36
[
14800254.001
]
[Cites]
Cancer. 1962 May-Jun;15:444-55
[
14459407.001
]
[Cites]
Breast J. 2005 Jan-Feb;11(1):2-8
[
15647071.001
]
[Cites]
J Clin Pathol. 2005 Feb;58(2):185-9
[
15677540.001
]
[Cites]
Histopathology. 2005 Mar;46(3):320-7
[
15720418.001
]
[Cites]
Am J Clin Pathol. 2005 Jan;123(1):36-44
[
15762278.001
]
[Cites]
Am J Surg Pathol. 2005 May;29(5):625-32
[
15832086.001
]
[Cites]
J Clin Pathol. 2005 Nov;58(11):1185-8
[
16254109.001
]
[Cites]
Am J Clin Pathol. 2000 Mar;113(3):374-82
[
10705818.001
]
(PMID = 16698948.001).
[ISSN]
0021-9746
[Journal-full-title]
Journal of clinical pathology
[ISO-abbreviation]
J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Actins; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Keratin-14; 0 / Neoplasm Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 3.4.24.11 / Neprilysin
[Other-IDs]
NLM/ PMC1860581
13.
Soares Leite D, Lima de Lima PD, Ferreira Leal M, Suchi Chen E, Casartelli C, de Arruda Cardoso Smith M, Rodríguez Burbano R:
Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation.
Clin Exp Med
; 2006 Dec;6(4):166-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Investigation of chromosome 21 aneuploidies in
breast
fibroadenomas by fluorescence in situ hybridisation.
Fibroadenoma (FA) is a
benign breast
tumour
that occurs in about 25% of women.
Cytogenetic studies suggest that numerical chromosomal aberrations may contribute to tumorigenesis, but chromosomal instability is still poorly characterised in
breast
cancer.
The aim of this study was to investigate numerical alterations of chromosome 21 in 15
breast
FAs.
Classical cytogenetics analysis showed that all cells were diploidies with modal number varying between 43 and 47 chromosomes, and clonal chromosome alterations in 46.7% of
tumours
.
The study
of benign
proliferations and comparison with chromosome alterations in their malignant counterparts should result in an understanding of the genes acting in cell proliferation alone and those that cause these cells to both undergo malignant transformation and become invasive.
[MeSH-major]
Aneuploidy.
Breast
Neoplasms
/ genetics. Chromosomes, Human, Pair 21 / genetics. Fibroadenoma / genetics. In Situ Hybridization, Fluorescence
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17191108.001).
[ISSN]
1591-8890
[Journal-full-title]
Clinical and experimental medicine
[ISO-abbreviation]
Clin. Exp. Med.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
14.
Huang ZH, Li LH, Hua D:
Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients.
Cancer Lett
; 2006 Nov 8;243(1):64-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Quantitative analysis of plasma circulating DNA at
diagnosis
and during follow-up
of breast
cancer patients.
The aim of the present project was to quantify the level of plasma DNA in patients with malignant or non-malignant
breast
diseases and in healthy controls, then investigate whether such measurements have diagnostic or prognostic value.
Plasma DNA from 121 women (61 patients with
breast
cancer, 33 control patients with
benign breast
diseases and 27 healthy control individuals) was quantified by a real-time quantitative polymerase chain reaction (PCR) method.
Plasma DNA concentration in
the breast
cancer patients (median 65 ng/ml) was significantly higher (P<0.05) than that in the control patients (median 22 ng/ml) or healthy control (median 13 ng/ml).
The data suggest that quantification of plasma circulating DNA may be a valuable complementary diagnostic tool in discriminate
breast
cancer from unaffected individuals and may be proposed as an early detection test as well as a new, noninvasive assay to follow-up patients.
[MeSH-major]
Breast
Neoplasms
/
diagnosis
. DNA,
Neoplasm
/ blood
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16412565.001).
[ISSN]
0304-3835
[Journal-full-title]
Cancer letters
[ISO-abbreviation]
Cancer Lett.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
[Chemical-registry-number]
0 / DNA, Neoplasm
15.
Benarroch-Gampel J, Riall TS:
Extrapancreatic malignancies and intraductal papillary mucinous neoplasms of the pancreas.
World J Gastrointest Surg
; 2010 Oct 27;2(10):363-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Extrapancreatic malignancies and intraductal papillary mucinous
neoplasms
of the pancreas.
Over the last two decades multiple studies have demonstrated an increased incidence of additional malignancies in patients with intraductal papillary mucinous
neoplasms
(IPMNs).
The majority of these additional cancers occur before or concurrent with the
diagnosis
of IPMN.
The gastrointestinal tract is most commonly involved in secondary malignancies, with
benign
colon polyps and colon cancer commonly seen in western countries and gastric cancer commonly seen in Asian countries.
Other extrapancreatic malignancies associated with IPMNs include
benign
and malignant esophageal
neoplasms
, gastrointestinal stromal
tumors
, carcinoid
tumors
, hepatobiliary cancers,
breast
cancers, prostate cancers, and lung cancers.
Routine screening studies (
breast
and prostate) should be carried out as currently recommended for patient's age both before and after the
diagnosis
of IPMN.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21160845.001).
[ISSN]
1948-9366
[Journal-full-title]
World journal of gastrointestinal surgery
[ISO-abbreviation]
World J Gastrointest Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
China
[Other-IDs]
NLM/ PMC2999205
[Keywords]
NOTNLM ; Intraductal papillary mucinous neoplasm / Invasive / Malignant potential / Non-invasive / Secondary malignancy
16.
Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM:
Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
Radiology
; 2008 Jul;248(1):79-87
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Invasive
breast
cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
PURPOSE: To retrospectively evaluate high-spatial-resolution signal enhancement ratio (SER) imaging for the prediction of disease recurrence in patients with
breast
cancer who underwent preoperative magnetic resonance (MR) imaging.
From 1995 to 2002, gadolinium-enhanced MR imaging data were acquired with a three time point high-resolution method in women undergoing neoadjuvant therapy for invasive
breast
cancers.
RESULTS:
Breast
tumor
volume calculated from the number of voxels with SER values above a threshold corresponding to the upper limit of mean redistribution rate constant in
benign
tumors
(0.88 minutes(-1)) and the volume of cancerous
breast
tissue infiltrating into the parenchyma were important predictors of disease recurrence.
All three prechemotherapy parameters (total
tumor
volume,
tumor
volumes with high and low SER) and the postchemotherapy
tumor
volume with high SER were significantly different between the two groups.
The multivariate Cox proportional hazards regression showed that, of the three prechemotherapy covariates, only the low SER and high SER
tumor
volumes (P = .017 and .049, respectively) were significant and independent predictors of
tumor
recurrence.
Tumor
volume with high SER was the only significant postchemotherapy covariate predictor (P = .038).
[MeSH-major]
Breast
Neoplasms
/
diagnosis
. Image Enhancement / methods. Magnetic Resonance Imaging / methods.
Neoplasm
Recurrence, Local /
diagnosis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) RSNA, 2008.
[Cites]
Med Phys. 1987 Jan-Feb;14(1):1-37
[
3031439.001
]
[Cites]
J Magn Reson Imaging. 1997 Jan-Feb;7(1):91-101
[
9039598.001
]
[Cites]
Radiology. 2005 Sep;236(3):789-800
[
16118161.001
]
[Cites]
J Magn Reson Imaging. 1999 Sep;10(3):260-6
[
10508285.001
]
[Cites]
Radiology. 1999 Apr;211(1):101-10
[
10189459.001
]
[Cites]
AJR Am J Roentgenol. 2005 Jun;184(6):1774-81
[
15908529.001
]
[Cites]
Breast J. 1999 Jan;5(1):13-21
[
11348250.001
]
[Cites]
Crit Rev Diagn Imaging. 1995;36(4):287-338
[
8845065.001
]
[Cites]
Clin Radiol. 1997 Jul;52(7):516-26
[
9240704.001
]
[Cites]
J Magn Reson Imaging. 2003 Oct;18(4):467-77
[
14508784.001
]
[Cites]
Magn Reson Imaging Clin N Am. 2001 May;9(2):321-32, vi
[
11493422.001
]
[Cites]
Magn Reson Med. 1995 Apr;33(4):564-8
[
7776889.001
]
[Cites]
J Magn Reson Imaging. 1999 Sep;10(3):223-32
[
10508281.001
]
[Cites]
Acta Radiol. 2003 Jul;44(4):373-8
[
12846686.001
]
[Cites]
Radiology. 2006 May;239(2):361-74
[
16543585.001
]
[Cites]
Cancer. 1996 May 1;77(9):1844-9
[
8646683.001
]
[Cites]
Br J Radiol. 1998 May;71(845):501-9
[
9691895.001
]
[Cites]
Breast Cancer Res Treat. 1997 Aug;45(1):39-46
[
9285115.001
]
[Cites]
Magn Reson Med. 2007 Sep;58(3):572-81
[
17685424.001
]
[Cites]
J Magn Reson Imaging. 2000 Dec;12(6):965-74
[
11105038.001
]
[Cites]
Radiology. 1995 Oct;197(1):33-8
[
7568850.001
]
[Cites]
Cancer. 2005 Aug 15;104(4):708-18
[
15971199.001
]
[Cites]
Acta Radiol. 1998 May;39(3):279-84
[
9571944.001
]
[Cites]
Eur J Radiol. 2005 Feb;53(2):199-205
[
15664283.001
]
[Cites]
Radiology. 1997 Dec;205(3):837-42
[
9393545.001
]
[Cites]
J Magn Reson Imaging. 1999 Dec;10(6):945-9
[
10581507.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):910-2
[
11183740.001
]
[Cites]
J Comput Assist Tomogr. 2002 May-Jun;26(3):376-86
[
12016367.001
]
[Cites]
J Comput Assist Tomogr. 1999 Jul-Aug;23(4):615-21
[
10433296.001
]
[Cites]
Br J Radiol. 1997 May;70(833):446-51
[
9227224.001
]
[Cites]
Eur Radiol. 2001;11(9):1645-50
[
11511885.001
]
[Cites]
Cancer. 1996 Jan 1;77(1):97-103
[
8630946.001
]
[Cites]
J Magn Reson Imaging. 2005 Oct;22(4):511-9
[
16161072.001
]
[Cites]
Magn Reson Imaging. 2004 May;22(4):475-81
[
15120166.001
]
(PMID = 18566170.001).
[ISSN]
1527-1315
[Journal-full-title]
Radiology
[ISO-abbreviation]
Radiology
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA069587; United States / NCI NIH HHS / CA / R01 CA116182
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
United States
17.
Fajdić J, Gotovac N, Hrgović Z, Kristek J, Horvat V, Kaufmann M:
Phyllodes tumors of the breast diagnostic and therapeutic dilemmas.
Onkologie
; 2007 Mar;30(3):113-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phyllodes
tumors
of the
breast
diagnostic and therapeutic dilemmas.
BACKGROUND: This article compares experiences in the
diagnosis
and treatment of phyllodes
tumors
from 2 regional institutions with the relevant literature.
PATIENTS AND METHODS: From 1991 to 2005, 2,848
breast
cancer patients were treated in our institutions, 36 (1.44%) for phyllodes
tumors
.
The average
tumor
size was 5.1 cm (range 1.4-19.6).
Wide excision with
tumor
-free margins was carried out in 29 (80.5%) cases and mastectomy in 7 (19.4%) cases.
RESULTS: Histology showed the phyllodes
tumors
to be
benign
in 27 (75.0%), malignant in 6 (16.6%), and borderline in 3 (8.3%) cases.
In this period, recurrences of 3 (8.3%) malignant and 2 (5.6%)
benign
phyllodes
tumors
were diagnosed and treated.
CONCLUSION: Our study shows that
tumor
size, margin infiltration, mitotic activity and degree of cellular atypia are important prognostic factors.
Although wide local excision is usually the treatment of choice,
tumor
recurrence is common.
Axillary lymphadenectomy in malignant phyllodes
tumors
is, in our opinion, still controversial.
[MeSH-major]
Breast
Neoplasms
/
diagnosis
. Phyllodes
Tumor
/
diagnosis
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Breast
/ pathology.
Diagnosis
, Differential. Female. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Mammography. Mastectomy. Mastectomy, Segmental. Middle Aged. Mitotic Index. Necrosis.
Neoplasm
Invasiveness / pathology.
Neoplasm
Recurrence, Local /
diagnosis
.
Neoplasm
Recurrence, Local / mortality.
Neoplasm
Recurrence, Local / pathology.
Neoplasm
Recurrence, Local / surgery. Prognosis. Reoperation. Survival Rate
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17341897.001).
[ISSN]
0378-584X
[Journal-full-title]
Onkologie
[ISO-abbreviation]
Onkologie
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
18.
Ye YB, Zhou ZF, Chen Q, Li JY, Chen X, Huang WW:
[The roles of soluble MICA in immune escape of breast tumor].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
; 2008 Sep;24(9):904-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[The roles of soluble MICA in immune escape
of breast
tumor
].
AIM: To determine the expression of soluble MICA (sMICA) in serum of patients with
breast
tumor
, and explore the roles of sMICA in immune escape.
The cytotoxicity of NK cells to
breast
cancer cells was observed with MTT assay.
RESULTS: sMICA was not detected in the serum of healthy person, but(76.8+/-22.3) ng/L in
breast benign
tumor
patients and (205.4+/-71.3) ng/L in
breast
malignant
tumor
patients.
There was positive correlation between sMICA levels and
breast
cancer stage.
IL-15 up-regulated the expression of NKG2D on NK cells and increased NK cells cytotoxicity to
breast
cancer cells.
CONCLUSION: sMICA level is positive correlated with
breast
cancer TNM stage. sMICA reduced the expression of NKG2D, impaired NK-mediated immune surveillance and led to immune escape
of breast
tumor
.
[MeSH-major]
Breast
Neoplasms
/ blood.
Breast
Neoplasms
/ immunology. Histocompatibility Antigens Class I / blood
[MeSH-minor]
Cells, Cultured. Cytotoxicity, Immunologic. Female. Humans. Killer Cells, Natural / immunology.
Neoplasm
Staging. Solubility
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18782524.001).
[ISSN]
1007-8738
[Journal-full-title]
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
[ISO-abbreviation]
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / Histocompatibility Antigens Class I; 0 / MHC class I-related chain A
19.
Goicoechea SM, Bednarski B, García-Mata R, Prentice-Dunn H, Kim HJ, Otey CA:
Palladin contributes to invasive motility in human breast cancer cells.
Oncogene
; 2009 Jan 29;28(4):587-98
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Palladin contributes to invasive motility in human
breast
cancer cells.
In this study, we found that the protein palladin, a molecular scaffold with an important function in actin organization, is expressed at higher overall levels in
tumors
compared with
benign breast
tissue, and also expressed significantly higher in four invasive
breast
cancer cell lines when compared with four non-invasive cell lines.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Biochem Cell Biol. 2006;38(11):1875-92
[
16790362.001
]
[Cites]
Exp Cell Res. 2006 Apr 15;312(7):974-82
[
16430883.001
]
[Cites]
Proteomics. 2006 Aug;6(15):4402-9
[
16807943.001
]
[Cites]
J Cell Physiol. 2006 Nov;209(2):568-79
[
16897755.001
]
[Cites]
J Invest Dermatol. 2006 Nov;126(11):2387-96
[
16794588.001
]
[Cites]
Proteomics. 2006 Dec;6(23):6300-16
[
17133371.001
]
[Cites]
PLoS Med. 2006 Dec;3(12):e516
[
17194196.001
]
[Cites]
Br J Cancer. 2007 Jan 29;96(2):296-305
[
17211471.001
]
[Cites]
Breast Cancer Res Treat. 1999 Dec;58(3):193-204
[
10718481.001
]
[Cites]
J Cell Biol. 2000 Aug 7;150(3):643-56
[
10931874.001
]
[Cites]
Cancer Res. 2001 Mar 1;61(5):1833-8
[
11280733.001
]
[Cites]
Cancer Res. 2001 Jul 1;61(13):5168-78
[
11431356.001
]
[Cites]
Mol Biol Cell. 2001 Sep;12(9):2721-9
[
11553711.001
]
[Cites]
Mol Biol Cell. 2001 Oct;12(10):3060-73
[
11598191.001
]
[Cites]
Exp Cell Res. 2002 Oct 15;280(1):64-74
[
12372340.001
]
[Cites]
Mol Biol Cell. 2003 Jun;14(6):2482-91
[
12808045.001
]
[Cites]
Trends Cell Biol. 2003 Jul;13(7):376-85
[
12837608.001
]
[Cites]
Trends Cell Biol. 2007 Mar;17(3):107-17
[
17275303.001
]
[Cites]
Cancer Res. 2007 Mar 15;67(6):2657-65
[
17363586.001
]
[Cites]
J Cell Biochem. 2007 Apr 1;100(5):1288-300
[
17115415.001
]
[Cites]
Circ Res. 2007 Mar 30;100(6):817-25
[
17322171.001
]
[Cites]
Biochim Biophys Acta. 2007 May;1773(5):642-52
[
16926057.001
]
[Cites]
Immunity. 2007 Jun;26(6):784-97
[
17570692.001
]
[Cites]
Exp Cell Res. 2007 Jul 15;313(12):2575-85
[
17537434.001
]
[Cites]
Cancer Lett. 2007 Oct 8;255(2):205-18
[
17537571.001
]
[Cites]
J Clin Invest. 2007 Oct;117(10):2962-73
[
17885682.001
]
[Cites]
BMC Cancer. 2007;7:198
[
17956604.001
]
[Cites]
J Biol Chem. 2008 Mar 7;283(10):6222-31
[
18180288.001
]
[Cites]
Mol Cell Neurosci. 2003 Aug;23(4):661-8
[
12932445.001
]
[Cites]
Cell Motil Cytoskeleton. 2004 Feb;57(2):84-95
[
14691948.001
]
[Cites]
Cell Motil Cytoskeleton. 2004 May;58(1):17-29
[
14983521.001
]
[Cites]
Mol Biol Cell. 2004 Apr;15(4):1600-8
[
14767055.001
]
[Cites]
J Cell Biol. 2004 May 10;165(3):421-32
[
15138294.001
]
[Cites]
FEBS Lett. 2004 May 21;566(1-3):30-4
[
15147863.001
]
[Cites]
Nat Rev Mol Cell Biol. 2004 Aug;5(8):647-57
[
15366708.001
]
[Cites]
Cancer Res. 1994 Nov 1;54(21):5702-10
[
7923219.001
]
[Cites]
J Cell Biol. 1998 Mar 23;140(6):1383-93
[
9508771.001
]
[Cites]
Clin Exp Metastasis. 1998 Aug;16(6):501-12
[
9872598.001
]
[Cites]
Oncogene. 1999 Aug 5;18(31):4440-9
[
10442635.001
]
[Cites]
Cancer Res. 2004 Dec 1;64(23):8585-94
[
15574765.001
]
[Cites]
Cancer Cell. 2005 Feb;7(2):155-65
[
15710328.001
]
[Cites]
Trends Cell Biol. 2005 Mar;15(3):138-45
[
15752977.001
]
[Cites]
J Cell Mol Med. 2005 Jan-Mar;9(1):208-21
[
15784178.001
]
[Cites]
Mol Cell Neurosci. 2005 Aug;29(4):507-15
[
15950489.001
]
[Cites]
Cancer Res. 2005 Jul 15;65(14):6130-8
[
16024614.001
]
[Cites]
Int Rev Cytol. 2005;246:31-58
[
16164966.001
]
[Cites]
Exp Cell Res. 2005 Oct 15;310(1):88-98
[
16125169.001
]
[Cites]
FEBS J. 2006 Jan;273(1):26-33
[
16367745.001
]
[Cites]
J Cell Sci. 2006 Mar 15;119(Pt 6):995-1004
[
16492705.001
]
[Cites]
Eur J Cell Biol. 2006 Apr;85(3-4):151-7
[
16546557.001
]
[Cites]
Eur J Cell Biol. 2006 Apr;85(3-4):213-8
[
16546563.001
]
[Cites]
J Cell Sci. 2006 Aug 15;119(Pt 16):3316-24
[
16868024.001
]
(PMID = 18978809.001).
[ISSN]
1476-5594
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / T32 CA009688; United States / NIGMS NIH HHS / GM / GM61743; United States / NIGMS NIH HHS / GM / R01 GM061743; United States / NIGMS NIH HHS / GM / GM061743-04; United States / NIGMS NIH HHS / GM / R01 GM061743-04; United States / NCI NIH HHS / CA / CA098240; United States / NCI NIH HHS / CA / CA09688; United States / NCI NIH HHS / CA / K08 CA098240
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / Actins; 0 / Cytoskeletal Proteins; 0 / Phosphoproteins; 0 / palladin protein, human; 0 / palladin protein, mouse
[Other-IDs]
NLM/ NIHMS72118; NLM/ PMC2633435
20.
Chen YW, Chuang YW, Lai YC, Hsieh JS, Liu GC, Hou MF:
Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor?
Ann Nucl Med
; 2006 Jan;20(1):45-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in
breast
tumor
?
OBJECTIVE: In this article, we will discuss the achievement of early dynamic lymphoscintigraphic protocol and compare detection of sentinel node between
benign
and malignant
breast
tumors
, and whether pathologic factor is related or not.
The average age of patients was 47.6 +/- 9.8 years and all of them were clinically suspected of having
breast
cancer.
The average
tumor
was 2.1 +/- 1.1 cm in size.
All patients underwent surgery sixteen to twenty hours later and had a final pathological
diagnosis
.
From the summation image of dynamic study, identified axillary sentinel nodal activity was found as 80% in the group
of benign breast
tumor
, but only 48% in the group of malignant
breast
tumor
.
However, this short period of protocol is not always achievable to detect sentinel node, especially in the group with
breast
malignant lesions.
[MeSH-major]
Breast
Neoplasms
/ radionuclide imaging.
Breast
Neoplasms
/ secondary. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Sentinel Lymph Node Biopsy / methods
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16485574.001).
[ISSN]
0914-7187
[Journal-full-title]
Annals of nuclear medicine
[ISO-abbreviation]
Ann Nucl Med
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
21.
Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G:
Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.
Prostate
; 2005 Feb 15;62(3):224-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Human protectin (CD59) is a regulator of complement activation that inhibits complement-mediated cell lysis, and thus might confer immune resistance to
tumor
cells.
CD59 expression has been described in a variety of human malignancies, including
breast
cancer.
The immunoreactivity of the
tumor
was evaluated as low versus high for statistical analysis.
Additionally, CD59 mRNA levels were determined by real-time PCR in matched (
tumor
/normal) microdissected tissues from 26 cases.
RESULTS: Cytoplasmic CD59 immunoreactivity was found in epithelia of prostate cancer, prostatic intraepithelial
neoplasia
,
benign
hyperplasia, atrophic, and normal glands.
High rates of CD59 expression were noted in 36% of prostate cancer cases and were significantly associated with
tumor
pT stage (P = 0.043), Gleason grade (P = 0.013) and earlier biochemical (PSA) relapse in Kaplan-Meier analysis (P = 0.0013).
On RNA level, we found an upregulation in 19.2% (five cases), although the general rate of CD59 transcript was significantly lower in
tumor
tissue (P = 0.03).
[MeSH-major]
Adenocarcinoma / immunology. Antigens, CD59 / biosynthesis.
Neoplasm
Recurrence, Local / immunology. Prostate-Specific Antigen / blood. Prostatic
Neoplasms
/ immunology
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer Screening
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2004 Wiley-Liss, Inc.
(PMID = 15389793.001).
[ISSN]
0270-4137
[Journal-full-title]
The Prostate
[ISO-abbreviation]
Prostate
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD59; 0 / RNA, Messenger; EC 3.4.21.77 / Prostate-Specific Antigen
22.
Engers R, Mueller M, Walter A, Collard JG, Willers R, Gabbert HE:
Prognostic relevance of Tiam1 protein expression in prostate carcinomas.
Br J Cancer
; 2006 Oct 23;95(8):1081-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The Rac-specific guanine nucleotide exchange factor, Tiam1, plays a major role in oncogenicity,
tumour
invasion and metastasis but its usefulness as a prognostic marker in human cancer has not been tested yet.
In the present study, Tiam1 expression was analysed in
benign
secretory epithelium, pre-neoplastic high-grade prostatic intraepithelium
neoplasia
(HG-PIN) and prostate carcinomas of 60 R0-resected radical prostatectomy specimens by semiquantitative immunohistochemistry.
Tiam1 proved significantly overexpressed in both HG-PIN (P<0.001) and prostate carcinomas (P<0.001) when compared to
benign
secretory epithelium.
> or =3.5-fold) in prostate carcinomas relative to the respective
benign
prostatic epithelium was statistically significantly associated with disease recurrence (P=0.016), the presence of lymph vessel invasion (P=0.031) and high Gleason scores (GS) (i.e.
Together, our data suggest that strong Tiam1 overexpression relative to the corresponding
benign
epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.
[MeSH-major]
Guanine Nucleotide Exchange Factors / biosynthesis. Prostatic Intraepithelial
Neoplasia
/ pathology. Prostatic
Neoplasms
/ pathology
[MeSH-minor]
Aged. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis.
Neoplasm
Invasiveness.
Neoplasm
Recurrence, Local. Prognosis. Prostatectomy
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Surg Pathol. 2001 Nov;25(11):1397-404
[
11684956.001
]
[Cites]
J Biol Chem. 2001 Jul 27;276(30):28443-50
[
11328805.001
]
[Cites]
Eur J Clin Invest. 2002 Jun;32(6):448-57
[
12059991.001
]
[Cites]
Nature. 2002 Jun 20;417(6891):867-71
[
12075356.001
]
[Cites]
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
[
12568441.001
]
[Cites]
Breast Cancer Res Treat. 2004 Mar;84(1):21-32
[
14999151.001
]
[Cites]
Am J Surg Pathol. 2004 Feb;28(2):239-43
[
15043314.001
]
[Cites]
Am J Clin Pathol. 2003 Dec;120 Suppl:S85-100
[
15298146.001
]
[Cites]
NCI Monogr. 1988;(7):15-8
[
3173500.001
]
[Cites]
Cell. 1994 May 20;77(4):537-49
[
7999144.001
]
[Cites]
Gynecol Oncol. 1994 May;53(2):220-7
[
8188083.001
]
[Cites]
Nature. 1995 Mar 30;374(6521):457-9
[
7700355.001
]
[Cites]
Nature. 1995 May 25;375(6529):338-40
[
7753201.001
]
[Cites]
Cell. 1995 Jun 30;81(7):1137-46
[
7600581.001
]
[Cites]
J Biol Chem. 1995 Oct 13;270(41):23934-6
[
7592586.001
]
[Cites]
Oncogene. 1995 Dec 7;11(11):2215-21
[
8570171.001
]
[Cites]
Mol Cell Biol. 1996 Jul;16(7):3707-13
[
8668187.001
]
[Cites]
Am J Surg Pathol. 1996 Mar;20(3):286-92
[
8772781.001
]
[Cites]
Science. 1997 Nov 21;278(5342):1464-6
[
9367959.001
]
[Cites]
Nature. 1997 Dec 11;390(6660):632-6
[
9403696.001
]
[Cites]
J Cell Biol. 1998 Nov 30;143(5):1385-98
[
9832565.001
]
[Cites]
Prostate Cancer Prostatic Dis. 2005;8(2):119-26
[
15809669.001
]
[Cites]
Carcinogenesis. 2006 Jan;27(1):1-22
[
16195239.001
]
[Cites]
J Biol Chem. 2006 Jan 6;281(1):543-8
[
16249175.001
]
[Cites]
Int J Cancer. 2000 Nov 1;88(3):369-76
[
11054665.001
]
[Cites]
Semin Cancer Biol. 2001 Apr;11(2):167-73
[
11322835.001
]
[Cites]
J Biol Chem. 2001 Nov 9;276(45):41889-97
[
11551917.001
]
(PMID = 17003780.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Guanine Nucleotide Exchange Factors; 0 / TIAM1 protein, human
[Other-IDs]
NLM/ PMC2360703
23.
Gozzi G, Martinoli C, Conti GM, Ganzetti A, Bodini M, Fiorentino C, Marini UP, Santini D, Bacigalupo L:
Screening mammography interpretation test: more frequent mistakes.
Radiol Med
; 2005 Mar;109(3):268-79
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The mammograms had been taken in the four standard projections and placed on four multi-panel diaphanoscopes, each displaying a set of 40 cases comprising
benign
and malignant cases in equal proportions.
As regards the 23 most frequently misread cases, these were 10/32 (31.25%) mammograms positive for malignancy and 13/128 (10.15%) negative mammograms or mammograms showing
benign
disease.
The 13 cases
of benign
disease--as established by histology or long-term follow-up--mistaken for malignancies by the test participants were fibrocystic
breast
disease in 5 cases, surgical scar in 1 case, ABBI scar in 1 case, radial scar in 2 cases, microcalcifications that had remained stable for years in 2 cases, focal sclero-adenosis in 1 case and sclero-elastosis in 1 case.
CONCLUSIONS: The errors were due to microcalcifications,
benign
disease simulating a
neoplasm
, overlapping tissue, visibility of a lesion in one projection only, lesion site in relation to the corpus mammae, missed areas of asymmetry.
Attention must be paid to these signs of focal
breast
disease since, if correctly evaluated, they enable the early
diagnosis
of low-grade carcinomas that frequently carry a favourable prognosis.
[MeSH-major]
Breast
Neoplasms
/ radiography. Diagnostic Errors. Mammography. Mass Screening. Radiology / standards
[MeSH-minor]
Adenocarcinoma / radiography.
Breast
Diseases / surgery. Calcinosis / radiography. Carcinoma in Situ / radiography. Carcinoma, Ductal,
Breast
/ radiography. Cicatrix / surgery. False Negative Reactions. False Positive Reactions. Female. Fibrocystic
Breast
Disease / radiography. Follow-Up Studies. Humans. Observer Variation
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Mammography
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15775896.001).
[ISSN]
0033-8362
[Journal-full-title]
La Radiologia medica
[ISO-abbreviation]
Radiol Med
[Language]
eng; ita
[Publication-type]
Journal Article
[Publication-country]
Italy
24.
Zhong XY, Ladewig A, Schmid S, Wight E, Hahn S, Holzgreve W:
Elevated level of cell-free plasma DNA is associated with breast cancer.
Arch Gynecol Obstet
; 2007 Oct;276(4):327-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Elevated level of cell-free plasma DNA is associated with
breast
cancer.
BACKGROUND: We analysed cell-free DNA (cfDNA) in the plasma of patients with both malignant and
benign breast
lesions by real-time quantitative PCR to determine whether the finding may have diagnostic and prognostic implications.
METHODS: Plasma samples were obtained from 33 patients with
breast
cancer, 32 patients with
benign breast
lesions and 50 healthy women as normal controls.
RESULTS: The mean concentrations of cfDNA in the plasma samples from patients with
breast
cancer, patients with
benign breast
lesions and normal controls were 2,285, 1,368 and 1,489 genome equivalents (GE) per millilitre, respectively.
The level of cfDNA in
the breast
cancer group was significantly higher than those in
the benign
lesion group and control group (P = 0.007 and 0.013, respectively).
These findings were associated with malignant
tumour
size.
CONCLUSIONS: Our results suggest that levels of cfDNA in the plasma are elevated in malignant
breast
cancer and correlated with
tumour
size.
These findings could have diagnostic and prognostic value for malignant
breast
tumours
.
[MeSH-major]
Breast
Neoplasms
/ blood. DNA / blood
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Biomarkers,
Tumor
/ blood.
Breast
Diseases / blood. Cell-Free System. Cohort Studies. Female. Humans. Middle Aged.
Neoplasm
Staging. Plasma / chemistry. Polymerase Chain Reaction
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17431649.001).
[ISSN]
0932-0067
[Journal-full-title]
Archives of gynecology and obstetrics
[ISO-abbreviation]
Arch. Gynecol. Obstet.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 9007-49-2 / DNA
25.
Javid SH, Carlson JW, Garber JE, Birdwell RL, Lester S, Lipsitz S, Golshan M:
Breast MRI wire-guided excisional biopsy: specimen size as compared to mammogram wire-guided excisional biopsy and implications for use.
Ann Surg Oncol
; 2007 Dec;14(12):3352-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Breast
MRI wire-guided excisional biopsy: specimen size as compared to mammogram wire-guided excisional biopsy and implications for use.
BACKGROUND:
Breast
magnetic resonance imaging (MRI) has been implemented as a screening tool for early detection and as a diagnostic test in the management
of breast
cancer.
We also sought to evaluate factors that might predict the presence
of breast
cancer in patients undergoing MRIbx.
METHODS: We reviewed consecutive cases
of breast
MRIbx from 2004 to 2006 performed by seven surgeons.
MRI was performed in patients with either a synchronous
breast
cancer or significant risk factors.
Eleven (15.5%) invasive
breast
cancers and eight cases (11.3%) of ductal carcinoma in situ (DCIS) were identified.
DCIS-containing MRIbx specimens were significantly larger than
benign
or invasive cancer-containing specimens.
CONCLUSIONS: In patients undergoing
breast
MRIbx, 27% were found to have DCIS or invasive
breast
cancer.
[MeSH-major]
Breast
Neoplasms
/
diagnosis
.
Breast
Neoplasms
/ surgery. Magnetic Resonance Imaging / methods
[MeSH-minor]
Biopsy, Needle. Carcinoma, Ductal,
Breast
/
diagnosis
. Carcinoma, Ductal,
Breast
/ surgery. Carcinoma, Intraductal, Noninfiltrating /
diagnosis
. Carcinoma, Intraductal, Noninfiltrating / surgery. Female. Humans. Mammography. Middle Aged.
Neoplasm
Invasiveness / pathology. Predictive Value of Tests. Prospective Studies
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17849165.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
26.
Dhingra KK, Mandal S, Roy S, Khurana N:
Malignant peripheral nerve sheath tumor of the breast: case report.
World J Surg Oncol
; 2007;5:142
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Malignant peripheral nerve sheath
tumor
of the
breast
: case report.
BACKGROUND: Malignant peripheral nerve sheath
tumor
is a rare soft tissue sarcoma of ectomesenchymal origin.
It is the malignant counterpart
of benign
soft tissue
tumors
like neurofibromas and schwannomas and may often follow them.
Breast
is an extremely rare location of this lesion and presentation as a
breast
lump in the absence of pain or previous
benign
neural
tumor
is even rarer.
CASE PRESENTATION: A 38-year-old female presented with complaints of painless, hard
breast
lump for three months which was clinically suspected to be a ductal carcinoma with inconclusive fine needle aspiration cytology.
Histopathology revealed a malignant spindle cell
tumor
which was confirmed to be malignant peripheral nerve sheath
tumor
on the basis of immunopositivity for vimentin, neurone specific enolase and S-100.
The differential
diagnosis
of malignant peripheral nerve sheath
tumor
should be considered by the clinician as well as the pathologists in the work-up of a
breast neoplasm
as treatment and prognosis of this rare malignancy is different.
[MeSH-major]
Breast
Neoplasms
/ pathology. Nerve Sheath
Neoplasms
/ pathology. Peripheral Nervous System
Neoplasms
/ pathology
[MeSH-minor]
Adult. Biomarkers,
Tumor
/ metabolism. Biopsy, Fine-Needle.
Diagnosis
, Differential. Female. Humans. Vimentin / metabolism
Genetic Alliance.
consumer health - Malignant peripheral nerve sheath tumor
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Orv Hetil. 1998 Jan 18;139(3):137-9
[
9467297.001
]
[Cites]
Cancer. 1984 Sep 15;54(6):1049-57
[
6432304.001
]
[Cites]
Cancer. 1986 May 15;57(10):2006-21
[
3082508.001
]
[Cites]
Arch Pathol Lab Med. 1988 Feb;112(2):155-60
[
2447857.001
]
[Cites]
J Surg Oncol. 1995 Aug;59(4):273-5
[
7630177.001
]
[Cites]
J Med Assoc Thai. 2006 Mar;89(3):377-9
[
16696423.001
]
[Cites]
Cancer Res. 2002 Mar 1;62(5):1573-7
[
11894862.001
]
[Cites]
J Clin Oncol. 1998 Jan;16(1):197-203
[
9440743.001
]
[Cites]
Breast J. 2003 Jul-Aug;9(4):332
[
12846874.001
]
[Cites]
J Gynecol Obstet Biol Reprod (Paris). 1998 Jun;27(4):441-4
[
9690165.001
]
[Cites]
Langenbecks Arch Chir. 1995;380(6):350-3
[
8559005.001
]
(PMID = 18154670.001).
[ISSN]
1477-7819
[Journal-full-title]
World journal of surgical oncology
[ISO-abbreviation]
World J Surg Oncol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Vimentin
[Other-IDs]
NLM/ PMC2246134
27.
Suga K, Kawakami Y, Hiyama A, Matsunaga N:
Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
Ann Nucl Med
; 2009 Jun;23(4):399-407
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Differentiation of FDG-avid loco-regional recurrent and compromised
benign
lesions after surgery for
breast
cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
OBJECTIVE: To evaluate the ability of dual-time point F-18-fluorodeoxy-glucose (FDG) PET/CT scans to differentiate FDG-avid loco-regional recurrent and compromised
benign
lesions after surgery for
breast
cancer.
METHODS: A total of 64 FDG-avid recurrent lesions (local
tumor
recurrence or lymph node metastases) in 52 patients and 38 FDG-avid compromised
benign
lesions after surgery in 37 patients were included in the study.
RESULTS: The average early SUVmax, delayed SUVmax and DeltaSUVmax% were 4.9 +/- 2.6, 6.0 +/- 3.6 and 18.2% +/- 18.8 in FDG-avid recurrent lesions, and 2.1 +/- 0.8, 1.8 +/- 1.0 and -17.8% +/- 21.3 in FDG-avid
benign
lesions, respectively.
Delayed SUVmax was significantly increased compared with early SUVmax in recurrent lesions (P < 0.0001), while it was decreased in
benign
lesions (P < 0.0001).
All the three parameters in recurrent lesions were significantly higher than those in
benign
lesions (P < 0.0001).
CONCLUSIONS: This approach with SUVmax estimation appears to improve the differentiation between FDG-avid loco-regional recurrent
of breast
cancer and compromised
benign
lesions after surgery, since delayed scanning significantly enhances the difference in FDG uptake between these lesions.
[MeSH-major]
Breast
Neoplasms
/ surgery. Fluorodeoxyglucose F18.
Neoplasm
Recurrence, Local /
diagnosis
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Diagnosis
, Differential. Female. Humans. Middle Aged. Positron-Emission Tomography. ROC Curve. Time Factors. Tomography, X-Ray Computed
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19452249.001).
[ISSN]
0914-7187
[Journal-full-title]
Annals of nuclear medicine
[ISO-abbreviation]
Ann Nucl Med
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0Z5B2CJX4D / Fluorodeoxyglucose F18
28.
Milot L, Guindi M, Gallinger S, Moulton CA, Brock KK, Dawson LA, Haider MA:
MR imaging correlates of intratumoral tissue types within colorectal liver metastases: a high-spatial-resolution fresh ex vivo radiologic-pathologic correlation study.
Radiology
; 2010 Mar;254(3):747-54
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In seven consecutive patients undergoing hepatic resection for liver metastases (primary colorectal in six,
breast
mistaken for colorectal in one), the resected fresh ex vivo liver specimen was examined with T1-weighted (repetition time msec/echo time msec, 9/4.4-4.8) and T2-weighted (2500/90) MR imaging by using a voxel size of 0.47 x 0.7 x 2 mm.
This SI pattern is unusual for common
benign
liver lesions and may be helpful in the MR imaging
diagnosis
of colorectal liver metastases. (c) RSNA, 2010.
[MeSH-major]
Colorectal
Neoplasms
/ pathology. Liver
Neoplasms
/
diagnosis
. Liver
Neoplasms
/ secondary. Magnetic Resonance Imaging / methods
[MeSH-minor]
Adult. Aged. Female. Humans. In Vitro Techniques. Linear Models. Male. Middle Aged.
Neoplasm
Staging. Prospective Studies
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20123902.001).
[ISSN]
1527-1315
[Journal-full-title]
Radiology
[ISO-abbreviation]
Radiology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
29.
Lee JM, Georgian-Smith D, Gazelle GS, Halpern EF, Rafferty EA, Moore RH, Yeh ED, D'Alessandro HA, Hitt RA, Kopans DB:
Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions.
Radiology
; 2008 Aug;248(2):398-405
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detecting nonpalpable recurrent
breast
cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions.
RESULTS: Of 554 mammograms (265 TRAM flap reconstructions), 546 (98.6%) had negative results (
Breast
Imaging Reporting and Data System category 1 or 2).
Eight (1.4%) had positive test results (
Breast
Imaging Reporting and Data System category 0, 3, 4, or 5).
All suspicious lesions underwent biopsy and had
benign
pathologic results.
No interval
breast
cancers were identified.
The detection rate for nonpalpable recurrent
breast
cancer was 0% (exact 95% confidence interval: 0.0%, 1.4%).
CONCLUSION: Routine screening mammography of TRAM flap reconstructions has a very low detection rate for nonpalpable recurrent
breast
cancer.
Decision analysis indicates that screening such women is less effective than screening asymptomatic women in their 40s for primary
breast
cancer.
[MeSH-major]
Breast
Neoplasms
/ radiography.
Breast
Neoplasms
/ surgery. Mammaplasty.
Neoplasm
Recurrence, Local / radiography. Rectus Abdominis / transplantation. Surgical Flaps
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Reconstruction
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18539887.001).
[ISSN]
1527-1315
[Journal-full-title]
Radiology
[ISO-abbreviation]
Radiology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
30.
Schiffhauer LM, Boger JN, Bonfiglio TA, Zavislan JM, Zuley M, Fox CA:
Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections.
BMC Cancer
; 2009;9:265
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Confocal microscopy of unfixed
breast
needle core biopsies: a comparison to fixed and stained sections.
BACKGROUND: Needle core biopsy, often in conjunction with ultrasonic or stereotactic guided techniques, is frequently used to diagnose
breast
carcinoma in women.
This paper reports the progress in developing techniques to rapidly screen needle core
breast
biopsy and surgical specimens at the point of care.
CSLM requires minimal tissue processing and has the potential to reduce the time from excision to
diagnosis
.
METHODS: Needle core
breast
specimens from 49 patients were imaged at the time of biopsy.
These lesions had been characterized under
the Breast
Imaging Reporting And Data System (BI-RADS) as category 3, 4 or 5.
Immediately following imaging, the specimens were fixed in buffered formalin and submitted for histological processing and pathological
diagnosis
.
RESULTS: The pathologic diagnoses by standard histology were 7 invasive ductal carcinomas, 2 invasive lobular carcinomas, 3 ductal carcinomas in-situ (CIS), 21 fibrocystic changes/proliferative conditions, 9 fibroadenomas, and 5 other/
benign
; two were excluded due to imaging difficulties.
Morphologic and cellular features
of benign
and cancerous lesions were identified in the confocal images and were comparable to standard histologic sections of the same tissue.
Morphologic and cellular features
of benign
and cancerous lesions were identified in the confocal images.
Additional studies are needed to 1.) establish correlation of the confocal and traditional histologic images for the various diseases of the
breast
; 2.) validate diagnostic use of CSLM and; 3.) further define features of borderline lesions such as well-differentiated ductal CIS vs. atypical hyperplasia.
[MeSH-major]
Biopsy, Needle / methods.
Breast
Neoplasms
/
diagnosis
.
Breast
Neoplasms
/ pathology. Microscopy, Confocal / methods
[MeSH-minor]
Biopsy. Cell Proliferation. Contrast Media / pharmacology. Female. Humans. Medical Oncology / methods.
Neoplasm
Invasiveness
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hum Pathol. 2002 Oct;33(10):975-82
[
12395369.001
]
[Cites]
Pancreatology. 2001;1(1):48-57
[
12120268.001
]
[Cites]
J Invest Dermatol. 2001 Nov;117(5):1137-43
[
11710924.001
]
[Cites]
Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1
[
11114647.001
]
[Cites]
BMC Cancer. 2008;8:21
[
18215290.001
]
[Cites]
J Biomed Opt. 2008 Sep-Oct;13(5):054001
[
19021381.001
]
[Cites]
J Biomed Opt. 2005 Sep-Oct;10(5):051602
[
16292950.001
]
[Cites]
J Invest Dermatol. 1999 Sep;113(3):293-303
[
10469324.001
]
[Cites]
Clin Dermatol. 2003 Sep-Oct;21(5):359-69
[
14678715.001
]
[Cites]
Dermatol Surg. 2003 Aug;29(8):839-46
[
12859385.001
]
[Cites]
J Biomed Opt. 2007 Sep-Oct;12(5):051901
[
17994884.001
]
(PMID = 19650910.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Contrast Media
[Other-IDs]
NLM/ PMC3087331
31.
Iyengar P, Ali SZ, Brogi E:
Fine-needle aspiration cytology of mammary adenomyoepithelioma: a study of 12 patients.
Cancer
; 2006 Aug 25;108(4):250-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Adenomyoepithelioma (AME) of the
breast
is a rare
neoplasm
that is characterized by a biphasic proliferation of epithelial and myoepithelial cells.
METHODS: The authors conducted a retrospective evaluation of cytologic findings in fine-needle aspiration biopsy (FNAB) material from 12 patients with histologically proven
benign
AMEs of the
breast
.
None of the patients were diagnosed originally with AME: Two
tumors
were classified as
benign
and consistent with fibroadenoma, 6
tumors
were atypical, 2
tumors
were suspicious for carcinoma, and 2
tumors
were positive for malignant cells.
CONCLUSIONS: Because of the varied histology of AME, cytologic
diagnosis
of this
neoplasm
can be very challenging.
Conservative
diagnosis
and further histologic evaluation is recommended for these patients.
[MeSH-major]
Adenoma / pathology. Biopsy, Fine-Needle.
Breast
Neoplasms
/ pathology. Myoepithelioma / pathology
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Clinical Trials as Topic.
Diagnosis
, Differential. Female. Humans. Middle Aged. Retrospective Studies
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2006 American Cancer Society.
(PMID = 16544319.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
32.
Liu HM, Wu FL, Chen X, Ye CS, Deng YJ:
[Value of ultrasonographic grading with high-frequency probes in distinguishing breast tumors].
Nan Fang Yi Ke Da Xue Xue Bao
; 2009 Oct;29(10):2115-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Value of ultrasonographic grading with high-frequency probes in distinguishing
breast
tumors
].
OBJECTIVE: To investigate the value of ultrasonographic grading with high-frequency probes in differentiating
benign
and malignant
breast
tumors
.
METHODS: Sixty-four women (mean age 44.5-/+13.7 years) with 79
breast
tumors
underwent high-frequency ultrasonography to examine the
tumor
number, size, aspect ratio, shape, boundaries, encapsulation, pseudopod, internal and rear echoes, calcifications, blood perfusion, abnormality lymph nodes in the axilla.
The
tumors
were graded based on these findings using a 10-point grading system.
RESULTS: Between the 46 women with
benign
tumors
and 18 with malignant
tumors
, no significant differences were found in the mean
tumor
number (1.5-/+1.3 vs 1.1-/+0.3, P>0.05) or size (55.0-/+19.2 mm vs 19.8-/+8.3 mm, P>0.05), but the mean age (41.4-/+12.4 years vs 52.4-/+14.1 years) and ultrasonographic grade (2.8-/+2.2 vs 7.3-/+1.7, P<0.05) differed significantly.
The ultrasonographic grade of the
breast
tumors
showed an obvious correlation to the nature of the
tumors
(r=0.695, P<0.001).
CONCLUSION: Grading
of breast
tumors
with high-frequency ultrasonography helps evaluate the nature of the
tumors
, and a higher score suggests increased probability of malignancy.
[MeSH-major]
Breast
Diseases / ultrasonography.
Breast
Neoplasms
/ ultrasonography. Ultrasonography, Mammary / methods
[MeSH-minor]
Adult. Aged.
Diagnosis
, Differential. Female. Humans. Middle Aged.
Neoplasm
Grading. Young Adult
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19861280.001).
[ISSN]
1673-4254
[Journal-full-title]
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
[ISO-abbreviation]
Nan Fang Yi Ke Da Xue Xue Bao
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
33.
Jing F, Zhang J, Tao J, Zhou Y, Jun L, Tang X, Wang Y, Hai H:
Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.
Onkologie
; 2007 Feb;30(1-2):14-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hypermethylation of
tumor
suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic
breast
cancer patients.
BACKGROUND: We investigated the hypermethylation status in serum of sporadic
breast
cancer patients.
MATERIAL AND METHODS: The hypermethylation status of BRCA1, p16 and 14-3-3sigma in cancerous tissues and the paired serum of 38 sporadic
breast
cancer patients was examined by methylation-specific PCR (MSP) assay.
Normal and
benign
tissue and serum control DNA were also examined to determine the specificity of hypermethylation.
RESULTS: Hypermethylation of 1 or more genes was found in 36/38 (95%) of sporadic
breast
cancers.
No methylated products of BRCA1, p16 and 14-3-3sigma were observed in serum DNA from healthy women and patients with
benign
tissue specimens.
A gene unmethylated in the
tumor
DNA was always found to be unmethylated in matched serum DNA.
CONCLUSIONS: Hypermethylation of BRCA1, p16 and 14-3-3sigma is present in all histologic types, stages and grades in sporadic
breast
cancer and can be detected in serum DNA.
It signifies that serum-based hypermethylation screening may enhance early detection of sporadic
breast
cancer.
[MeSH-major]
Biomarkers,
Tumor
/ blood. Biomarkers,
Tumor
/ genetics.
Breast
Neoplasms
/ blood.
Breast
Neoplasms
/ genetics. DNA Methylation. Genes,
Tumor
Suppressor
[MeSH-minor]
14-3-3 Proteins. Adult. Aged. Cyclin-Dependent Kinase Inhibitor p16 / blood. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Mutational Analysis / methods. Exonucleases / blood. Exonucleases / genetics. Exoribonucleases. Female. Humans. Middle Aged.
Neoplasm
Proteins / blood.
Neoplasm
Proteins / genetics. Reproducibility of Results. Sensitivity and Specificity. Ubiquitin-Protein Ligases / blood. Ubiquitin-Protein Ligases / genetics
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17264521.001).
[ISSN]
0378-584X
[Journal-full-title]
Onkologie
[ISO-abbreviation]
Onkologie
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human; EC 6.3.2.- / BRAP protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
34.
Mainiero MB, Cinelli CM, Koelliker SL, Graves TA, Chung MA:
Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance.
AJR Am J Roentgenol
; 2010 Nov;195(5):1261-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the
breast
cancer patient: an algorithm based on
tumor
size and lymph node appearance.
OBJECTIVE: The objective of our study was to evaluate the utility of ultrasound-guided fine-needle aspiration (FNA) of the axillary lymph nodes in
breast
cancer patients depending on the size of the primary
tumor
and the appearance of the lymph nodes.
SUBJECTS AND METHODS: Data were collected about
tumor
size, lymph node appearance, and the results of ultrasound-guided FNA and axillary surgery of 224 patients with
breast
cancer undergoing 226 ultrasound-guided FNA.
Lymph nodes were classified as
benign
if the cortex was even and measured < 3 mm, indeterminate if the cortex was even but measured ≥ 3 mm or measured < 3 mm but was focally thickened, and suspicious if the cortex was focally thickened and measured ≥ 3 mm or the fatty hilum was absent.
The results of ultrasound-guided FNAs were analyzed by the sonographic appearance of the axillary lymph nodes and by the size of the primary
tumor
.
The sensitivity of ultrasound-guided FNA was 29% in patients with primary
tumors
≤ 1 cm, 50% in patients with
tumors
> 1 to ≤ 2 cm, 69% in patients with
tumors
> 2 to ≤ 5 cm, and 100% in patients with
tumors
> 5 cm.
CONCLUSION: Ultrasound-guided FNA of the axillary lymph nodes is most useful in the preoperative assessment of patients with large
tumors
(> 2 cm) or lymph nodes that appear abnormal.
[MeSH-major]
Axilla / pathology. Biopsy, Fine-Needle / methods.
Breast
Neoplasms
/ pathology. Lymphatic Metastasis / pathology. Ultrasonography, Interventional
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Breast
Neoplasms
, Male / pathology.
Breast
Neoplasms
, Male / surgery.
Breast
Neoplasms
, Male / ultrasonography. Female. Humans. Male. Middle Aged.
Neoplasm
Staging. Preoperative Care. Prospective Studies. Sensitivity and Specificity. Sentinel Lymph Node Biopsy
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
AJR Am J Roentgenol. 2011 Jul;197(1):W194; author reply W195
[
21700988.001
]
(PMID = 20966338.001).
[ISSN]
1546-3141
[Journal-full-title]
AJR. American journal of roentgenology
[ISO-abbreviation]
AJR Am J Roentgenol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
35.
Bisdas S, Baghi M, Huebner F, Mueller C, Knecht R, Vorbuchner M, Ruff J, Gstoettner W, Vogl TJ:
In vivo proton MR spectroscopy of primary tumours, nodal and recurrent disease of the extracranial head and neck.
Eur Radiol
; 2007 Jan;17(1):251-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
In vivo proton MR spectroscopy of primary
tumours
, nodal and recurrent disease of the extracranial head and neck.
Benign
and malignant
neoplasms
as well as metastatic lymph nodes of 39 patients were examined using localized single voxel magnetic resonance spectroscopy (MRS) [repetition time (TR) 1500, echo time (TE) 135) at 1.5 T.
The Cho/Cr ratios in all malignant
neoplasms
(mean: 5.2, range: 1.7-17.8) were significantly elevated relative to those in the normal muscle structures (mean: 0.9, range: 0.2-1.4), while those in
the benign
neoplasms
were elevated (mean: 24.4, range: 1.4-59.7) with respect to those in the malignant ones.
The average Cho/Cr ratio in the metastatic lymph nodes was significantly higher (mean: 4.8, range: 3.3-5.6) than that for
benign
lymphoid hyperplasia (mean: 2.2, range: 1.0-3.0).
[MeSH-major]
Head and Neck
Neoplasms
/
diagnosis
. Magnetic Resonance Spectroscopy.
Neoplasm
Recurrence, Local /
diagnosis
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Humans. Lymphatic Metastasis /
diagnosis
. Male. Middle Aged
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 1989 Jun;86(12):4402-6
[
2734292.001
]
[Cites]
Magn Reson Med. 1993 Apr;29(4):436-40
[
8385259.001
]
[Cites]
Breast Cancer Res. 2005;7(4):149-52
[
15987466.001
]
[Cites]
AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1696-704
[
15569733.001
]
[Cites]
NMR Biomed. 1998 Nov;11(7):360-9
[
9859942.001
]
[Cites]
AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1057-72
[
9194433.001
]
[Cites]
AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1133-8
[
10871028.001
]
[Cites]
Radiology. 1997 Sep;204(3):661-6
[
9280241.001
]
[Cites]
Eur Radiol. 2005 Apr;15(4):645-52
[
15627189.001
]
[Cites]
J Comput Assist Tomogr. 2004 Mar-Apr;28(2):233-46
[
15091129.001
]
[Cites]
AJNR Am J Neuroradiol. 2004 Mar;25(3):484-90
[
15037477.001
]
[Cites]
Am J Med. 1994 Apr;96(4):383-8
[
8166160.001
]
[Cites]
NMR Biomed. 1998 Oct;11(6):266-72
[
9802468.001
]
[Cites]
Technol Cancer Res Treat. 2004 Dec;3(6):557-65
[
15560713.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1381-9
[
12873684.001
]
[Cites]
AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12
[
11290466.001
]
[Cites]
AJNR Am J Neuroradiol. 2000 Nov-Dec;21(10):1930-5
[
11110549.001
]
[Cites]
AJNR Am J Neuroradiol. 2000 Jan;21(1):183-93
[
10669248.001
]
[Cites]
Magn Reson Med. 2001 May;45(5):765-9
[
11323802.001
]
[Cites]
Invasion Metastasis. 1993;13(2):57-71
[
8225853.001
]
[Cites]
Cancer Res. 2005 Apr 15;65(8):3030-4
[
15833828.001
]
(PMID = 16703309.001).
[ISSN]
0938-7994
[Journal-full-title]
European radiology
[ISO-abbreviation]
Eur Radiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
36.
Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD:
Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
Am J Obstet Gynecol
; 2005 Apr;192(4):1230-7; discussion 1237-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Benign
gynecologic conditions among participants in
the Breast
Cancer Prevention Trial.
OBJECTIVE: This study was undertaken to report on
the benign
gynecologic conditions occurring among women with an intact uterus at enrollment in
the Breast
Cancer Prevention Trial of the National Surgical Adjuvant
Breast
and Bowel Project.
STUDY DESIGN: The incidence rates of several
benign
gynecologic conditions were determined and risks were compared among women receiving tamoxifen and those receiving placebo, based on risk ratios (RRs) with 95% CIs.
[MeSH-major]
Antineoplastic Agents, Hormonal / adverse effects.
Breast
Neoplasms
/ therapy. Genital Diseases, Female / chemically induced. Genital Diseases, Female / pathology.
Neoplasm
Recurrence, Local / prevention & control. Tamoxifen / adverse effects
[MeSH-minor]
Adult. Age Distribution. Aged. Chemotherapy, Adjuvant. Confidence Intervals. Dose-Response Relationship, Drug. Female. Humans. Incidence. Middle Aged.
Neoplasm
Staging. Probability. Reference Values. Risk Assessment
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
TAMOXIFEN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Am J Obstet Gynecol. 2006 Apr;194(4):1204-5; author reply 1205
[
16580343.001
]
(PMID = 15846210.001).
[ISSN]
0002-9378
[Journal-full-title]
American journal of obstetrics and gynecology
[ISO-abbreviation]
Am. J. Obstet. Gynecol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69974
[Publication-type]
Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
37.
Kallel R, Bahri Zouari I, Gouiaa N, Charfi S, Daoud E, Ayadi L, Makni S, Daoud J, Sellami Boudawara T:
[Adenoid cystic carcinoma of the breast].
Cancer Radiother
; 2009 Jul;13(4):323-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Adenoid cystic carcinoma of the
breast
].
[Transliterated title]
Carcinome adénoïde kystique
du sein
.
Adenoid cystic carcinoma of the
breast
is a rare
neoplasm
, accounting for only 0.1% of all malignant
breast
tumours
.
The clinical criteria is not specific and the radiographic examination showed a
benign
-appearing
tumour
.
The preoperative
diagnosis
is possible with fine-needle aspiration cytology.
The
diagnosis
is made by histological examination, presented a difficult differential
diagnosis
with cribriform carcinoma; so it is necessary to use histochemical or immunohistochemical techniques.
Compared to other locations, adenoid cystic carcinoma of the
breast
has a favorable prognosis.
The aim of our study is to describe the epidemiological, clinicopathological characteristics, the treatment and the prognosis of this rare type
of breast
tumour
.
[MeSH-major]
Breast
Neoplasms
. Carcinoma, Adenoid Cystic
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Biomarkers,
Tumor
/ analysis. Combined Modality Therapy / methods.
Diagnosis
, Differential. Female. Humans. Middle Aged. Young Adult
Genetic Alliance.
consumer health - Adenoid Cystic Carcinoma
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19464219.001).
[ISSN]
1769-6658
[Journal-full-title]
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
[ISO-abbreviation]
Cancer Radiother
[Language]
fre
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
France
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Number-of-references]
30
38.
Cornelis A, Verjans M, Van den Bosch T, Wouters K, Van Robaeys J, Janssens JP, Working Group on Hormone Dependent Cancers (European Cancer Prevention Organization):
Efficacy and safety of direct and frontal macrobiopsies in breast cancer.
Eur J Cancer Prev
; 2009 Aug;18(4):280-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Efficacy and safety of direct and frontal macrobiopsies in
breast
cancer.
Recent innovations in tissue acquisition from the human
breast
have led to the development of unique direct frontal systems.
Efficacy was considered optimal if the
diagnosis
by transcutaneous biopsy was identical to the surgical specimen in case of malignancy or in line with clinical follow-up when
benign
.
One hundred and seventy-three women (aged 22-95 years) with a suspect lesion in
the breast
were eligible for transdermal biopsy.
Sample quality was evaluated by comparing the pathology results of the samples with definitive pathology at subsequent surgery or follow-up in case
of benign
lesions.
All patients had sufficient sample size (up to 5 mm diameter/20 mm length) to make a reliable
diagnosis
.
There were three false-negative diagnoses, leaving a correct
diagnosis
in 170 patients.
[MeSH-major]
Biopsy, Needle / methods.
Breast
Neoplasms
/ pathology
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged.
Neoplasm
Staging. Young Adult
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19352188.001).
[ISSN]
1473-5709
[Journal-full-title]
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
[ISO-abbreviation]
Eur. J. Cancer Prev.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
England
39.
Rozenchan PB, Carraro DM, Brentani H, de Carvalho Mota LD, Bastos EP, e Ferreira EN, Torres CH, Katayama ML, Roela RA, Lyra EC, Soares FA, Folgueira MA, Góes JC, Brentani MM:
Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts.
Int J Cancer
; 2009 Dec 15;125(12):2767-77
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Reciprocal changes in gene expression profiles of cocultured
breast
epithelial cells and primary fibroblasts.
The importance of epithelial-stroma interaction in normal
breast
development and
tumor
progression has been recognized.
To identify genes that were regulated by these reciprocal interactions, we cocultured a nonmalignant (MCF10A) and a
breast
cancer derived (MDA-MB231) basal cell lines, with fibroblasts isolated from
breast benign
-disease adjacent tissues (NAF) or with carcinoma-associated fibroblasts (CAF), in a transwell system.
Our data indicate that interactions between
breast
fibroblasts and basal epithelial cells resulted in alterations in the genomic profiles of both cell types which may help to clarify some aspects of this heterotypic signaling.
[MeSH-major]
Breast
Neoplasms
/ genetics.
Breast
Neoplasms
/ pathology. Epithelial Cells / metabolism. Fibroblasts / metabolism. Gene Expression Profiling.
Neoplasm
Proteins / genetics
[MeSH-minor]
Biomarkers,
Tumor
/ genetics. Biomarkers,
Tumor
/ metabolism. Blotting, Western.
Breast
/ cytology. Cell Proliferation. Coculture Techniques. Female. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction.
Tumor
Cells, Cultured
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2009 UICC.
(PMID = 19530251.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger
40.
Wright TG, Singh VK, Li JJ, Foley JH, Miller F, Jia Z, Elliott BE:
Increased production and secretion of HGF alpha-chain and an antagonistic HGF fragment in a human breast cancer progression model.
Int J Cancer
; 2009 Sep 1;125(5):1004-15
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Increased production and secretion of HGF alpha-chain and an antagonistic HGF fragment in a human
breast
cancer progression model.
Invasive human
breast
carcinomas frequently coexpress increased hepatocyte growth factor (HGF) and its receptor Met, suggesting that establishment of an autocrine HGF loop is important in malignant disease.
This study examines the expression patterns of HGF and Met activation during tumorigenesis and metastasis using a MCF10A-based model of Ha-Ras-induced human
breast
cancer progression.
Compared to
the benign
parent cell line, premalignant and malignant cell lines exhibit increased secretion of full length HGF alpha-chain and elevated Met tyrosine phosphorylation in complete medium.
These results are the first demonstration of an antagonistic approximately 55 kDa HGF fragment secreted during
breast
carcinoma progression, which may have a negative regulatory effect on HGF signaling in premalignant
breast
epithelial cells.
[MeSH-major]
Breast
Neoplasms
/ metabolism. Hepatocyte Growth Factor / metabolism. Peptide Fragments / metabolism. Proto-Oncogene Proteins c-met / metabolism
[MeSH-minor]
Blotting, Western. Cell Transformation, Neoplastic. Culture Media, Conditioned / pharmacology. Disease Progression. Genes, ras. Humans. Mesoderm / cytology. Mesoderm / metabolism.
Neoplasm
Invasiveness. Phosphorylation. Tyrosine / metabolism
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
L-TYROSINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2009 UICC.
(PMID = 19415747.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Culture Media, Conditioned; 0 / Peptide Fragments; 42HK56048U / Tyrosine; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
41.
Ławicki S, Szmitkowski M, Wojtukiewicz M:
The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Clin Chim Acta
; 2006 Sep;371(1-2):112-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The pretreatment plasma level and diagnostic utility of M-CSF in
benign breast
tumor
and
breast
cancer patients.
BACKGROUND: In the present study, we investigated the plasma levels of M-CSF and commonly accepted
tumor
marker (antigen CA 15-3) in
breast
cancer patients in relation to the group with
benign breast
tumor
and to the healthy controls.
Additionally, we compared the plasma level of M-CSF with the
tumor
stage
of breast
cancer and defined the diagnostic criteria: sensitivity, specificity, the positive and the negative predictive values.
METHODS: M-CSF and CA 15-3 were measured in 80 patients with
breast
cancer, 17 patients with
benign breast
tumor
and in 30 healthy subjects.
RESULTS: There were statistically significant differences in the levels of circulating M-CSF and CA 15-3 in
the breast
cancer patients comparing to the group with
benign breast
tumor
and to the control group.
The levels of M-CSF and CA 15-3 were also significantly higher in patients with more advanced
tumor
stage.
We observed a higher range of the diagnostic sensitivity of M-CSF in more advanced
breast
tumor
stage.
CONCLUSIONS: These results suggest that M-CSF is the good candidate for a
breast
cancer
tumor
marker.
[MeSH-major]
Biomarkers,
Tumor
/ blood.
Breast
Neoplasms
/ blood.
Breast
Neoplasms
/
diagnosis
. Macrophage Colony-Stimulating Factor / blood. Mucin-1 / blood
[MeSH-minor]
Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged.
Neoplasm
Staging. ROC Curve. Reagent Kits, Diagnostic. Sensitivity and Specificity
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16631152.001).
[ISSN]
0009-8981
[Journal-full-title]
Clinica chimica acta; international journal of clinical chemistry
[ISO-abbreviation]
Clin. Chim. Acta
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Reagent Kits, Diagnostic; 81627-83-0 / Macrophage Colony-Stimulating Factor
42.
Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P, Benign Breast Diseases Study Group:
Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
Proc Natl Acad Sci U S A
; 2008 Sep 23;105(38):14533-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of a gain-of-function mutation of the prolactin receptor in women with
benign breast
tumors
.
Given the essential role of this hormonal system in
breast
physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence
of breast
diseases with high proliferative potential.
Multiple fibroadenomas (MFA) are
benign breast
tumors
which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on
the breast
.
Constitutive activity of PrlR(I146L) in
the breast
sample from a patient was supported by increased STAT5 signaling.
[MeSH-major]
Breast
Neoplasms
/ genetics.
Breast
Neoplasms
/ metabolism. Fibroadenoma / genetics. Fibroadenoma / metabolism. Mutation, Missense. Receptors, Prolactin / genetics. Receptors, Prolactin / metabolism
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Guide to Pharmacology.
gene/protein/disease-specific - Prolactin-releasing peptide receptor - overview and references
.
Guide to Pharmacology.
gene/protein/disease-specific - PrRP receptor - data and references
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
SciCrunch.
OMIM: Data: Gene Annotation
.
SciCrunch.
Clinical Genomic Database: Data: Gene Annotation
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Cancer. 2004 Feb 20;108(5):665-71
[
14696092.001
]
[Cites]
Endocrinology. 2006 Sep;147(9):4056-66
[
16809439.001
]
[Cites]
Curr Med Res Opin. 2004 Apr;20(4):533-40
[
15119991.001
]
[Cites]
J Clin Oncol. 2004 Jun 1;22(11):2053-60
[
15169792.001
]
[Cites]
Acta Obstet Gynecol Scand. 1987;66(6):483-8
[
3321867.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4031-5
[
7537382.001
]
[Cites]
Mol Endocrinol. 1996 Jan;10(1):45-56
[
8838144.001
]
[Cites]
J Biol Chem. 1996 Nov 22;271(47):29707-14
[
8939904.001
]
[Cites]
J Clin Endocrinol Metab. 1998 Feb;83(2):667-74
[
9467590.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35
[
16900392.001
]
[Cites]
Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81
[
17024156.001
]
[Cites]
Endocrinology. 2007 Mar;148(3):989-1008
[
17138649.001
]
[Cites]
Br J Cancer. 2007 Mar 12;96(5):841-4
[
17299388.001
]
[Cites]
BMC Med Genet. 2007;8:72
[
18053149.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53
[
18246319.001
]
[Cites]
Oncogene. 2003 Jul 24;22(30):4664-74
[
12879011.001
]
[Cites]
Front Biosci. 2000 Mar 1;5:D343-52
[
10704433.001
]
[Cites]
Nat Struct Biol. 2000 Sep;7(9):808-15
[
10966654.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Aug;86(8):3826-32
[
11502819.001
]
[Cites]
J Endocrinol. 2001 Oct;171(1):R1-4
[
11572805.001
]
[Cites]
J Clin Pathol. 2001 Dec;54(12):956-60
[
11729217.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):49-66
[
12160086.001
]
[Cites]
Endocrine. 2003 Feb-Mar;20(1-2):177-90
[
12668884.001
]
[Cites]
Recent Prog Horm Res. 2003;58:297-323
[
12795425.001
]
[Cites]
J Biol Chem. 2003 Sep 19;278(38):35988-99
[
12824168.001
]
[Cites]
Endocr Rev. 1998 Jun;19(3):225-68
[
9626554.001
]
[Cites]
J Biol Chem. 1999 Apr 9;274(15):10024-34
[
10187780.001
]
[Cites]
J Natl Cancer Inst. 1999 Apr 7;91(7):629-34
[
10203283.001
]
[Cites]
N Engl J Med. 2005 Jul 21;353(3):275-85
[
16034013.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Feb;91(2):555-62
[
16278261.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Apr;91(4):1513-9
[
16434456.001
]
[Cites]
J Endocrinol. 2006 Aug;190(2):271-85
[
16899561.001
]
[Cites]
Biol Reprod. 2004 Mar;70(3):718-28
[
14613905.001
]
(PMID = 18779591.001).
[ISSN]
1091-6490
[Journal-full-title]
Proceedings of the National Academy of Sciences of the United States of America
[ISO-abbreviation]
Proc. Natl. Acad. Sci. U.S.A.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Enzyme Inhibitors; 0 / Receptors, Prolactin; 0 / STAT5 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
[Other-IDs]
NLM/ PMC2567233
[Investigator]
Bachelot A; Belaroussi B; Bensimhon J; Berdah J; Blin MJ; Boudinet A; Brethon B; Bricaire C; Caby J; Caillaud G; Carel JC; Chabbert-Buffet N; Charitanski H; Chretien C; Clough K; Courtillot C; Delattre G; Denys I; Desthieux-Ngo K; Detoeuf M; Dhainault C; Duflos C; Fiori O; Genestie C; Gibaud G; Gompel A; Gracia C; Grimard A; Hofman C; Hofman H; Kuttenn F; Laki F; Lanty C; Lefranc JP; Le Frere-Belda MA; Leger D; Martinez F; May A; Meng L; Nos C; Pelletier D; Perrin A; Plu-Bureau G; Raccah-Tebbeca B; Saiovici JC; Salmon R; Sibout M; Sigal-Zafrani B; Thalabard JC; Thibaud E; Thoury A; Touraine P; Triana-Rabi KB; Uzan S; Viriot J; Yacoub S
43.
Kargozaran H, Yuan SY, Breslin JW, Watson KD, Gaudreault N, Breen A, Wu MH:
A role for endothelial-derived matrix metalloproteinase-2 in breast cancer cell transmigration across the endothelial-basement membrane barrier.
Clin Exp Metastasis
; 2007;24(7):495-502
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A role for endothelial-derived matrix metalloproteinase-2 in
breast
cancer cell transmigration across the endothelial-basement membrane barrier.
The objective of this study was to test the hypothesis that active MMP-2 derived from endothelial cells facilitated the transmigration
of breast
cancer cells across the microvascular barrier.
Gelatin zymography was used to assess latent and active MMP-2 production in conditioned media from MDA-MB-231 human
breast
cancer cells, human lung microvascular endothelial cells (HLMVEC) and co-culture of these two cells.
We suggest that the interaction between malignant cells and peritumoral
benign
tissues including the vascular endothelium may serve as an important mechanism in the regulation of
tumor
invasion and metastasis.
[MeSH-major]
Basement Membrane / physiology.
Breast
Neoplasms
/ blood supply. Cell Movement. Endothelium, Vascular / metabolism. Matrix Metalloproteinase 2 / physiology.
Neoplasm
Metastasis
[MeSH-minor]
Coculture Techniques. Female. Humans.
Neoplasm
Invasiveness. RNA, Small Interfering / pharmacology.
Tumor
Cells, Cultured
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Invest. 1997 May 15;99(10 ):2509-17
[
9153295.001
]
[Cites]
Cancer Res. 1997 May 15;57(10):2055-60
[
9158005.001
]
[Cites]
Int J Cancer. 1999 May 31;81(5):761-6
[
10328230.001
]
[Cites]
Arch Dermatol Res. 2005 Oct;297(4):154-60
[
16047212.001
]
[Cites]
Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H741-50
[
16172166.001
]
[Cites]
Cancer Metastasis Rev. 2006 Mar;25(1):9-34
[
16680569.001
]
[Cites]
J Neurooncol. 2007 Jan;81(1):39-48
[
16850107.001
]
[Cites]
J Biol Chem. 2004 Jan 9;279(2):1562-9
[
14581478.001
]
[Cites]
Cancer Res. 2004 Jan 15;64(2):652-8
[
14744781.001
]
[Cites]
Curr Opin Cell Biol. 1989 Oct;1(5):1009-19
[
2697287.001
]
[Cites]
J Surg Res. 1999 Jun 15;84(2):162-7
[
10357914.001
]
[Cites]
Semin Oncol. 1993 Oct;20(5):538-47
[
7692605.001
]
[Cites]
Am J Physiol Lung Cell Mol Physiol. 2005 Aug;289(2):L217-23
[
15821015.001
]
[Cites]
Microsc Res Tech. 1998 Nov 1;43(3):265-75
[
9840805.001
]
[Cites]
Mol Cancer Ther. 2005 Feb;4(2):281-90
[
15713899.001
]
[Cites]
Clin Exp Metastasis. 2003;20(1):45-50
[
12650606.001
]
[Cites]
Mol Med. 2000 May;6(5):450-60
[
10952024.001
]
[Cites]
Clin Exp Metastasis. 2002;19(1):79-85
[
11918086.001
]
[Cites]
Mol Cancer Res. 2004 Feb;2(2):73-80
[
14985463.001
]
[Cites]
Endocrinology. 2003 May;144(5):1656-63
[
12697668.001
]
[Cites]
Clin Exp Metastasis. 2003;20(5):407-12
[
14524529.001
]
[Cites]
Clin Cancer Res. 1999 Aug;5(8):1982-8
[
10473075.001
]
[Cites]
Ann N Y Acad Sci. 1999 Jun 30;878:647-9
[
10415797.001
]
[Cites]
Breast Cancer Res. 2005;7(5):R661-8
[
16168111.001
]
[Cites]
Genes Dev. 2000 Jan 15;14(2):163-76
[
10652271.001
]
[Cites]
J Histochem Cytochem. 1999 Dec;47(12):1575-80
[
10567441.001
]
[Cites]
Oncogene. 2002 Aug 22;21(37):5765-72
[
12173047.001
]
[Cites]
Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):205-22
[
12784997.001
]
[Cites]
Int J Cancer. 2004 Dec 10;112(5):738-46
[
15386367.001
]
[Cites]
Annu Rev Cell Dev Biol. 2001;17:463-516
[
11687497.001
]
[Cites]
J Biol Chem. 1999 Aug 27;274(35):24930-4
[
10455168.001
]
[Cites]
Clin Exp Metastasis. 1997 Mar;15(2):111-20
[
9062387.001
]
[Cites]
Int J Mol Med. 2006 Apr;17(4):583-90
[
16525713.001
]
[Cites]
Trends Cell Biol. 2001 Nov;11(11):S37-43
[
11684441.001
]
[Cites]
Oncol Res. 1996;8(12):503-11
[
9160354.001
]
[Cites]
Bioessays. 1999 Nov;21(11):940-9
[
10517867.001
]
[Cites]
Microcirculation. 2000 Dec;7(6 Pt 1):395-403
[
11142336.001
]
[Cites]
J Biol Chem. 1995 Mar 10;270(10):5331-8
[
7890645.001
]
[Cites]
Clin Exp Metastasis. 2002;19(8):697-702
[
12553375.001
]
[Cites]
Breast Cancer Res. 2000;2(4):252-7
[
11250717.001
]
[Cites]
Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1057-62
[
14630629.001
]
[Cites]
Biochem Pharmacol. 2004 Feb 15;67(4):643-54
[
14757164.001
]
[Cites]
Drug Discov Today. 2001 May 1;6(9):478-482
[
11344033.001
]
[Cites]
J Biol Chem. 2001 Jun 8;276(23):20458-65
[
11278959.001
]
[Cites]
Circ Res. 2002 Jun 14;90(11):1214-21
[
12065325.001
]
(PMID = 17653824.001).
[ISSN]
0262-0898
[Journal-full-title]
Clinical & experimental metastasis
[ISO-abbreviation]
Clin. Exp. Metastasis
[Language]
eng
[Grant]
United States / NHLBI NIH HHS / HL / HL061507; United States / NHLBI NIH HHS / HL / HL073324; United States / NHLBI NIH HHS / HL / HL084542
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / RNA, Small Interfering; EC 3.4.24.24 / Matrix Metalloproteinase 2
44.
Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE, Lo JY:
Do serum biomarkers really measure breast cancer?
BMC Cancer
; 2009 May 28;9:164
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Do serum biomarkers really measure
breast
cancer?
BACKGROUND: Because screening mammography for
breast
cancer is less effective for premenopausal women, we investigated the feasibility of a diagnostic blood test using serum proteins.
RESULTS: The classifiers were able to distinguish normal tissue from
breast
cancer with a classification performance of AUC = 0.82 +/- 0.04 with the proteins MIF, MMP-9, and MPO.
The classifiers distinguished normal tissue from
benign
lesions similarly at AUC = 0.80 +/- 0.05.
However, the serum proteins
of benign
and malignant lesions were indistinguishable (AUC = 0.55 +/- 0.06).
The classification tasks of normal vs. cancer and normal vs.
benign
selected the same top feature: MIF, which suggests that the biomarkers indicated inflammatory response rather than cancer.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Biomark. 2006;2(6):235-48
[
17264395.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):334-41
[
17301268.001
]
[Cites]
Ann Surg Oncol. 2007 Sep;14(9):2470-6
[
17594124.001
]
[Cites]
Med Decis Making. 2000 Jul-Sep;20(3):323-31
[
10929855.001
]
[Cites]
Med Phys. 2000 Jul;27(7):1509-22
[
10947254.001
]
[Cites]
Semin Oncol. 2001 Feb;28(1):53-67
[
11254867.001
]
[Cites]
Proteomics. 2001 Oct;1(10):1205-15
[
11721633.001
]
[Cites]
Science. 2002 Jun 28;296(5577):2391-4
[
12089442.001
]
[Cites]
Clin Chem. 2002 Aug;48(8):1194-7
[
12142372.001
]
[Cites]
Clin Chem. 2002 Aug;48(8):1296-304
[
12142387.001
]
[Cites]
Cancer Res. 2002 Nov 15;62(22):6740-9
[
12438275.001
]
[Cites]
Expert Opin Ther Targets. 2003 Apr;7(2):153-64
[
12667094.001
]
[Cites]
Proteomics. 2003 Apr;3(4):433-9
[
12687611.001
]
[Cites]
J Neurochem. 2003 Jul;86(2):519-28
[
12871593.001
]
[Cites]
Bioinformatics. 2003 Aug 12;19(12):1484-91
[
12912828.001
]
[Cites]
Thyroid. 2003 Jun;13(6):547-51
[
12930598.001
]
[Cites]
Radiology. 2003 Oct;229(1):3-8
[
14519861.001
]
[Cites]
Med Phys. 2004 Jan;31(1):81-90
[
14761024.001
]
[Cites]
Clin Chem. 2004 Mar;50(3):559-63
[
14726467.001
]
[Cites]
Cancer. 2004 Oct 15;101(8):1767-75
[
15386335.001
]
[Cites]
Anticancer Res. 2004 Sep-Oct;24(5B):3221-4
[
15510614.001
]
[Cites]
Proc Natl Acad Sci U S A. 1976 Dec;73(12):4329-33
[
188033.001
]
[Cites]
Radiology. 1984 Feb;150(2):335-7
[
6691085.001
]
[Cites]
Radiology. 1987 Jan;162(1 Pt 1):167-70
[
3024209.001
]
[Cites]
Invest Radiol. 1988 Oct;23(10):729-33
[
3056868.001
]
[Cites]
Blood. 1989 May 1;73(6):1504-12
[
2653458.001
]
[Cites]
Breast Cancer Res Treat. 1989 Mar;13(2):123-33
[
2730960.001
]
[Cites]
Cancer. 1990 Jan 15;65(2):193-9
[
2295042.001
]
[Cites]
Endocrinol Jpn. 1989 Dec;36(6):873-9
[
2483831.001
]
[Cites]
Immunol Today. 1993 Oct;14(10):506-12
[
7506035.001
]
[Cites]
J Clin Endocrinol Metab. 1995 Mar;80(3):922-6
[
7883851.001
]
[Cites]
J Clin Invest. 1995 Mar;95(3):1370-6
[
7883984.001
]
[Cites]
J Exp Med. 1996 Jan 1;183(1):147-57
[
8551218.001
]
[Cites]
Am J Prev Med. 1996 Sep-Oct;12(5):340-1
[
8909643.001
]
[Cites]
FASEB J. 1996 Dec;10(14):1607-13
[
9002552.001
]
[Cites]
Clin Biochem. 1997 Feb;30(1):53-6
[
9056110.001
]
[Cites]
Infect Immun. 1997 Nov;65(11):4734-7
[
9353058.001
]
[Cites]
Cell. 1998 May 1;93(3):411-22
[
9590175.001
]
[Cites]
Biochimie. 1998 Aug-Sep;80(8-9):673-87
[
9865490.001
]
[Cites]
J Urol. 1999 Aug;162(2):293-306
[
10411025.001
]
[Cites]
Science. 1999 Jul 30;285(5428):727-9
[
10426993.001
]
[Cites]
Oncology. 2004;67(5-6):359-67
[
15713991.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7
[
15824174.001
]
[Cites]
Gynecol Oncol. 2005 May;97(2):529-34
[
15863156.001
]
[Cites]
J Thromb Haemost. 2008 Sep;6(9):1586-94
[
18541003.001
]
[Cites]
Cancer Control. 2007 Oct;14(4):360-8
[
17914336.001
]
[Cites]
Pathol Oncol Res. 2007;13(4):360-4
[
18158573.001
]
[Cites]
J Proteome Res. 2008 Apr;7(4):1508-17
[
18257519.001
]
[Cites]
J Proteome Res. 2008 Apr;7(4):1419-26
[
18303830.001
]
[Cites]
J Proteome Res. 2008 Apr;7(4):1395-402
[
18303834.001
]
[Cites]
Cancer Biomark. 2008;4(2):73-81
[
18503158.001
]
[Cites]
Am J Obstet Gynecol. 2008 Sep;199(3):215-23
[
18468571.001
]
[Cites]
J Proteome Res. 2009 Jan;8(1):362-73
[
19053527.001
]
[Cites]
Cancer Treat Rev. 2000 Apr;26(2):91-102
[
10772967.001
]
[Cites]
Bioinformatics. 2005 May 15;21(10):2394-402
[
15713736.001
]
[Cites]
Intern Med J. 2005 Jul;35(7):419-26
[
15958113.001
]
[Cites]
Tumour Biol. 2005 Nov-Dec;26(6):281-93
[
16254457.001
]
[Cites]
Clin Chem. 2006 Mar;52(3):345-51
[
16410341.001
]
[Cites]
Breast Cancer Res Treat. 2006 Mar;96(1):83-90
[
16322896.001
]
[Cites]
Hell J Nucl Med. 2006 Jan-Apr;9(1):60-4
[
16617400.001
]
[Cites]
BMC Bioinformatics. 2006;7:197
[
16606446.001
]
[Cites]
IEEE Trans Med Imaging. 2006 May;25(5):571-81
[
16689261.001
]
[Cites]
Br J Haematol. 2006 Jun;133(6):692-4
[
16704450.001
]
[Cites]
Brain. 2006 Nov;129(Pt 11):3042-50
[
17071923.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19472-7
[
17159154.001
]
[Cites]
N Engl J Med. 2006 Dec 21;355(25):2631-9
[
17182988.001
]
[Cites]
Proteomics. 2007 Jan;7(2):299-312
[
17205601.001
]
(PMID = 19476629.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA 84955; United States / NCI NIH HHS / CA / R01 CA-112437-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
[Other-IDs]
NLM/ PMC2696469
45.
Huang YD, Zhang S:
[Focal adhesion kinase expression and angiogenesis in breast carcinoma].
Nan Fang Yi Ke Da Xue Xue Bao
; 2007 Sep;27(9):1370-3
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Focal adhesion kinase expression and angiogenesis in
breast
carcinoma].
OBJECTIVE: To investigate the expression of focal adhesion kinase (FAK) in
breast
carcinoma tissues and its association with microvessel density (MVD), and explore the relationship between FAK-mediated cell signaling and angiogenesis in
breast
carcinoma.
METHODS: FAK and CD34 expressions were examined by immunohistochemistry with SP method in 88
breast
carcinoma tissues and 30 tissues
of benign breast
disease.
The correlations of FAK protein expression with MVD marked with CD34 and clinicopathological parameters were analyzed in
breast
carcinoma.
RESULTS: In the 88
breast
carcinomas, the positivity rate of FAK was 68.2% (60/88) with MVD of (34.52-/+13.11) /HPE, showing significant differences from those of the
benign
disease group (P<0.01).
FAK expression and MVD in
breast
carcinoma tissues were positively related to
tumor
size, axillary lymph node metastasis and clinical stage (P<0.05), but not to the patients' age or histopathological grade of the
tumors
(P>0.05).
In
breast
carcinoma, the expression of FAK was positively related to MVD (P<0.01).
CONCLUSIONS: FAK protein expression and MVD are closely correlated with the invasion and metastasis
of breast
carcinoma.
FAK expression can promote angiogenesis
of breast
carcinoma.
[MeSH-major]
Breast
Neoplasms
/ genetics.
Breast
Neoplasms
/ physiopathology. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Gene Expression Regulation, Neoplastic. Neovascularization, Pathologic / metabolism
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Middle Aged.
Neoplasm
Invasiveness / genetics
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17884781.001).
[ISSN]
1673-4254
[Journal-full-title]
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
[ISO-abbreviation]
Nan Fang Yi Ke Da Xue Xue Bao
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases
46.
Weaver J, Billings SD:
Postradiation cutaneous vascular tumors of the breast: a review.
Semin Diagn Pathol
; 2009 Aug;26(3):141-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Postradiation cutaneous vascular
tumors
of the
breast
: a review.
Postradiation vascular
tumors
fall into two categories:.
(1) postradiation cutaneous angiosarcoma, malignant vascular
neoplasms
with significant morbidity and mortality; and (2) atypical vascular lesions (AVL), vascular
tumors
that reportedly behave in a
benign
manner.
Postradiation vascular
tumors
not only present a therapeutic problem for clinicians, but they present an increasingly common diagnostic dilemma for pathologists.
This latter view point is supported by the significant clinical and histologic overlap found between both
tumors
.
[MeSH-major]
Breast
Neoplasms
/ radiotherapy. Hemangiosarcoma / pathology.
Neoplasms
, Radiation-Induced / pathology. Skin
Neoplasms
/ pathology
[MeSH-minor]
Adult. Aged. Female. Humans. Middle Aged.
Neoplasm
Recurrence, Local. Prognosis
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20043513.001).
[ISSN]
0740-2570
[Journal-full-title]
Seminars in diagnostic pathology
[ISO-abbreviation]
Semin Diagn Pathol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
21
47.
Eloubeidi MA, Cerfolio RJ, Chen VK, Desmond R, Syed S, Ojha B:
Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans.
Ann Thorac Surg
; 2005 Jan;79(1):263-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The reference standard included thoracotomy with complete lymphadenectomy in patients with lung cancer or if EUS-FNA was
benign
, repeat clinical imaging, or long-term follow-up.
[MeSH-major]
Biopsy, Fine-Needle. Carcinoma, Non-Small-Cell Lung / secondary. Esophagoscopy. Lung
Neoplasms
/ pathology. Lymphatic Diseases / pathology. Lymphatic Metastasis / pathology.
Neoplasm
Staging / methods. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Interventional
[MeSH-minor]
Aged.
Breast
Neoplasms
/ pathology. Carcinoma / pathology. Carcinoma / radiography. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma / ultrasonography. Colonic
Neoplasms
/ pathology. Endometrial
Neoplasms
/ pathology. Female. Fluorodeoxyglucose F18. Granuloma /
diagnosis
. Histiocytosis / complications. Histiocytosis /
diagnosis
. Histoplasmosis / complications. Histoplasmosis /
diagnosis
. Humans. Kidney
Neoplasms
/ pathology. Lung Diseases / complications. Lymphoma / pathology. Lymphoma / radiography. Lymphoma / radionuclide imaging. Lymphoma / ultrasonography. Male. Mediastinum. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sarcoidosis / complications. Sarcoidosis /
diagnosis
. Silicosis / complications. Silicosis /
diagnosis
. Urinary Bladder
Neoplasms
/ pathology
Genetic Alliance.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Lymphatic Diseases
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15620955.001).
[ISSN]
1552-6259
[Journal-full-title]
The Annals of thoracic surgery
[ISO-abbreviation]
Ann. Thorac. Surg.
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
48.
Maxwell AJ:
Ultrasound-guided vacuum-assisted excision of breast papillomas: review of 6-years experience.
Clin Radiol
; 2009 Aug;64(8):801-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Ultrasound-guided vacuum-assisted excision
of breast
papillomas: review of 6-years experience.
AIM: To review the outcome of vacuum-assisted removal
of breast
papillomas performed in the Bolton
Breast
Unit.
MATERIALS AND METHODS: Twenty-six
benign breast
papillomas were excised using an ultrasound-guided, vacuum-assisted technique under local anaesthetic over a 6-year period.
Subsequent
breast
imaging (mostly routine screening mammography) was reviewed and evidence of recurrence recorded.
All three recurrent lesions were surgically excised and confirmed to be
benign
papillomas.
[MeSH-major]
Breast
Neoplasms
/ surgery. Papilloma, Intraductal / surgery. Ultrasonography, Interventional
[MeSH-minor]
Aged. Biopsy / methods.
Breast
/ pathology. Female. Humans. Middle Aged.
Neoplasm
Recurrence, Local / surgery.
Neoplasm
Recurrence, Local / ultrasonography. Treatment Outcome. Ultrasonography, Mammary. Vacuum
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19589419.001).
[ISSN]
1365-229X
[Journal-full-title]
Clinical radiology
[ISO-abbreviation]
Clin Radiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
49.
Hirshoren N, Weinberger JM, Neuman T, Ilan O, Ben-Yaakov A:
Recurrent vascular leiomyoma of the larynx: clinical and histopathologic characteristics and treatment.
Ear Nose Throat J
; 2010 Aug;89(8):382-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Laryngeal vascular leiomyomas are uncommon
benign
tumors
that seldom recur following complete excision.
The choice of excision procedure-via direct laryngoscopy or an open approach-is dictated by
tumor
size, the expected amount of blood loss, and any comorbidities the patient may have.
We report an unusual case of a recurrent laryngeal vascular leiomyoma in a 64-year-old woman who also had a concurrent parathyroid adenoma and a history
of breast
carcinoma.
[MeSH-major]
Angiomyoma / surgery. Laryngeal
Neoplasms
/ surgery.
Neoplasm
Recurrence, Local / surgery
[MeSH-minor]
Adenoma / surgery. Female. Humans. Laryngoscopy. Larynx / pathology. Laser Therapy. Magnetic Resonance Imaging. Medical Records. Middle Aged.
Neoplasms
, Multiple Primary / surgery. Parathyroid
Neoplasms
/ surgery. Reoperation. Respiration Disorders / etiology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20737377.001).
[ISSN]
1942-7522
[Journal-full-title]
Ear, nose, & throat journal
[ISO-abbreviation]
Ear Nose Throat J
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
50.
Tozaki M, Yamashiro N, Suzuki T, Kawano N, Ozaki S, Sakamoto N, Abe S, Ogawa T, Katayama N, Tsunoda Y, Fukuma E:
MR-guided vacuum-assisted breast biopsy: is it an essential technique?
Breast Cancer
; 2009;16(2):121-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MR-guided vacuum-assisted
breast
biopsy: is it an essential technique?
Histopathological findings were invasive ductal carcinoma in one (3%); ductal carcinoma in situ (DCIS) in seven (23%); and
benign
in 22 (73%).
[MeSH-major]
Breast
/ pathology.
Breast
Neoplasms
/ pathology. Carcinoma, Ductal,
Breast
/ pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Magnetic Resonance Imaging
[MeSH-minor]
Adult. Aged. Biopsy, Needle / instrumentation. Biopsy, Needle / methods. Female. Humans. Mammography / instrumentation. Middle Aged.
Neoplasm
Staging. Prognosis. Retrospective Studies
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18807122.001).
[ISSN]
1880-4233
[Journal-full-title]
Breast cancer (Tokyo, Japan)
[ISO-abbreviation]
Breast Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
51.
Tse GM, Niu Y, Shi HJ:
Phyllodes tumor of the breast: an update.
Breast Cancer
; 2010;17(1):29-34
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phyllodes
tumor
of the
breast
: an update.
Phyllodes
tumor
is an uncommon biphasic
breast
tumor
, with the ability to recur and metastasize, and it behaves biologically like a stromal
neoplasm
.
Traditionally, phyllodes
tumors
are graded by the use of a set of histologic data into
benign
, borderline, and malignant.
In most series, all phyllodes
tumors
may recur, but only the borderline and malignant phyllodes
tumors
metastasize.
The expression of many biological markers, including p53, hormone receptors, proliferation markers, angiogenesis group of markers, c-kit, CD10 and epidermal growth factor receptor have been explored, and many have been shown to be variably expressed, depending on the grade of the
tumor
.
These markers are, however, of limited value in predicting the behavior of the
tumor
.
Recently investigators have reported a plethora of genetic changes in phyllodes
tumors
, the most consistent of which seems to be 1q gain by comparative genomic hybridization.
It is foreseeable that more exciting data will be generated to help us to understand the etiology and pathogenesis of phyllodes
tumor
.
[MeSH-major]
Biomarkers,
Tumor
/ metabolism.
Breast
Neoplasms
/ pathology. Phyllodes
Tumor
/ pathology
[MeSH-minor]
Female. Humans.
Neoplasm
Staging. Prognosis
Genetic Alliance.
consumer health - Phyllodes Tumor
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19434472.001).
[ISSN]
1880-4233
[Journal-full-title]
Breast cancer (Tokyo, Japan)
[ISO-abbreviation]
Breast Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Biomarkers, Tumor
52.
Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ:
Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
Arch Pathol Lab Med
; 2006 Oct;130(10):1516-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phyllodes
tumor
: a clinicopathologic and immunohistochemical study of 30 cases.
CONTEXT: Phyllodes
tumors
(PTs) of the
breast
are biphasic
neoplasms
composed of epithelium and a spindle-cell stroma.
Currently, PTs are classified as
benign
, borderline, or malignant based on histopathologic features.
DESIGN: Sixteen
benign
, 8 borderline, and 6 malignant PTs with follow-up were examined for reactivity across a panel of immunohistochemical stains, including c-Kit, endothelin 1, p16, p21, p53, and Ki-67.
Tumor
variables were compared among
tumor
subgroups and between
tumors
that did and did not recur.
RESULTS: Of the 30 PTs, 4 recurred (1
benign
, 2 borderline, 1 malignant).
One patient with a malignant
tumor
died of metastatic disease 34 months after initial
diagnosis
.
The overall positive rate of c-Kit immunoreactivity was 13% in
benign
, 63% in borderline, and 67% in malignant PTs.
Endothelin 1 epithelial cytoplasmic staining was seen in 100%
of benign
, 50% of borderline, and 17% of malignant PTs.
Additionally, p16, p21, p53, and Ki-67 were differentially expressed among
benign
, borderline, and malignant
tumors
.
CONCLUSIONS: Stromal c-Kit positivity and epithelial endothelin 1 negativity are more often associated with malignant PTs; however, only positive margin status is significantly associated with
tumor
behavior.
[MeSH-major]
Breast
Neoplasms
/ metabolism.
Breast
Neoplasms
/ pathology. Phyllodes
Tumor
/ metabolism. Phyllodes
Tumor
/ pathology
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Biomarkers,
Tumor
/ metabolism. Disease Progression. Endothelin-1 / metabolism. Epithelium / metabolism. Female. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. Mastectomy. Mastectomy, Segmental. Middle Aged.
Neoplasm
Recurrence, Local. Prognosis. Proto-Oncogene Proteins c-kit / metabolism. Staining and Labeling.
Tumor
Suppressor Protein p53 / metabolism
Genetic Alliance.
consumer health - Phyllodes Tumor
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17090194.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Endothelin-1; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
53.
Oo KZ, Xiao PQ:
Infiltrating syringomatous adenoma of the nipple: clinical presentation and literature review.
Arch Pathol Lab Med
; 2009 Sep;133(9):1487-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Infiltrating syringomatous adenoma of the nipple is a rare
neoplasm of the breast
.
Despite its
benign
behavior, syringomatous adenoma of the nipple usually shows infiltrative expansile proliferation into adjacent tissue and underlying
breast
tissue.
Histologically and clinically, syringomatous adenoma of the nipple is often confused with tubular carcinoma as well as low-grade adenosquamous carcinoma of the
breast
.
Special attention given to this
tumor
by pathologists and clinicians can avoid misdiagnosis and unnecessary treatment.
[MeSH-major]
Breast
Neoplasms
/ pathology. Nipples / pathology. Sweat Gland
Neoplasms
/ pathology. Syringoma / pathology
[MeSH-minor]
Adenocarcinoma /
diagnosis
. Adolescent. Adult. Aged. Child.
Diagnosis
, Differential. Female. Humans. Middle Aged. Young Adult
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19722761.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
16
54.
Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H:
Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
BMC Cancer
; 2009;9:72
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The purpose of this study was to evaluate the expression of topoIIalpha in various types of salivary gland
tumors
and its biological significance.
METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20
benign
tumors
(10 pleomorphic adenomas and 10 Warthin's
tumors
).
RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all
benign
tumors
were negative (p < 0.001).
[MeSH-major]
Antigens,
Neoplasm
/ biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Salivary Gland
Neoplasms
/ enzymology
MedlinePlus Health Information.
consumer health - Salivary Gland Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Head Neck. 2000 Aug;22(5):489-97
[
10897109.001
]
[Cites]
Head Neck. 2008 May;30(5):680-3
[
17972317.001
]
[Cites]
Clin Cancer Res. 2002 Apr;8(4):1061-7
[
11948114.001
]
[Cites]
Clin Cancer Res. 2002 May;8(5):1107-16
[
12006526.001
]
[Cites]
Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40
[
12042765.001
]
[Cites]
Lancet Oncol. 2002 Apr;3(4):235-43
[
12067686.001
]
[Cites]
ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32
[
12624503.001
]
[Cites]
Am J Clin Pathol. 2003 May;119(5):715-22
[
12760291.001
]
[Cites]
Clin Cancer Res. 2003 Oct 15;9(13):4682-8
[
14581337.001
]
[Cites]
Int J Oncol. 2004 Jan;24(1):201-9
[
14654958.001
]
[Cites]
Anticancer Res. 2003 Sep-Oct;23(5A):3965-70
[
14666704.001
]
[Cites]
Clin Cancer Res. 2004 Feb 1;10(3):944-6
[
14871971.001
]
[Cites]
J Otolaryngol. 2003 Oct;32(5):328-31
[
14974865.001
]
[Cites]
Mod Pathol. 2004 Jun;17(6):637-45
[
15044918.001
]
[Cites]
Arch Otolaryngol. 1984 Mar;110(3):172-6
[
6322732.001
]
[Cites]
Cancer. 1984 Sep 15;54(6):1062-9
[
6088017.001
]
[Cites]
Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683
[
9597678.001
]
[Cites]
Pathol Res Pract. 2005;200(11-12):791-9
[
15792122.001
]
[Cites]
Breast Cancer Res. 2005;7(3):R374-84
[
15987433.001
]
[Cites]
J Clin Oncol. 2006 Jun 10;24(17):2673-8
[
16763282.001
]
[Cites]
Cancer Treat Rev. 2007 Feb;33(1):64-77
[
17113234.001
]
[Cites]
Oral Oncol. 2007 Sep;43(8):735-41
[
17113340.001
]
[Cites]
Head Neck. 2007 Nov;29(11):1002-9
[
17427971.001
]
[Cites]
Hum Pathol. 2001 Jun;32(6):596-604
[
11431714.001
]
(PMID = 19250538.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
[Other-IDs]
NLM/ PMC2654461
55.
Chan E, Nimnual AS:
Deregulation of the cell cycle by breast tumor kinase (Brk).
Int J Cancer
; 2010 Dec 1;127(11):2723-31
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Deregulation of the cell cycle by
breast
tumor
kinase (Brk).
Brk is a cytoplasmic nonreceptor tyrosine kinase that is overexpressed in
breast
tumors
but undetectable in normal or
benign
mammary tissues.
Brk promotes proliferation of human mammary epithelial cells and
tumor
growth in a mouse model, but the role of Brk in cell cycle regulation is not known.
Deregulation of the cell cycle is a key event in
neoplasia
, and thus, the mechanism presented here likely contributes to
breast
cancer development.
[MeSH-major]
Breast
Neoplasms
/ enzymology.
Breast
Neoplasms
/ pathology. Cell Cycle / physiology.
Neoplasm
Proteins / metabolism. Protein-Tyrosine Kinases / metabolism
[MeSH-minor]
Cell Growth Processes / physiology. Cell Line,
Tumor
. Cell Nucleus / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Down-Regulation. Female. Forkhead Transcription Factors / antagonists & inhibitors. Forkhead Transcription Factors / genetics. Forkhead Transcription Factors / metabolism. G1 Phase / physiology. Humans. RNA, Small Interfering / administration & dosage. RNA, Small Interfering / genetics. S Phase / physiology. Transfection
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20162673.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / FOXO3 protein, human; 0 / Forkhead Transcription Factors; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / PTK6 protein, human
56.
Pierce A, Saldova R, Abd Hamid UM, Abrahams JL, McDermott EW, Evoy D, Duffy MJ, Rudd PM:
Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients.
Glycobiology
; 2010 Oct;20(10):1283-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative
breast
cancer patients.
One of the most urgent requirements in
breast
cancer is the development of a blood-based test for early detection and prognosis.
Previously published results found a significant difference between specific glycan levels in patients with advanced
breast
cancer and healthy controls.
Agalactosyl biantennary glycans (FA2) and glycans containing the sialyl Lewis x epitope (A3F1G1 and A2F1G1) were measured using high throughput normal-phase high-performance liquid chromatography in combination with exoglycosidase digestions in sera from 52 patients with early
breast
cancer (21 with lymph node-negative and 20 with lymph node-positive disease) and 134 women with
benign breast
disease.
Lymph node status is the single most important determinant of survival in early stage
breast
cancer.
As high levels of these glycans were associated with nodal metastases, their measurement may provide a new non-invasive approach to determining prognosis in women with newly diagnosed
breast
cancer.
[MeSH-major]
Adenocarcinoma, Mucinous / blood.
Breast
Neoplasms
/ blood. Carcinoma, Ductal,
Breast
/ blood. Carcinoma, Lobular / blood. Lymph Nodes / metabolism. Polysaccharides / blood
[MeSH-minor]
Antigens, CD15 / blood. Axilla. Chromatography, High Pressure Liquid. Female. Humans. Lymphatic Metastasis. Middle Aged.
Neoplasm
Staging. Prognosis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20581008.001).
[ISSN]
1460-2423
[Journal-full-title]
Glycobiology
[ISO-abbreviation]
Glycobiology
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD15; 0 / Polysaccharides; 0 / sialyl Lewis X antigen
57.
Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, Cramer D:
p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Cancer Epidemiol Biomarkers Prev
; 2010 Mar;19(3):859-68
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This group included women subsequently diagnosed with invasive serous ovarian cancer (n = 60), nonserous ovarian cancers (n = 30), and women with
benign
disease (n = 30).
RESULTS: p53-AAb were detected in 25 of 60 (41.7%) of serous cases, 4 of 30 (13.3%) nonserous cases, 3 of 30 (10%)
benign
disease cases, and 10 of 120 (8.3%) controls (combined P = 0.0002).
p53-AAb did not significantly improve the detection of cases [area under the curve (AUC), 0.69] or the discrimination
of benign
versus malignant disease (AUC, 0.64) compared with CA 125 (AUC, 0.99) or HE4 (AUC, 0.98).
In multivariate analysis among cases, p53-AAb correlated only with a family history
of breast
cancer (P = 0.01).
Genetic Alliance.
consumer health - Ovarian cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81
[
18843033.001
]
[Cites]
Clin Cancer Res. 2008 Sep 15;14(18):5785-93
[
18794088.001
]
[Cites]
Gynecol Oncol. 2009 Jan;112(1):40-6
[
18851871.001
]
[Cites]
Gynecol Oncol. 2009 Jul;114(1):12-7
[
19398128.001
]
[Cites]
Gynecol Oncol. 2009 Jan;112(1):47-54
[
19007974.001
]
[Cites]
Oncology. 1999 Nov;57(4):324-9
[
10575320.001
]
[Cites]
Clin Biochem. 2000 Feb;33(1):53-62
[
10693987.001
]
[Cites]
Cancer. 2000 Mar 15;88(6):1432-7
[
10717627.001
]
[Cites]
Cancer Res. 2000 Apr 1;60(7):1777-88
[
10766157.001
]
[Cites]
Br J Cancer. 2000 Nov;83(10):1338-43
[
11044359.001
]
[Cites]
Gynecol Oncol. 2001 Feb;80(2):189-93
[
11161858.001
]
[Cites]
Cancer. 2003 Jan 15;97(2):389-404
[
12518363.001
]
[Cites]
Hum Mutat. 2003 Mar;21(3):285-91
[
12619114.001
]
[Cites]
Cancer Detect Prev. 2003;27(3):182-6
[
12787724.001
]
[Cites]
J Clin Oncol. 2003 Nov 1;21(21):3940-7
[
12975461.001
]
[Cites]
Cancer Immunol Immunother. 2003 Dec;52(12):715-38
[
12920480.001
]
[Cites]
Clin Cancer Res. 2003 Nov 1;9(14):5120-6
[
14613989.001
]
[Cites]
J Proteome Res. 2004 Mar-Apr;3(2):261-7
[
15113102.001
]
[Cites]
Dis Markers. 2004;20(2):53-70
[
15322314.001
]
[Cites]
J Natl Cancer Inst. 1988 Apr 6;80(3):208-9
[
3162284.001
]
[Cites]
J Immunol. 1991 Aug 15;147(4):1338-43
[
1831223.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3439-42
[
1373500.001
]
[Cites]
JAMA. 1993 Mar 3;269(9):1123-6
[
8433467.001
]
[Cites]
J Clin Oncol. 1995 Jan;13(1):70-8
[
7799045.001
]
[Cites]
Cancer Detect Prev. 1995;19(2):151-5
[
7750102.001
]
[Cites]
Cancer. 1995 Oct 1;76(7):1201-8
[
8630898.001
]
[Cites]
Cancer. 1996 Nov 15;78(10):2146-52
[
8918407.001
]
[Cites]
Gynecol Oncol. 1999 Jan;72(1):76-81
[
9889034.001
]
[Cites]
Anticancer Res. 1999 Jan-Feb;19(1B):875-8
[
10216509.001
]
[Cites]
Int J Gynecol Cancer. 2004 Nov-Dec;14(6):1086-96
[
15571614.001
]
[Cites]
J Proteome Res. 2005 Jul-Aug;4(4):1123-33
[
16083262.001
]
[Cites]
N Engl J Med. 2005 Sep 22;353(12):1224-35
[
16177248.001
]
[Cites]
Cancer Res. 2006 Jan 15;66(2):1181-90
[
16424057.001
]
[Cites]
J Clin Oncol. 2006 Feb 10;24(5):762-8
[
16391298.001
]
[Cites]
Br J Cancer. 2006 Sep 4;95(5):627-33
[
16880779.001
]
[Cites]
J Pathol. 2007 Jan;211(1):26-35
[
17117391.001
]
[Cites]
Arthritis Res Ther. 2006;8(4):R109
[
16846526.001
]
[Cites]
J Immunol. 2007 Mar 15;178(6):3831-6
[
17339482.001
]
[Cites]
Ann Oncol. 2007 May;18(5):868-73
[
17347129.001
]
[Cites]
Int J Cancer. 2007 Aug 1;121(3):606-14
[
17415711.001
]
[Cites]
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8
[
17671125.001
]
[Cites]
Nat Med. 2007 Sep;13(9):1050-9
[
17704786.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17494-9
[
17954908.001
]
[Cites]
Clin Cancer Res. 2007 Dec 1;13(23):6984-92
[
18056174.001
]
[Cites]
Gynecol Oncol. 2007 Dec;107(3):526-31
[
17920110.001
]
[Cites]
Dis Markers. 2007;23(5-6):397-410
[
18057523.001
]
[Cites]
Clin Cancer Res. 2008 Jan 1;14(1):89-96
[
18172257.001
]
[Cites]
Clin Cancer Res. 2008 Feb 1;14(3):764-71
[
18245537.001
]
[Cites]
J Proteome Res. 2008 Apr;7(4):1490-9
[
18311903.001
]
[Cites]
PLoS One. 2008;3(7):e2633
[
18612378.001
]
[Cites]
Gynecol Oncol. 2008 Sep;110(3):365-73
[
18571704.001
]
[Cites]
Am J Surg Pathol. 2008 Nov;32(11):1667-74
[
18769340.001
]
(PMID = 20200435.001).
[ISSN]
1538-7755
[Journal-full-title]
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
[ISO-abbreviation]
Cancer Epidemiol. Biomarkers Prev.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U01 CA117374-05; United States / NCI NIH HHS / CA / U01 CA117374; United States / NCI NIH HHS / CA / U01 CA086381-05; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / UO1 CA086381; United States / NCI NIH HHS / CA / CA117374-05; United States / NCI NIH HHS / CA / CA086381-05
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / Tumor Suppressor Protein p53; 0 / beta-Defensins
[Other-IDs]
NLM/ NIHMS174572; NLM/ PMC2838192
58.
Stolnicu S, Rădulescu D, Pleşea IE, Dobru D, Podoleanu C, Pintilei DR:
The value of intraoperative diagnosis in breast lesions.
Rom J Morphol Embryol
; 2006;47(2):119-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The value of intraoperative
diagnosis
in
breast
lesions.
Frozen section examination is aimed at making a preoperative
diagnosis
, determining
the benign
or malignant nature of a
breast
lesion, but also the most suitable surgical procedure.
The sensitivity and specificity of this method and the causes of discrepancies were analyzed in a retrospective study of 2 177
breast
lesions.
METHOD: 1,150 frozen sections from 2,177
breast
lesions were performed in the interval 1999-2005.
The following terms were used for describing the intraoperative
diagnosis
: negative, positive, and await paraffin section.
After the frozen section
diagnosis
was made, the frozen tissue was thawed to room temperature and fixed in formalin overnight for further paraffin processing.
In 7% of the cases the
diagnosis
could not be made on frozen section.
CONCLUSIONS: Despite the raging popularity of aspiration cytology, frozen section still stands out as the method of choice for rapid
diagnosis
.
[MeSH-major]
Breast
Diseases / surgery.
Breast
Neoplasms
/ surgery
[MeSH-minor]
Carcinoma in Situ / pathology. Fibrocystic
Breast
Disease / pathology. Humans. Intraoperative Period.
Neoplasm
Invasiveness. Retrospective Studies
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17106518.001).
[ISSN]
1220-0522
[Journal-full-title]
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
[ISO-abbreviation]
Rom J Morphol Embryol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Romania
59.
Zakaria S, Pantvaidya G, Ghosh K, Degnim AC:
Paget's disease of the breast: accuracy of preoperative assessment.
Breast Cancer Res Treat
; 2007 Apr;102(2):137-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Paget's disease of the
breast
: accuracy of preoperative assessment.
BACKGROUND: Routine preoperative assessment may not accurately assess the extent of underlying cancer in patients with Paget's disease (PD) of the
breast
.
In the subgroup of 40 women with a
benign
mammogram and no palpable mass, invasive cancer occurred in 5% and the majority (68%) had ductal carcinoma in situ which extended beyond the nipple.
Women with a palpable mass and a suspicious mammogram had significantly worse survival compared to those with a
benign
mammogram and no palpable mass (P = 0.008).
Underlying cancer is common even in women with a
benign
mammogram and no palpable mass.
Although
breast
conservation is an attractive option in patients with PD, mammography and physical exam may significantly underestimate the presence and extent of underlying disease.
[MeSH-major]
Breast
Neoplasms
/
diagnosis
. Paget's Disease, Mammary /
diagnosis
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Axilla. Carcinoma, Ductal,
Breast
/
diagnosis
. Carcinoma, Ductal,
Breast
/ surgery. Carcinoma, Intraductal, Noninfiltrating /
diagnosis
. Carcinoma, Intraductal, Noninfiltrating / surgery. Female. Humans. Lymphatic Metastasis. Mammography. Middle Aged.
Neoplasm
Invasiveness.
Neoplasm
Staging. Preoperative Care. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Mammary
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17028984.001).
[ISSN]
0167-6806
[Journal-full-title]
Breast cancer research and treatment
[ISO-abbreviation]
Breast Cancer Res. Treat.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
60.
Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A:
Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
Mod Pathol
; 2006 Feb;19(2):307-19
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal,
benign
and malignant
breast
tissue.
NGFR is reported to act as a
tumour
suppressor, negatively regulating cell growth and proliferation.
NGFR expression was immunohistochemically analysed in normal
breast
tissue and in 140
benign
, biphasic and preinvasive
breast
lesions, in 22
tumours
with myoepithelial differentiation and in two cohorts
of breast
cancer patients: a series of 245 invasive
breast
carcinomas studied with tissue microarrays and 37 high-grade invasive ductal carcinomas with basal-like immunophenotype.
Myoepithelial cells
of benign
proliferations and pre-invasive lesions were consistently positive for NGFR.
Positivity for NGFR was observed in 11 out of 245 (4.5%)
breast
carcinomas, nine out of 20 (45%) metaplastic
breast
carcinomas and 14 out of 37 (38%) basal-like
breast
carcinomas.
NGFR expression in invasive
tumours
significantly correlated with that of cytokeratins 5/6 (P<0.05), 14 (P<0.0001) and 17 (P<0.0005) and EGFR (P<0.0001) and displayed an inverse correlation with oestrogen and progesterone receptors (both, P<0.0001).
This study demonstrates the usefulness of NGFR as a new adjunct marker to identify myoepithelial cells in preinvasive lesions and myoepithelial differentiation in
breast
carcinomas.
Furthermore, provisional data in a small number of basal-like
breast
carcinomas suggest that NGFR may identify a subgroup of basal-like
breast
carcinomas with good prognosis.
[MeSH-major]
Breast
/ pathology.
Breast
Neoplasms
/ pathology. Nerve Tissue Proteins / analysis. Receptors, Growth Factor / analysis
[MeSH-minor]
Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic
Breast
Disease / metabolism. Fibrocystic
Breast
Disease / pathology. Humans. Immunohistochemistry. Keratin-14. Keratin-5. Keratin-6. Keratins / analysis. Myoepithelioma / metabolism. Myoepithelioma / pathology.
Neoplasm
Invasiveness. Receptors, Estrogen / analysis. Receptors, Nerve Growth Factor. Receptors, Progesterone / analysis. Survival Analysis
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16424897.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / KRT14 protein, human; 0 / KRT5 protein, human; 0 / KRT6A protein, human; 0 / KRT6B protein, human; 0 / KRT6C protein, human; 0 / Keratin-14; 0 / Keratin-5; 0 / Keratin-6; 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Growth Factor; 0 / Receptors, Nerve Growth Factor; 0 / Receptors, Progesterone; 68238-35-7 / Keratins
61.
Fon LJ, Lioe TF, Mulligan KA, Johnston PG, McCormick D, Spence RA:
Prognostic significance of glycoprotein pMQ1 in breast cancer.
Br J Surg
; 2006 Mar;93(3):309-14
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic significance of glycoprotein pMQ1 in
breast
cancer.
Cerebral metastases from
breast
cancer have also been found to contain pMQ1-positive cells.
This study aimed to determine the role of pMQ1 in primary
breast
cancer.
METHODS:
Breast
cancer specimens were analysed for pMQ1 by immunohistochemistry.
Kaplan-Meier analyses were performed to compare clinical outcome between pMQ1-positive and pMQ1-negative
tumours
.
RESULTS: pMQ1 was expressed in most of the
breast
cancer specimens.
The surrounding normal tissue margins and
benign breast
tissues always lacked pMQ1 expression.
CONCLUSION: pMQ1 appears to be a
tumour
-associated protein.
[MeSH-major]
Breast
Neoplasms
/ chemistry. Glycoproteins / analysis.
Neoplasm
Proteins / analysis
[MeSH-minor]
Adult. Aged.
Breast
/ chemistry. Female. Follow-Up Studies. Humans. Ki-67 Antigen / analysis. Lymphatic Metastasis. Middle Aged.
Neoplasm
Recurrence, Local / pathology.
Neoplasm
Staging. Prognosis. Receptors, Estrogen / analysis.
Tumor
Suppressor Protein p53 / analysis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
(PMID = 16392102.001).
[ISSN]
0007-1323
[Journal-full-title]
The British journal of surgery
[ISO-abbreviation]
Br J Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Tumor Suppressor Protein p53; 0 / pMQ1 glycoprotein, human
62.
Sandhya B, Babu V, Parthasarathy G, Kate V, Ananthakrishnan N, Krishnan R:
Primary leiomyosarcoma of the breast: A case report and review of literature.
Indian J Surg
; 2010 Jul;72(Suppl 1):286-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary leiomyosarcoma of the
breast
: A case report and review of literature.
Leiomyosarcomas of the
breast
are rare
tumours
.
We describe herein a case of primary leiomyosarcoma of the
breast
in a 54-year-old woman whose preoperative clinical and cytological findings indicated a
benign breast
tumour
.
Histopathological examination of the mastectomy specimen suggested a
diagnosis
of leiomyosarcoma, which was subsequently confirmed by immunohistochemical analysis.
Primary leiomyosarcoma of the
breast
is very rare and is difficult to diagnose preoperatively as it needs immuno-histochemical staining.
It is necessary to excise the
tumour
with sufficient margins to prevent local recurrence.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Surg Today. 1997;27(11):1082-5
[
9413066.001
]
[Cites]
Pathol Oncol Res. 2001;7(2):151-3
[
11458280.001
]
[Cites]
Surg Today. 2002;32(8):716-9
[
12181723.001
]
[Cites]
Arch Gynecol Obstet. 2003 Feb;267(4):233-5
[
12592426.001
]
[Cites]
Breast J. 2003 Nov-Dec;9(6):494-6
[
14616945.001
]
[Cites]
Diagn Cytopathol. 2003 Sep;29(3):172-8
[
12951688.001
]
[Cites]
Acta Cytol. 2003 Sep-Oct;47(5):783-6
[
14526679.001
]
(PMID = 23133273.001).
[ISSN]
0972-2068
[Journal-full-title]
The Indian journal of surgery
[ISO-abbreviation]
Indian J Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Other-IDs]
NLM/ PMC3451846
[Keywords]
NOTNLM ; Breast / Phyllodes Sandhya / Stromal tumours
63.
Giorgi Rossi P, Chini F, Barca A, Baiocchi D, Federici A, Farchi S, Borgia P:
Efficacy of disease management profiles. The mammographic screening program of Lazio.
Tumori
; 2008 May-Jun;94(3):297-303
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHOD: In the study period (1/7/99-30/6/01), six
breast
cancer screening programs were active in 12 health districts in the Lazio region of Italy.
Screening histories of all the incident cases of women surgically treated for a
breast neoplasm
were reconstructed (not contacted, contacted, non-participants, participants).
RESULTS: We identified 3251 women who were treated for malignant
neoplasms
of the
breast
and 1562 treated for
benign
neoplasms
.
The incidence of malignant
neoplasms
was higher in the women contacted for screening (incidence rate ratio, 1.45; 95% CI, 1.32-1.60), and the incidence of treatment for non-malignancies was similar in the two populations (incidence rate ratio, 1.00: 95% CI, 0.86-1.16).
Women contacted for screening showed a higher incidence of localized and in situ
tumors
, whereas the incidence of non-localized and metastatic
tumors
was basically the same in the two groups.
CONCLUSIONS: The first round of screening programs led to more surgical interventions, a similar incidence of mastectomy and of interventions for
benign neoplasm
, but a lower incidence of unnecessary treatment.
[MeSH-major]
Breast
Neoplasms
/ diagnostic imaging.
Breast
Neoplasms
/ surgery. Mammography. Mass Screening. Mastectomy / methods
[MeSH-minor]
Aged. Carcinoma in Situ / diagnostic imaging. Carcinoma in Situ / surgery. Early
Diagnosis
. Female. Humans. Incidence. Italy / epidemiology. Middle Aged.
Neoplasm
Staging. Odds Ratio. Program Evaluation. Research Design
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Mammography
.
MedlinePlus Health Information.
consumer health - Mastectomy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18705394.001).
[ISSN]
0300-8916
[Journal-full-title]
Tumori
[ISO-abbreviation]
Tumori
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
64.
Da Silva L, Buck L, Simpson PT, Reid L, McCallum N, Madigan BJ, Lakhani SR:
Molecular and morphological analysis of adenoid cystic carcinoma of the breast with synchronous tubular adenosis.
Virchows Arch
; 2009 Jan;454(1):107-14
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Molecular and morphological analysis of adenoid cystic carcinoma of the
breast
with synchronous tubular adenosis.
Adenoid cystic carcinoma (ACC) of the
breast
is a rare
tumour
.
Its recognition as a special type
of breast
carcinoma is very important because its prognosis is better than the not-otherwise-specified invasive ductal carcinoma and its treatment may not include axillary dissection.
Tubular adenosis (TA) is a very rare condition of the
breast
that is histologically
benign
; however, it has been described in association with invasive ductal carcinoma.
There are scant data regarding the molecular genomic alterations in ACC of the
breast
and no data has been presented on TA.
Herein, we provide a morphological characterisation of TA arising synchronically with ACC in
the breast
.
These molecular data highlight the genomic instability of TA, a
benign
florid proliferation intermingled with ACC, and do not provide evidence of molecular evolution from TA to ACC.
[MeSH-major]
Breast
Neoplasms
/ complications.
Breast
Neoplasms
/ pathology. Carcinoma, Adenoid Cystic / complications. Carcinoma, Adenoid Cystic / pathology. Fibrocystic
Breast
Disease / complications. Fibrocystic
Breast
Disease / pathology
[MeSH-minor]
Actins / metabolism.
Breast
/ metabolism.
Breast
/ pathology. Cell Proliferation. DNA,
Neoplasm
. Female. Genomic Instability / genetics. Humans. Keratin-19 / metabolism. Keratin-7 / metabolism. Middle Aged. S100 Proteins / metabolism
Genetic Alliance.
consumer health - Adenoid Cystic Carcinoma
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 2002 Apr 15;94(8):2119-27
[
12001107.001
]
[Cites]
Am J Surg Pathol. 2002 Apr;26(4):413-20
[
11914618.001
]
[Cites]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Aug;82(2):187-92
[
8863309.001
]
[Cites]
Lab Invest. 2007 May;87(5):430-9
[
17372589.001
]
[Cites]
Hum Pathol. 1987 Dec;18(12):1276-81
[
2824330.001
]
[Cites]
Am J Surg Pathol. 1996 Jan;20(1):46-54
[
8540608.001
]
[Cites]
Am J Surg Pathol. 1986 Apr;10(4):237-45
[
3706610.001
]
[Cites]
Cancer. 1975 Jul;36(1):1-85
[
173455.001
]
[Cites]
Cytometry. 1998 Mar 1;31(3):163-73
[
9515715.001
]
[Cites]
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91
[
16857790.001
]
[Cites]
J Microsc. 2005 Apr;218(Pt 1):52-61
[
15817063.001
]
[Cites]
Mod Pathol. 2005 Dec;18(12):1623-31
[
16258515.001
]
[Cites]
Breast Cancer Res Treat. 2005 Oct;93(3):189-90
[
16142443.001
]
[Cites]
Ann Diagn Pathol. 2004 Feb;8(1):39-42
[
15129910.001
]
[Cites]
Virchows Arch. 1998 Feb;432(2):119-22
[
9504855.001
]
[Cites]
Arch Pathol Lab Med. 1977 Jun;101(6):302-6
[
193456.001
]
[Cites]
Lab Invest. 2008 May;88(5):464-73
[
18332873.001
]
[Cites]
Breast Cancer Res. 2007;9(1):R4
[
17217540.001
]
[Cites]
Semin Diagn Pathol. 2003 Nov;20(4):279-304
[
14694981.001
]
[Cites]
Cancer. 1995 Jul 15;76(2):250-8
[
8625100.001
]
[Cites]
Histopathology. 1987 Mar;11(3):305-15
[
2828217.001
]
[Cites]
Am J Surg Pathol. 2005 Jun;29(6):734-46
[
15897740.001
]
[Cites]
J Pathol. 2008 Oct;216(2):141-50
[
18720457.001
]
[Cites]
Am J Surg Pathol. 2008 Apr;32(4):544-52
[
18300793.001
]
[Cites]
Am J Surg Pathol. 2003 Aug;27(8):1052-60
[
12883237.001
]
[Cites]
Breast Cancer Res. 2007;9(5):R65
[
17910759.001
]
[Cites]
Am J Clin Pathol. 1993 Nov;100(5):507-13
[
7504394.001
]
[Cites]
Lab Invest. 2000 Jun;80(6):831-6
[
10879734.001
]
[Cites]
Surg Gynecol Obstet. 1966 Jun;122(6):1289-94
[
5941852.001
]
[Cites]
Int Semin Surg Oncol. 2006 Jun 30;3:17
[
16813652.001
]
[Cites]
Int J Surg Pathol. 2000 Oct;8(4):303-315
[
11494007.001
]
[Cites]
Am J Surg Pathol. 1993 Feb;17(2):99-109
[
8422116.001
]
[Cites]
Breast Cancer Res Treat. 2004 Oct;87(3):225-32
[
15528965.001
]
[Cites]
Am J Surg Pathol. 1983 Dec;7(8):731-7
[
6660348.001
]
[Cites]
Histopathology. 1983 Mar;7(2):169-80
[
6852780.001
]
[Cites]
Cancer. 1969 Oct;24(4):740-5
[
4309694.001
]
[Cites]
J Clin Pathol. 1975 Aug;28(8):647-55
[
171285.001
]
[Cites]
Am J Surg Pathol. 1983 Mar;7(2):137-44
[
6859388.001
]
[Cites]
Clin Cancer Res. 2000 Mar;6(3):782-9
[
10741697.001
]
[Cites]
Am J Clin Pathol. 1973 May;59(5):653-8
[
4349849.001
]
[Cites]
J Pathol. 2005 Nov;207(3):260-8
[
16167361.001
]
[Cites]
Eur J Cancer. 1995 Dec;31A(13-14):2289-95
[
8652258.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
[
11553815.001
]
(PMID = 19031084.001).
[ISSN]
0945-6317
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Actins; 0 / DNA, Neoplasm; 0 / Keratin-19; 0 / Keratin-7; 0 / S100 Proteins
65.
Chowdary MV, Kalyan Kumar K, Mathew S, Rao L, Krishna CM, Kurien J:
Biochemical correlation of Raman spectra of normal, benign and malignant breast tissues: a spectral deconvolution study.
Biopolymers
; 2009 Jul;91(7):539-46
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Biochemical correlation of Raman spectra of normal,
benign
and malignant
breast
tissues: a spectral deconvolution study.
The aim of this study was to understand and correlate spectral features and biochemical changes in normal, fibroadenoma and infiltrating ductal carcinoma
of breast
tissues using Raman spectra that were part of the spectroscopic models developed and evaluated by us earlier.
This study has revealed that fat (1301 and 1440 cm(-1)), collagen (1246, 1271, and 1671 cm(-1)) and DNA (1340 and 1480 cm(-1)) bands have strong presence in normal,
benign
and malignant
breast
tissues, respectively.
Thus the finding of this study further demonstrates the efficacy Raman spectroscopic approaches in diagnostic applications as well as in understanding molecular phenomenon in
breast
cancers.
[MeSH-major]
Breast
/ pathology.
Breast
Neoplasms
/ pathology. Spectrum Analysis, Raman
[MeSH-minor]
Collagen / chemistry. DNA,
Neoplasm
/ chemistry. Female. Humans. Lipids / chemistry.
Neoplasm
Proteins / chemistry. Vibration
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2009 Wiley Periodicals, Inc.
(PMID = 19226625.001).
[ISSN]
0006-3525
[Journal-full-title]
Biopolymers
[ISO-abbreviation]
Biopolymers
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA, Neoplasm; 0 / Lipids; 0 / Neoplasm Proteins; 9007-34-5 / Collagen
66.
Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE:
Development of a multimarker assay for early detection of ovarian cancer.
J Clin Oncol
; 2010 May 01;28(13):2159-66
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PATIENTS AND METHODS: Ninety-six serum biomarkers were analyzed in sera from healthy women and from patients with ovarian cancer,
benign
pelvic
tumors
, and
breast
, colorectal, and lung cancers, using multiplex xMAP bead-based immunoassays.
This panel was selective for ovarian cancer showing SN of 33% for
benign
pelvic disease, SN of 6% for
breast
cancer, SN of 0% for colorectal cancer, and SN of 36% for lung cancer.
[MeSH-major]
Biomarkers,
Tumor
/ blood. Immunoassay. Mass Screening / methods. Ovarian
Neoplasms
/
diagnosis
[MeSH-minor]
Aged. Aged, 80 and over. Algorithms. CA-125 Antigen / blood. Carcinoembryonic Antigen / blood. Data Interpretation, Statistical. Early Detection of Cancer. Epididymal Secretory Proteins / analysis. Female. Humans. Middle Aged. Monte Carlo Method.
Neoplasm
Staging. Predictive Value of Tests. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Vascular Cell Adhesion Molecule-1 / blood. beta-Defensins
Genetic Alliance.
consumer health - Ovarian cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Clin Oncol. 2010 May 1;28(13):2128-30
[
20368556.001
]
[Cites]
Cancer Chemother Biol Response Modif. 1999;18:418-34
[
10800496.001
]
[Cites]
Life Sci. 2001 Jan 12;68(8):861-72
[
11213356.001
]
[Cites]
Gynecol Oncol. 2005 Dec;99(3):656-63
[
16112717.001
]
[Cites]
Br J Cancer. 2001 Mar 2;84(5):643-50
[
11237385.001
]
[Cites]
J Clin Oncol. 2003 May 15;21(10 Suppl):194s-199s
[
12743134.001
]
[Cites]
Mol Cell Proteomics. 2004 Apr;3(4):355-66
[
14764655.001
]
[Cites]
Mol Pathol. 2002 Apr;55(2):110-20
[
11950960.001
]
[Cites]
J Cancer Res Clin Oncol. 1989;115(5):456-8
[
2808485.001
]
[Cites]
Gynecol Obstet Invest. 1999;48(2):133-7
[
10461006.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37
[
10067810.001
]
[Cites]
Gynecol Oncol. 2009 Jan;112(1):47-54
[
19007974.001
]
[Cites]
Gynecol Oncol. 1988 Jun;30(2):265-73
[
3163666.001
]
[Cites]
J Clin Oncol. 2003 Mar 15;21(6):1035-43
[
12637468.001
]
[Cites]
Cancer. 2001 Dec 1;92(11):2837-44
[
11753957.001
]
[Cites]
Anticancer Res. 1997 Nov-Dec;17(6D):4735-7
[
9494598.001
]
[Cites]
Clin Biochem. 2003 Mar;36(2):135-43
[
12633763.001
]
[Cites]
Dis Markers. 2007;23(5-6):419-31
[
18057525.001
]
[Cites]
JAMA. 1995 Dec 27;274(24):1926-30
[
8568986.001
]
[Cites]
Cancer Res. 2000 Apr 15;60(8):2190-6
[
10786683.001
]
[Cites]
Tumour Biol. 1993;14(2):105-15
[
8392219.001
]
[Cites]
Aust N Z J Obstet Gynaecol. 2005 Jun;45(3):211-4
[
15904446.001
]
[Cites]
Curr Oncol Rep. 2002 Mar;4(2):165-74
[
11822989.001
]
[Cites]
J Endocrinol Invest. 2004 Jun;27(6):528-34
[
15717649.001
]
[Cites]
Curr Opin Obstet Gynecol. 2001 Feb;13(1):61-4
[
11176234.001
]
[Cites]
Cancer. 1975 May;35(5):1377-81
[
47262.001
]
[Cites]
Int J Cancer. 2003 Sep 10;106(4):605-10
[
12845660.001
]
[Cites]
Clin Exp Metastasis. 1999 Mar;17(2):131-40
[
10411105.001
]
[Cites]
Hum Reprod. 1989 Jan;4(1):1-12
[
2651469.001
]
[Cites]
Br J Obstet Gynaecol. 1993 Dec;100(12):1120-4
[
8297846.001
]
[Cites]
Gene. 1999 Oct 1;238(2):375-85
[
10570965.001
]
[Cites]
Gynecol Oncol. 2007 Oct;107(1):58-65
[
17659325.001
]
[Cites]
J Surg Oncol. 1990 Jun;44(2):97-9
[
2355747.001
]
[Cites]
N Engl J Med. 1983 Oct 13;309(15):883-7
[
6310399.001
]
[Cites]
Gastroenterology. 2005 Aug;129(2):464-75
[
16083703.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7
[
15824174.001
]
[Cites]
Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10
[
10883018.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3
[
18708375.001
]
[Cites]
Clin Cancer Res. 2001 Aug;7(8):2380-6
[
11489816.001
]
[Cites]
Br J Cancer. 1993 Jul;68(1):122-4
[
7686390.001
]
[Cites]
Acta Obstet Gynecol Scand. 1997 Mar;76(3):283-5
[
9093148.001
]
[Cites]
Cancer Lett. 2007 Apr 28;249(1):61-79
[
17275179.001
]
[Cites]
Semin Surg Oncol. 1994 Jul-Aug;10(4):242-8
[
8091065.001
]
[Cites]
Ann Acad Med Singapore. 1998 Sep;27(5):676-82
[
9919339.001
]
[Cites]
Br J Obstet Gynaecol. 1992 Apr;99(4):329-32
[
1581280.001
]
[Cites]
Clin Cancer Res. 2008 Feb 15;14(4):1065-72
[
18258665.001
]
[Cites]
Br J Cancer. 1994 Dec;70(6):1186-7
[
7981074.001
]
[Cites]
Crit Rev Clin Lab Sci. 2004;41(3):265-312
[
15307634.001
]
[Cites]
Clin Sci (Lond). 2006 Mar;110(3):279-91
[
16464170.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82
[
15890779.001
]
[Cites]
Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82
[
11520365.001
]
[Cites]
Cancer Treat Res. 2002;107:247-58
[
11775453.001
]
[Cites]
Gynecol Oncol. 1988 Jan;29(1):66-75
[
3422208.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Sep;84(9):3030-5
[
10487660.001
]
[Cites]
Cancer Res. 2003 Jun 1;63(11):2771-4
[
12782581.001
]
[Cites]
J Clin Oncol. 2004 Oct 15;22(20):4059-66
[
15381683.001
]
[Cites]
Medscape Womens Health. 1996 Nov;1(11):3
[
9746655.001
]
[Cites]
Anticancer Res. 2006 Nov-Dec;26(6C):4721-8
[
17214332.001
]
[Cites]
Eur J Cancer Prev. 1998 Feb;7(1):23-35
[
9511849.001
]
[Cites]
Gynecol Oncol. 2004 Oct;95(1):9-15
[
15385104.001
]
[Cites]
Lancet. 1999 Apr 10;353(9160):1207-10
[
10217079.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13
[
12582019.001
]
[Cites]
J Clin Oncol. 2005 Nov 1;23(31):7919-26
[
16258091.001
]
[Cites]
Gynecol Oncol. 1997 Jul;66(1):27-30
[
9234916.001
]
[Cites]
Cytokine. 2009 Jan;45(1):44-9
[
19058974.001
]
[Cites]
Biomed Biochim Acta. 1986;45(3):371-84
[
3518711.001
]
[Cites]
Med Oncol. 2008;25(3):279-83
[
18071928.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
Anticancer Res. 1994 Nov-Dec;14(6B):2743-6
[
7532929.001
]
[Cites]
Br J Obstet Gynaecol. 1997 Sep;104(9):1024-9
[
9307529.001
]
[Cites]
Anticancer Res. 1998 Jul-Aug;18(4B):2891-4
[
9713482.001
]
[Cites]
Eur J Gynaecol Oncol. 2000;21(2):135-40
[
10843471.001
]
[Cites]
Fertil Steril. 2003 Oct;80(4):1068-9; author reply 1069-70
[
14556841.001
]
[Cites]
Cancer Res. 2003 Jul 1;63(13):3695-700
[
12839961.001
]
[Cites]
Br J Obstet Gynaecol. 1979 Nov;86(11):901-4
[
116672.001
]
[Cites]
J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51
[
8411259.001
]
[Cites]
Hum Reprod. 2005 Jan;20(1):117-21
[
15513972.001
]
[Cites]
Tumour Biol. 2002 May-Jun;23(3):185-92
[
12218299.001
]
[Cites]
Cancer Invest. 1995;13(2):227-38
[
7874576.001
]
[Cites]
Immunol Invest. 2006;35(2):167-79
[
16698675.001
]
[Cites]
Eur Cytokine Netw. 2009 Mar;20(1):21-6
[
19318317.001
]
[Cites]
Gynecol Oncol. 1998 Jun;69(3):248-52
[
9648596.001
]
[Cites]
Anticancer Res. 2000 Jan-Feb;20(1B):569-72
[
10769727.001
]
[Cites]
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81
[
16343244.001
]
[Cites]
Cancer Res. 2004 Aug 15;64(16):5882-90
[
15313933.001
]
[Cites]
Int J Oncol. 2005 Feb;26(2):379-84
[
15645122.001
]
[Cites]
Eur J Obstet Gynecol Reprod Biol. 2005 May 1;120(1):87-90
[
15866092.001
]
[Cites]
Biomed Pharmacother. 2004 Jan;58(1):24-38
[
14739059.001
]
[Cites]
Cancer. 2007 Jul 15;110(2):297-308
[
17569106.001
]
[Cites]
Eur J Clin Chem Clin Biochem. 1994 Mar;32(3):201-7
[
8031969.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1641-6
[
16985025.001
]
[Cites]
Am Fam Physician. 2003 Sep 15;68(6):1075-82
[
14524394.001
]
(PMID = 20368574.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / CA105009; United Kingdom / Medical Research Council / / G9901012; United States / NCI NIH HHS / CA / R01 CA108990; United Kingdom / Medical Research Council / / G0801228; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA086381
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / Vascular Cell Adhesion Molecule-1; 0 / beta-Defensins
[Other-IDs]
NLM/ PMC2860434
67.
Czecior E, Namysłowski G, Misiołek M, Scierski W, Polok A, Lisowska G, Mrówka-Kata K, Orecka B, Pawlas P:
[Strategy of the sinonasal tumors treatment].
Otolaryngol Pol
; 2007;61(4):559-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Strategy of the sinonasal
tumors
treatment].
INTRODUCTION: The sinonasal
tumors
belong to rare diseases.
They state 0.2-0.8% of all the malignant
neoplasms
and about 3% of head and neck
tumors
.
These
tumors
are two times frequent observed in men than in women, mainly between 50 and 70 years old.
In the sinonasal complex besides the primary are seen also the metastatic
tumors
.
They state about 1% of all
tumors
(kidney, testum,
breast
, pulmonary).
AIM: The aim of our study was to retrospective analysis of the sinonasal
tumors
, treated in the ENT Department Silesian Medical University in Zabrze.
MATERIAL AND METHODS: 26 patients treated in the ENT Department Silesian Medical University in Zabrze between 2000 and 2006 suffered from the sinonasal
tumors
were retrospectively analyzed.
RESULTS: In the histological examination in 4 patients
the benign neoplasm
and in 22 patients malignant
tumors
were diagnosed.
On the basis of the CT and MRI examination as well as the description of the surgical procedure we stated that in 13 cases the primary localization
of neoplasm
was the maxillary sinus, in 5 cases ethmoidal cells, in 3 nasal cavity.
In one patient the estimation of primary
tumor
localization was not possible, because of the very large extension of the
neoplasm
.
The choice of the surgical procedure was depend on the
tumor
extension and localization.
[MeSH-major]
Nose
Neoplasms
/
diagnosis
. Nose
Neoplasms
/ surgery. Paranasal Sinus
Neoplasms
/
diagnosis
. Paranasal Sinus
Neoplasms
/ surgery
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18260251.001).
[ISSN]
0030-6657
[Journal-full-title]
Otolaryngologia polska = The Polish otolaryngology
[ISO-abbreviation]
Otolaryngol Pol
[Language]
pol
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Poland
68.
Rotstein AH, Neerhut PK:
Ultrasound characteristics of histologically proven grade 3 invasive ductal breast carcinoma.
Australas Radiol
; 2005 Dec;49(6):476-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Ultrasound characteristics of histologically proven grade 3 invasive ductal
breast
carcinoma.
High-grade invasive ductal carcinoma (IDC) may paradoxically display features similar to
benign breast
masses.
For each
tumour
, four features were assessed: margin, attenuation characteristics, echotexture and depth versus width ratio.
Eighty-seven per cent of
tumours
had an aggressive margin with an echogenic rind, microlobulation or angular margins.
Six per cent of the
tumours
were isoechoic and difficult to appreciate on ultrasound.
To ensure that malignant lesions are correctly categorized, it is important that interfaces between the
tumour
and adjacent
breast
parenchyma are meticulously evaluated in a real-time fashion rather than viewed as a single still image.
[MeSH-major]
Breast
Neoplasms
/ ultrasonography. Carcinoma, Ductal,
Breast
/ ultrasonography. Ultrasonography, Mammary
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Diagnosis
, Differential. Female. Humans. Middle Aged.
Neoplasm
Invasiveness. Retrospective Studies
Genetic Alliance.
consumer health - invasive ductal carcinoma
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16351611.001).
[ISSN]
0004-8461
[Journal-full-title]
Australasian radiology
[ISO-abbreviation]
Australas Radiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
69.
Riddle ND, Yamauchi H, Caracciolo JT, Cheong D, Khakpour N, Bui MM:
Giant cell tumor of the anterior rib masquerading as a breast mass: a case report and review of current literature.
Cases J
; 2010;3:51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Giant cell
tumor
of the anterior rib masquerading as a
breast
mass: a case report and review of current literature.
INTRODUCTION: Giant cell
tumor
(GCT) is an aggressive, but usually
benign
bone
neoplasm
most commonly arising in the metaphysis/epiphyses of long bones.
While they are categorized as
benign
tumors
, they can be locally aggressive and clinically have metastatic potential.
The most common locations of this
tumor
include the distal femur, proximal tibia, and distal radius.
We report a GCT arising in an atypical location and mimicking a
breast
mass.
Radiologically, the initial impression included a deep-seated
breast
cancer with local chest wall invasion.
CONCLUSION: The histological features of bland mononuclear and multinucleated giant cells along with the lack of any additional mesenchymal elements led to the
diagnosis
of giant cell
tumor
.
Resection of
tumor
was performed.
This case is important as it shows where the physician must keep this
diagnosis
in mind whenever a deeply located
breast
mast is present.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Skeletal Radiol. 1992;21(7):482-8
[
1439904.001
]
[Cites]
Respir Med. 1991 Sep;85(5):435-6
[
1759012.001
]
[Cites]
J Surg Oncol. 1989 Feb;40(2):128-31
[
2492623.001
]
[Cites]
Intern Med. 2007;46(14):1151-2
[
17634719.001
]
[Cites]
Skeletal Radiol. 2003 Feb;32(2):107-10
[
12589492.001
]
[Cites]
Pediatr Hematol Oncol. 2003 Jun;20(4):351-5
[
12746169.001
]
[Cites]
Arch Orthop Trauma Surg. 2000;120(3-4):231-2
[
10738893.001
]
(PMID = 20205847.001).
[ISSN]
1757-1626
[Journal-full-title]
Cases journal
[ISO-abbreviation]
Cases J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2825505
70.
Watermann DO, Tempfer CB, Hefler LA, Parat C, Stickeler E:
Ultrasound criteria for ductal invasive breast cancer are modified by age, tumor size, and axillary lymph node status.
Breast Cancer Res Treat
; 2005 Jan;89(2):127-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Ultrasound criteria for ductal invasive
breast
cancer are modified by age,
tumor
size, and axillary lymph node status.
PURPOSE: To evaluate the influence of distinct clinicopathological parameters on ultrasound criteria for ductal invasive
breast
cancer.
PATIENTS AND METHODS: The hardcopy prints of 337 ductal invasive
breast
cancers were analyzed.
Ten ultrasound criteria (shape, orientation, echogenicity, echo pattern, calcifications, margin, margin contour, lesion boundary, surrounding tissue, and posterior acoustic features) were defined and correlated to age,
tumor
size, axillary lymph node status, and histological grading in a multivariate analysis.
RESULTS:
Tumors
in women < or = 50 years displayed more often an indistinct margin (p = 0.003) and an enhanced/indifferent posterior ultrasound transmission (p = 0.008).
Tumors
in an advanced T-stage showed more frequently an irregular shape ( p = 0.006), an orientation parallel to the skin ( p = 0.01), hypoechogenicity ( p < 0.0001), and less often calcifications ( p = 0.002).
CONCLUSION:
Breast
ultrasound criteria, which are used to differentiate
benign
from malignant
breast
lesions, are influenced by age, size and lymph node status.
These clinical conditions should be considered in the ultrasound
diagnosis
of breast
lesions.
[MeSH-major]
Breast
Neoplasms
/ pathology.
Breast
Neoplasms
/ ultrasonography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Lymphatic Metastasis.
Neoplasm
Staging / methods
[MeSH-minor]
Adult. Age Factors. Aged.
Diagnosis
, Differential. Female. Humans. Middle Aged. Multivariate Analysis. Reference Values. Retrospective Studies
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15692754.001).
[ISSN]
0167-6806
[Journal-full-title]
Breast cancer research and treatment
[ISO-abbreviation]
Breast Cancer Res. Treat.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
71.
Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, Scolyer RA, Lee CS:
Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution.
Breast
; 2009 Jun;18(3):165-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phyllodes
tumours
of the
breast
: a clinicopathological analysis of 65 cases from a single institution.
The aim of this study was to document the clinical and pathological features of a large single institutional series of ethnically diverse patients with phyllodes
tumours
(PTs), and to determine which characteristics were predictive of outcome.
Sixty five PTs were analysed; 34 were
benign
, 23 borderline and eight malignant (34 low grade and 31 high grade PTs on a two tiered grading system).
A greater percentage of higher grade
tumours
recurred and women of Asian origin had a higher recurrence rate compared to the non-Asian patients.
The mean age at
diagnosis
significantly increased with
tumour
grade.
The mean
tumour
volume also significantly increased with grade.
Tumour
grade was the only parameter related significantly to outcome.
[MeSH-major]
Breast
Neoplasms
/ epidemiology.
Neoplasm
Recurrence, Local / epidemiology. Phyllodes
Tumor
/ epidemiology
[MeSH-minor]
Aged. Female. Humans. Mastectomy / statistics & numerical data. Middle Aged.
Neoplasm
Staging / statistics & numerical data. New South Wales / epidemiology. Survival Analysis. Treatment Outcome. Women's Health
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19329316.001).
[ISSN]
1532-3080
[Journal-full-title]
Breast (Edinburgh, Scotland)
[ISO-abbreviation]
Breast
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
72.
Navas Cañete A, Olcoz Monreal FJ, García Laborda E, Pérez Aznar JM:
[Pseudoangiomatous stromal hyperplasia: magnetic resonance findings in two cases].
Radiologia
; 2007 Jul-Aug;49(4):275-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Transliterated title]
Hiperplasia pseudoangiomatosa estromal: hallazgos en resonancia magnética
de
dos casos.
Pseudoangiomatous stromal hyperplasia (PASH) is a
benign breast
tumor
of uncertain etiology, although marked hormonal influence clearly plays a role in this disease.
The differential
diagnosis
is important because this is an uncommon lesion that can simulate malignant lesions both at clinical and radiological examination, and even the histological results can be confusing.
[MeSH-major]
Breast
/ pathology.
Breast
Diseases /
diagnosis
. Magnetic Resonance Imaging
Genetic Alliance.
consumer health - Pseudoangiomatous stromal hyperplasia
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17594891.001).
[ISSN]
0033-8338
[Journal-full-title]
Radiología
[ISO-abbreviation]
Radiologia
[Language]
spa
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Spain
73.
Yilmaz MH, Ozguroglu M, Mert D, Turna H, Demir G, Adaletli I, Ulus S, Halac M, Kanberoğlu K:
Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study.
Med Oncol
; 2008;25(3):257-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic
breast
cancer of the axial skeleton: a comparative study.
PATIENTS AND METHODS: A total of 59 patients (58 women and 1 man, age range 28-83 years, mean age 53.0 years) with histopathologically proven
breast
cancer during a 15-month period (between April 2003 and January 2004) were included in the study.
Four lesions detected by MRI were classified as of uncertain origin (grade 2) and 36 lesions were regarded as definitely
benign
(grade 1).
A total of 29 lesions were considered as of uncertain origin (grade 2), and 26 lesions were regarded as definitely
benign
(grade 1).
About five lesions were graded as grade 2 in scintigraphy, while MRI graded them as degeneration or
benign
compression (Grade 1).
[MeSH-major]
Bone
Neoplasms
/ secondary.
Breast
Neoplasms
/ pathology. Magnetic Resonance Imaging
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Diphosphonates. Female. Humans. Male. Middle Aged.
Neoplasm
Staging. Organotechnetium Compounds. Predictive Value of Tests. Radiography. Radionuclide Imaging. Sensitivity and Specificity. Whole Body Imaging
Genetic Alliance.
consumer health - Breast Cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Comput Assist Tomogr. 1989 Jul-Aug;13(4):598-602
[
2745777.001
]
[Cites]
CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1
[
10200775.001
]
[Cites]
Radiology. 1993 Jul;188(1):249-52
[
8511306.001
]
[Cites]
Skeletal Radiol. 1986;15(1):1-9
[
3941915.001
]
[Cites]
AJR Am J Roentgenol. 1986 Feb;146(2):353-8
[
3484586.001
]
[Cites]
Cancer. 1997 Oct 15;80(8 Suppl):1595-607
[
9362427.001
]
[Cites]
Radiol Clin North Am. 1987 Nov;25(6):1155-70
[
3671711.001
]
[Cites]
Clin Orthop Relat Res. 1982 Sep;(169):38-43
[
6179682.001
]
[Cites]
Clin Nucl Med. 1989 Oct;14 (10 ):742-9
[
2805524.001
]
[Cites]
Blood. 1991 Aug 1;78(3):728-38
[
1859885.001
]
[Cites]
Cancer. 1987 Nov 15;60(10 ):2524-31
[
3664434.001
]
[Cites]
Clin Orthop Relat Res. 1986 Sep;(210):18-30
[
3757360.001
]
[Cites]
AJR Am J Roentgenol. 1990 Nov;155(5):1043-8
[
2120933.001
]
[Cites]
Clin Radiol. 1976 Jan;27(1):9-15
[
177243.001
]
[Cites]
Semin Nucl Med. 1995 Apr;25(2):76-91
[
7597422.001
]
[Cites]
Skeletal Radiol. 1990;19(2):113-6
[
2321040.001
]
[Cites]
Spine (Phila Pa 1976). 1996 Oct 1;21(19):2243-50
[
8902969.001
]
[Cites]
Magn Reson Imaging. 1994;12 (6):829-35
[
7968282.001
]
[Cites]
Eur J Radiol. 2001 Oct;40(1):16-23
[
11673003.001
]
[Cites]
Eur J Cancer Clin Oncol. 1982 Jul;18(7):629-36
[
6889965.001
]
[Cites]
Magn Reson Imaging. 1991;9(3):349-55
[
1881253.001
]
[Cites]
J Clin Oncol. 1994 Jul;12(7):1415-21
[
8021732.001
]
[Cites]
Nucl Med Commun. 1992 Jun;13(6):429-31
[
1407869.001
]
[Cites]
Cancer. 1986 Jul 1;58(1):178-82
[
2423224.001
]
[Cites]
AJR Am J Roentgenol. 1997 Dec;169(6):1655-61
[
9393186.001
]
[Cites]
Am J Med. 1986 Sep;81(3):381-6
[
2428242.001
]
[Cites]
J Comput Assist Tomogr. 1989 Jul-Aug;13(4):717-9
[
2745798.001
]
[Cites]
Radiology. 1989 Jul;172(1):215-8
[
2740506.001
]
[Cites]
Eur Radiol. 2004 Dec;14 (12 ):2297-302
[
15243716.001
]
[Cites]
Radiol Clin North Am. 1990 Mar;28(2):471-83
[
2408106.001
]
[Cites]
Magn Reson Imaging. 1992;10(2):169-76
[
1564986.001
]
[Cites]
Semin Oncol. 1991 Apr;18(2):158-69
[
2014400.001
]
[Cites]
Eur J Nucl Med. 1993 Nov;20(11):1063-9
[
8287874.001
]
[Cites]
J Comput Assist Tomogr. 1999 Jan-Feb;23 (1):123-9
[
10050822.001
]
[Cites]
Br J Cancer. 1973 Apr;27(4):336-40
[
4701705.001
]
[Cites]
Lancet. 1983 Sep 10;2(8350):613-6
[
6136757.001
]
[Cites]
Br J Urol. 1995 Jan;75(1):54-8
[
7850297.001
]
[Cites]
AJR Am J Roentgenol. 1977 Dec;129(6):1095-6
[
74204.001
]
[Cites]
J Nucl Med. 1996 Jun;37(6):975-8
[
8683325.001
]
[Cites]
J Nucl Med. 1993 Dec;34(12 ):2191-8
[
8254410.001
]
(PMID = 18040900.001).
[ISSN]
1357-0560
[Journal-full-title]
Medical oncology (Northwood, London, England)
[ISO-abbreviation]
Med. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Diphosphonates; 0 / Organotechnetium Compounds; 0 / technetium 99m methylene bisphosphonate
74.
Zhou M, Johnson N, Blanchard D, Bryn S, Nelson J:
Real-world application of breast-specific gamma imaging, initial experience at a community breast center and its potential impact on clinical care.
Am J Surg
; 2008 May;195(5):631-5; discussion 635
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Real-world application
of breast
-specific gamma imaging, initial experience at a community
breast
center and its potential impact on clinical care.
BACKGROUND:
Breast
-specific gamma imaging (BSGI) has brought scintimammography back to the forefront by using a dedicated small field-of-view system designed to detect and localize lesions down to 2 mm.
We reviewed our initial experience to evaluate the impact of this technology at our community
breast
center.
RESULTS: A total of 128 patients underwent BSGI because of suspicious imaging, abnormal physical examination, or high risk with dense
breasts
.
BSGI was positive in 12 of 107 patients with
breast
imaging reporting and data system (BI-RADS) 1, 2, or 3.
Of the 21 patients with BI-RADS 4, 18 were BSGI negative (11 with
benign
biopsy, 7 observed), and 3 were BSGI positive with 2 being cancer.
Forty-eight patients with a new
diagnosis
of cancer obtained BSGI for further work-up.
It was positive at a new location in 6 cases: 2 cases were new cancers in the contralateral
breast
, 1 was in the ipsilateral
breast
, and the remaining 3 had
benign
pathology.
CONCLUSIONS: BSGI has played an important role in our clinical management
of breast
patients with complex
breast
tissue.
BSGI is also a good adjunctive imaging tool in the work-up of newly diagnosed
breast
cancer patients.
[MeSH-major]
Breast
Neoplasms
/ radionuclide imaging. Mass Screening. Outcome Assessment (Health Care) / standards
[MeSH-minor]
Adult. Benchmarking. Community Health Centers. Female. Humans.
Neoplasm
Staging. Radiopharmaceuticals. Registries. Retrospective Studies. Risk Adjustment. Survival Analysis. Technetium Tc 99m Sestamibi. United States
MedlinePlus Health Information.
consumer health - Breast Cancer
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18374889.001).
[ISSN]
1879-1883
[Journal-full-title]
American journal of surgery
[ISO-abbreviation]
Am. J. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
75.
Destounis SV, Vogt C, Arieno AL, Morgan RC:
Difficult management of a rapidly growing benign phyllodes tumor in a 49-year-old woman.
J Ultrasound Med
; 2010 Jul;29(7):1125-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Difficult management of a rapidly growing
benign
phyllodes
tumor
in a 49-year-old woman.
[MeSH-major]
Breast
Neoplasms
. Phyllodes
Tumor
[MeSH-minor]
Female. Humans. Middle Aged.
Neoplasm
Recurrence, Local / surgery
Genetic Alliance.
consumer health - Phyllodes Tumor
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20587436.001).
[ISSN]
1550-9613
[Journal-full-title]
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
[ISO-abbreviation]
J Ultrasound Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
76.
Ismail MF, Aly MS, Khaled HM, Mohamed HM:
Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
Ger Med Sci
; 2009;7:Doc03
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with
breast
cancer.
Breast
cancer is a leading cause of cancer-related deaths in women worldwide.
Amplification of the two oncogenes HER-2/neu and c-myc and inactivation of the
tumor
suppressor gene p53 are frequently encountered in
breast
carcinomas.
The study was conducted on 34 tissue samples obtained from 33 females and 1 male with
breast
carcinomas and 17 samples obtained from 16 females and 1 male with
benign breast
lesions.
Results revealed that the level of HER-2/neu, c-myc and p53 in the malignant group was significantly increased as compared to
the benign
group.
The sensitivity of the investigated markers significantly increased with larger
tumor
size.
Concerning
tumor
grade, HER-2/neu and p53 showed a significant increase in low-grade
tumors
whereas c-myc showed a highly significant increase in high-grade
tumors
.
[MeSH-major]
Breast
Neoplasms
/ genetics. In Situ Hybridization, Fluorescence / methods. Proto-Oncogene Proteins c-myc / analysis. Receptor, ErbB-2 / analysis.
Tumor
Suppressor Protein p53 / analysis
[MeSH-minor]
Adolescent. Adult. Aged. Biomarkers,
Tumor
/ analysis. Biopsy.
Breast
Neoplasms
, Male /
diagnosis
.
Breast
Neoplasms
, Male / epidemiology.
Breast
Neoplasms
, Male / genetics. Egypt / epidemiology. Female. Humans. Male. Middle Aged.
Neoplasm
Staging / methods. Nucleic Acid Amplification Techniques / methods. Prevalence. Young Adult
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Pathol. 2000 Jan;156(1):183-91
[
10623666.001
]
[Cites]
Diagn Mol Pathol. 2007 Dec;16(4):207-10
[
18043283.001
]
[Cites]
Breast Cancer Res Treat. 2000 Feb;59(3):211-21
[
10832591.001
]
[Cites]
Indian J Exp Biol. 2000 Mar;38(3):225-30
[
10927863.001
]
[Cites]
Ann Oncol. 2000 Jun;11(6):647-63
[
10942052.001
]
[Cites]
Acta Oncol. 2000;39(3):327-33
[
10987229.001
]
[Cites]
Endocr Relat Cancer. 2000 Sep;7(3):143-64
[
11021963.001
]
[Cites]
Oncogene. 2000 Dec 11;19(53):6093-101
[
11156522.001
]
[Cites]
Oncogene. 2000 Dec 11;19(53):6102-14
[
11156523.001
]
[Cites]
Int J Cancer. 2001 Jul 20;95(4):266-70
[
11400121.001
]
[Cites]
Tumour Biol. 2001 Sep-Oct;22(5):337-44
[
11553865.001
]
[Cites]
Cancer Res. 2002 Mar 1;62(5):1481-8
[
11888924.001
]
[Cites]
Breast Cancer Res Treat. 2002 Jul;74(1):25-31
[
12150449.001
]
[Cites]
Cancer. 2003 Feb 1;97(3):690-4
[
12548612.001
]
[Cites]
Br J Cancer. 2004 Apr 19;90(8):1612-9
[
15083194.001
]
[Cites]
J Pathol. 2004 Aug;203(4):918-26
[
15258994.001
]
[Cites]
Am J Clin Pathol. 2004 Aug;122(2):246-55
[
15323142.001
]
[Cites]
Nature. 1986 Feb 27-Mar 5;319(6056):783-4
[
3005871.001
]
[Cites]
Science. 1987 Jan 9;235(4785):177-82
[
3798106.001
]
[Cites]
Histopathology. 1991 Nov;19(5):403-10
[
1757079.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5
[
1351679.001
]
[Cites]
Nature. 1992 Jul 2;358(6381):15-6
[
1614522.001
]
[Cites]
Cell Growth Differ. 1993 Jan;4(1):41-7
[
8424905.001
]
[Cites]
Curr Opin Genet Dev. 1995 Feb;5(1):97-104
[
7749333.001
]
[Cites]
J Pathol. 1995 Nov;177(3):225-32
[
8551383.001
]
[Cites]
Oncogene. 1996 Jul 4;13(1):63-72
[
8700555.001
]
[Cites]
Hum Pathol. 1998 Apr;29(4):323-9
[
9563780.001
]
[Cites]
Breast Cancer Res Treat. 1998 May;49(1):35-9
[
9694609.001
]
[Cites]
J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9
[
9731732.001
]
[Cites]
Genes Chromosomes Cancer. 1998 Oct;23(2):100-8
[
9739012.001
]
[Cites]
Oncogene. 1999 May 13;18(19):3004-16
[
10378696.001
]
[Cites]
Am J Clin Pathol. 1999 Oct;112(4):459-69
[
10510669.001
]
[Cites]
Cancer. 2005 Mar 1;103(5):900-5
[
15643600.001
]
[Cites]
Cancer Res. 2005 Mar 1;65(5):1909-17
[
15753390.001
]
[Cites]
Oncol Rep. 2005 Apr;13(4):633-41
[
15756435.001
]
[Cites]
Histopathology. 2005 Apr;46(4):431-41
[
15810955.001
]
[Cites]
Rev Med Chir Soc Med Nat Iasi. 2004 Jul-Sep;108(3):657-61
[
15832994.001
]
[Cites]
Hum Pathol. 2005 Jun;36(6):634-9
[
16021569.001
]
[Cites]
Breast Cancer Res. 2005;7(5):R598-604
[
16168103.001
]
[Cites]
Indian J Pathol Microbiol. 2004 Jul;47(3):340-2
[
16295419.001
]
[Cites]
Breast J. 2005 Nov-Dec;11(6):433-9
[
16297088.001
]
[Cites]
Clin Exp Metastasis. 2005;22(6):495-502
[
16320112.001
]
[Cites]
Breast Cancer Res. 2005;7(6):R1058-79
[
16457687.001
]
[Cites]
J Clin Pathol. 2006 Apr;59(4):424-8
[
16497871.001
]
[Cites]
Cancer Res. 2006 May 15;66(10):5330-7
[
16707459.001
]
[Cites]
Oncologist. 2006 Sep;11(8):857-67
[
16951389.001
]
[Cites]
Int J Oncol. 2006 Oct;29(4):973-80
[
16964393.001
]
[Cites]
Int J Biol Markers. 2006 Jul-Sep;21(3):131-40
[
17013794.001
]
[Cites]
Hua Xi Yi Ke Da Xue Xue Bao. 1998 Dec;29(4):399-401
[
10743237.001
]
(PMID = 19675743.001).
[ISSN]
1612-3174
[Journal-full-title]
German medical science : GMS e-journal
[ISO-abbreviation]
Ger Med Sci
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
[Other-IDs]
NLM/ PMC2716551
[Keywords]
NOTNLM ; HER-2/neu / breast cancer / c-myc / fluorescent in situ hybridization (FISH) / genetic alterations / p53
77.
Yuan Y, Liu H, Sahin A, Dai JL:
Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness.
Int J Cancer
; 2005 Feb 10;113(4):654-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Reactivation of SYK expression by inhibition of DNA methylation suppresses
breast
cancer cell invasiveness.
The gene product of spleen tyrosine kinase (SYK) has been implicated in the suppression
of breast
cancer invasion.
We previously reported that SYK expression is lost in a subset
of breast
cancer; primarily by methylation-mediated gene silencing.
In our study, we explored the possibility of using a DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine (AZA), to suppress
breast
cancer cell invasion by restoring SYK expression.
SYK promoter hypermethylation was found infrequent in pathologically normal mammary tissues or
benign
lesions (<5%).
All these results suggested a potential use of SYK methylation as a valuable biomarker to detect early cancerous lesions and support the use of AZA as a new reagent to the management of advanced
breast
cancer.
[MeSH-major]
Azacitidine / analogs & derivatives.
Breast
Neoplasms
/ prevention & control. DNA Methylation. Enzyme Precursors / antagonists & inhibitors. Enzyme Precursors / genetics. Gene Expression Regulation, Neoplastic.
Neoplasm
Invasiveness / prevention & control. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / genetics
[MeSH-minor]
Antimetabolites, Antineoplastic / pharmacology.
Breast
/ metabolism. Carcinoma, Ductal / genetics. Carcinoma, Ductal / prevention & control. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / prevention & control. Cell Proliferation / drug effects. DNA Modification Methylases / antagonists & inhibitors. Female. Gene Silencing. Humans. Intracellular Signaling Peptides and Proteins. Phenotype. Stilbenes / pharmacology
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Hazardous Substances Data Bank.
AZACITIDINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15455373.001).
[ISSN]
0020-7136
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01CA100278
[Publication-type]
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Enzyme Precursors; 0 / Intracellular Signaling Peptides and Proteins; 0 / Stilbenes; 4339-71-3 / 3,3',4,5'-tetrahydroxystilbene; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; M801H13NRU / Azacitidine
78.
Königsberg R, Rögelsperger O, Jäger W, Thalhammer T, Klimpfinger M, De Santis M, Hudec M, Dittrich C:
Cell cycle dysregulation influences survival in high risk breast cancer patients.
Cancer Invest
; 2008 Aug;26(7):734-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cell cycle dysregulation influences survival in high risk
breast
cancer patients.
Recent immunohistological studies suggested that dysregulation of cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), and p27(kip1) are of prognostic value in patients with
breast
cancer.
Our study represents the first comprehensive immunohistochemical cell cycle marker analysis for cdc25A, cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), p27(kip1), and pRb in
tumor
tissue and adjacent
benign breast
tissue from 69 primarily untreated
breast
cancer patients.
RESULTS: Sixty-nine patients with untreated, invasive
breast
cancer (n = 69) were divided into a low/ intermediate and a high risk group according to the St. Gallen 2005 consensus conference.
A subgroup of high risk
breast
cancer patients characterized in addition by overexpression of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) experienced a shortened mean survival of 222.03, 235.71, 257.25, 239.18, and 261.94 weeks, respectively.
Regarding
benign breast
tissue adjacent to
breast
cancer tissue, 59.4% of the patients investigated overexpressed cdc25A, 23.2% overexpressed pRb, and 63.2% exerted dysregulation of p27(kip1) while they proved to be negative for immunohistochemical staining regarding all other markers tested.
CONCLUSION: The immunohistological analyses of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) have the potential for further refining the risk assessment in patients with untreated
breast
cancer who belong to the high risk category defined according to the St. Gallen 2005 consensus conference.
[MeSH-major]
Biomarkers,
Tumor
/ analysis.
Breast
Neoplasms
/ chemistry.
Breast
Neoplasms
/ mortality. Cell Cycle. Cell Cycle Proteins / analysis. Cell Proliferation
[MeSH-minor]
Adult. Cyclin A / analysis. Cyclin D. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Cyclin-Dependent Kinase Inhibitor p27. Cyclins / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / analysis. Kaplan-Meier Estimate.
Neoplasm
Invasiveness. Proportional Hazards Models. Retinoblastoma Protein / analysis. Retrospective Studies. Risk Assessment. Treatment Outcome. cdc25 Phosphatases / analysis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18665474.001).
[ISSN]
1532-4192
[Journal-full-title]
Cancer investigation
[ISO-abbreviation]
Cancer Invest.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclin D; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Retinoblastoma Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / CDC25A protein, human; EC 3.1.3.48 / cdc25 Phosphatases
79.
Sotheran W, Domjan J, Jeffrey M, Wise MH, Perry PM:
Phyllodes tumours of the breast--a retrospective study from 1982-2000 of 50 cases in Portsmouth.
Ann R Coll Surg Engl
; 2005 Sep;87(5):339-44
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phyllodes
tumours
of the
breast
--a retrospective study from 1982-2000 of 50 cases in Portsmouth.
INTRODUCTION: This study is a retrospective analysis of 50 phyllodes
tumours
to determine the optimal surgical procedure for these types of
tumours
.
Fifty patients with phyllodes
tumours
were identified.
These comprised 29
benign
, 12 borderline and 9 malignant phyllodes
tumours
.
RESULTS: All
benign
phyllodes
tumours
were treated with
breast
-conserving surgery, these included 16
tumours
over 40 mm.
Borderline and malignant lesions were treated by
breast
-conserving surgery or mastectomy.
The recurrence rate for all
tumours
was 14%.
Malignant and borderline phyllodes
tumours
had a recurrence rate of 28%.
Tumours
excised with a wide margin did not seem to recur.
Breast
-conserving surgery appeared to be as effective as mastectomy.
Recurrence occurred in 1/29
benign
tumours
.
CONCLUSIONS:
Breast
-conserving surgery is the treatment of choice for all
benign
lesions.
[MeSH-major]
Breast
Neoplasms
/ surgery. Phyllodes
Tumor
/ surgery
[MeSH-minor]
Adolescent. Adult. Aged. Female. Humans. Middle Aged.
Neoplasm
Recurrence, Local / etiology.
Neoplasm
Recurrence, Local / pathology. Retrospective Studies
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16176692.001).
[ISSN]
1478-7083
[Journal-full-title]
Annals of the Royal College of Surgeons of England
[ISO-abbreviation]
Ann R Coll Surg Engl
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC1963973
80.
Ke F, Wu JM, Yao JE, Bai YJ, Guo AL:
[Application of suspension array assay to detect marker genes expression of circulating tumor cells for early prediction of breast cancer metastasis].
Zhonghua Yi Xue Za Zhi
; 2007 Aug 28;87(32):2257-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Application of suspension array assay to detect marker genes expression of circulating
tumor
cells for early prediction
of breast
cancer metastasis].
OBJECTIVE: To develop a suspension array assay to detect the expression of multiple genes in the circulating
breast
cancer cells simultaneously so as to identify the marker genes for human
breast
cancer metastasis.
METHODS: Peripheral blood samples were obtained from 73
breast
cancer patients, including 31
breast
cancer metastasis patients, 30 patients with
benign breast
diseases, and 40 healthy women, and peripheral blood mononuclear cells (PBMCs) were isolated.
PCR was used to amplify 8
breast
cancer-related genes: hMAM, HER2, CK19, SBEM, EPG2, hTERT, beta-HGG, and B305D.
COX proportional hazard model was used to find the independent prognostic predictors
of breast
cancer metastasis.
The expression of SBEM-mRNA in the peripheral blood was correlated with the stage
of breast
cancer (P < 0.05); and hMAM, SBEM, HER2, and ER could be considered as the independent prognostic predictors
of breast
cancer metastasis (all P < 0.05).
CONCLUSION: The suspension array assay thus developed is practical in
diagnosis
of the prognosis
of breast
cancer.
The expression of hMAM, SBEM, and HER2 in peripheral blood can be considered as the independent prognostic predictors
of breast
cancer metastasis.
[MeSH-major]
Breast
Neoplasms
/ genetics.
Breast
Neoplasms
/ pathology. Gene Expression Regulation, Neoplastic. Neoplastic Cells, Circulating / metabolism
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Globins / genetics. Globins / metabolism. Humans. Keratin-19 / genetics. Keratin-19 / metabolism. Middle Aged.
Neoplasm
Metastasis.
Neoplasm
Recurrence, Local.
Neoplasm
Staging. Postoperative Period. Prognosis. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism. Survival Analysis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18001545.001).
[ISSN]
0376-2491
[Journal-full-title]
Zhonghua yi xue za zhi
[ISO-abbreviation]
Zhonghua Yi Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Keratin-19; 9004-22-2 / Globins; EC 2.7.10.1 / Receptor, ErbB-2
81.
Braendle W, Kuhl H, Mueck A, Birkhäuser M, Thaler C, Kiesel L, Neulen J:
[Does hormonal contraception increase the risk for tumors?].
Ther Umsch
; 2009 Feb;66(2):129-35
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Does hormonal contraception increase the risk for
tumors
?].
A non-contraceptive benefit of oral hormonal contraceptives (OC) is a diminished risk for certain
benign
as well as malignant
tumours
, such as
benign breast
tumours
, uterine fibroids and ovarian cysts.
Modern data do not suggest an increased risk for
breast
carcinoma in OC users.
[MeSH-major]
Contraceptives, Oral, Hormonal / adverse effects.
Neoplasms
/ chemically induced
[MeSH-minor]
Adult. Age Factors. Case-Control Studies. Female. Genital
Neoplasms
, Female / chemically induced. Genital
Neoplasms
, Female / genetics. Humans. Long-Term Care. Middle Aged. Risk Factors. Young Adult
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19180433.001).
[ISSN]
0040-5930
[Journal-full-title]
Therapeutische Umschau. Revue thérapeutique
[ISO-abbreviation]
Ther Umsch
[Language]
ger
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Contraceptives, Oral, Hormonal
[Number-of-references]
47
82.
Varazashvili Varazi LM, Osmanova VR, Barkadze KI:
[Study of serum levels of magnesium in the patients with malignant tumors].
Georgian Med News
; 2006 Jul;(136):35-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Study of serum levels of magnesium in the patients with malignant
tumors
].
The main goal of the study was the evaluation of serum levels of magnesium in the practically healthy persons (control group), the patients with different malignant
tumors
(abdominal, pulmonary, uterus,
breast
, esophagus, rectum), as well as
benign
tumors
of the
breast
/the uterus and the inflammatory pulmonary diseases.
It has been found that, in comparison with norm (23.9 mkg/ml), there is statistically significant increase in serum mean levels of Mg in the patients with malignant
tumors
of almost all sites investigated.
Abdominal/
breast
and lung malignant
tumors
are exclusive from this point of view: we have found that Mg content is near the normal mean levels in the former cases (24.7 mkg/ml and 25.3 mkg/ml, respectively) and below the average normal value in lung malignant
tumors
(20.5 mkg/ml).
It has been ascertained that there is no significant difference between the serum average levels of Mg in the control group and in the patients with pulmonary inflammatory diseases, as well as between the Mg-content in practically health persons and in those with
breast benign
tumors
.
Thus, assessment of serum Mg levels seems to be useful in differential
diagnosis
in oncopulmonary and oncomammology clinics.
[MeSH-major]
Biomarkers,
Tumor
/ blood. Magnesium / blood.
Neoplasms
/ blood
[MeSH-minor]
Diagnosis
, Differential. Humans. Prognosis
Hazardous Substances Data Bank.
MAGNESIUM, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16905841.001).
[ISSN]
1512-0112
[Journal-full-title]
Georgian medical news
[ISO-abbreviation]
Georgian Med News
[Language]
rus
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Georgia (Republic)
[Chemical-registry-number]
0 / Biomarkers, Tumor; I38ZP9992A / Magnesium
[Number-of-references]
14
83.
Ciatto S, Houssami N, Ambrogetti D, Bianchi S, Bonardi R, Brancato B, Catarzi S, Risso GG:
Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies.
Breast Cancer Res Treat
; 2007 Mar;101(3):291-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Accuracy and underestimation of malignancy
of breast
core needle biopsy: the Florence experience of over 4000 consecutive biopsies.
Breast
core needle biopsy (CNB) is used for sampling
breast
lesions in both the screening and diagnostic context.
We present the accuracy
of breast
CNB from a consecutive series of 4035 core biopsies, using methods that minimise selection and verification bias.
False negatives occurred in 4.4% (3.4-5.4%) of cases, and where core histology was
benign
but discordant with (suspicious) imaging and/or clinical findings the likelihood of malignancy was 33.1% (18.5-47.7%), emphasising the importance of correlating all test information in
breast
diagnosis
.
[MeSH-major]
Breast
/ pathology.
Breast
Neoplasms
/ pathology
[MeSH-minor]
Biopsy, Fine-Needle / methods.
Breast
Diseases / pathology.
Breast
Diseases / ultrasonography.
Diagnosis
, Differential. Follow-Up Studies. Humans. Hyperplasia /
diagnosis
. Hyperplasia / pathology.
Neoplasm
Invasiveness. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Stereotaxic Techniques. Ultrasonography, Mammary
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16823506.001).
[ISSN]
0167-6806
[Journal-full-title]
Breast cancer research and treatment
[ISO-abbreviation]
Breast Cancer Res. Treat.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
84.
Leinung S, Möbius C, Udelnow A, Hauss J, Würl P:
Histopathological outcome of 597 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience.
Eur J Surg Oncol
; 2007 May;33(4):508-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Histopathological outcome of 597 isolated soft tissue
tumors
suspected of soft tissue sarcoma: a single-center 12-year experience.
BACKGROUND: The aim of this present report was to analyze the patients referred to us with the presumptive
diagnosis
of soft tissue sarcoma (STS).
RESULTS: We treated 597 patients with soft tissue
tumors
.
Open biopsy revealed soft tissue sarcoma in 318 cases,
benign
mesenchymal
tumor
in 124 cases and isolated metastases (ISTM) from carcinomas in 98 patients; other pathologies were found in 57 patients.
The primary carcinomas were lung cancer in 26 patients,
breast
cancer in 19 patients, renal carcinoma in 16 patients, carcinoma of the esophagus in 12 patients, colonic carcinoma in 5 patients, thyroid gland cancer in 6 patients, and in 14 patients carcinoma of unknown primary was diagnosed.
CONCLUSIONS: In our collective with soft tissue
tumor
, 50% of the patients had the
diagnosis
of soft tissue sarcoma, 20% presented with a metastasis of carcinoma and 20% had a
benign
tumor
.
Referring to our results, in patients with the presumptive
diagnosis
of soft tissue sarcomas, soft tissue metastasis of a primary carcinoma was unexpectedly common, indicating that greater consideration should be given to this differential
diagnosis
.
[MeSH-major]
Sarcoma / pathology. Soft Tissue
Neoplasms
/ pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged.
Neoplasm
Metastasis
Genetic Alliance.
consumer health - Soft tissue sarcoma
.
MedlinePlus Health Information.
consumer health - Soft Tissue Sarcoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17081724.001).
[ISSN]
0748-7983
[Journal-full-title]
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
[ISO-abbreviation]
Eur J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
85.
Wu KJ, Weng ZY, Lin GF, Wu XR, Li FM, Zhang YC:
[The effect of breast cancer specific gene 1 in the prognosis of breast cancer].
Zhonghua Wai Ke Za Zhi
; 2005 Mar 1;43(5):294-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[The effect
of breast
cancer specific gene 1 in the prognosis
of breast
cancer].
OBJECTIVE: To detect
breast
cancer specific gene 1 (BCSG1) expression in different
breast
tissue, analysis its correlation with clinical parameters and evaluate the prognosis
of breast
cancer.
METHODS: The expression of BCSG1 was detected by reverse transcription-polymerase chain reaction (RT-PCR) in surgical specimens from 84 cases
of breast
disease patients selected randomly at XinHua Hospital affiliated with Shanghai Second Medical University from September 1999 to December 2002.
Of 84 cases, 72 case were
breast
cancer.
Statistic analysis BCSG1 gene expression correlation with clinical parameters
of breast
cancer.
72
breast
cancers were followed up (4 - 43 months) to set up independent prognosis factor by survival analysis.
RESULTS: BCSG1 was undetectable in all
benign breast
lesions, while was detectable in 36.1% of all
breast
cancer samples (26/72), in which 79.2% of stage III/IV cases were positive (19/24).
The expression of BCSG1 was tightly correlated with the stage (P = 0.000) and the size of
tumor
(P = 0.007).
Both ER (P = 0.027) and BCSG1 (P = 0.001) were the independent prognosis factor
of breast
cancer.
CONCLUSION: BCSG1 is one of independent
tumor
marker
of breast
cancer, the expression of BCSG1 is closely correlated to the stage
of breast
cancer and the
tumor
size.
Maybe, BCSG1 is a new prognosis factor
of breast
cancer.
[MeSH-major]
Breast
Neoplasms
/ genetics.
Neoplasm
Proteins / genetics. gamma-Synuclein / genetics
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Gene Expression. Humans. Middle Aged.
Neoplasm
Staging. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15842935.001).
[ISSN]
0529-5815
[Journal-full-title]
Zhonghua wai ke za zhi [Chinese journal of surgery]
[ISO-abbreviation]
Zhonghua Wai Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SNCG protein, human; 0 / gamma-Synuclein
86.
Pieta B, Opala T, Wilczak M, Grodecka-Gazdecka S, Kramer L, Samulak D, Wieznowska-Maczyńska K:
Past obstetric history and risk of malignant breast neoplasms.
Eur J Gynaecol Oncol
; 2008;29(4):374-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Past obstetric history and risk of malignant
breast
neoplasms
.
Many studies indicate hormonal disorders as a crucial reason for
breast
pathology.
They are also probably responsible for the development
of benign
neoplasms
and play a role in the origin and development
of breast
carcinoma.
Although the mammary gland is under the influence of many steroid and peptide hormones such as thyroid hormones, prolactin, growth hormone, glucocorticosteroids, it is estrogen that plays an important role in the development
of breast
cancer.
The purpose of the study was to analyze the obstetrical past of patients and the potential influence on the risk of developing malignant
breast
neoplasms
.
The participants in the study were healthy women with no changes in mammary glands (control group) and women with diagnosed malignant or
benign breast
neoplasms
(study group).
Hormonal disorders in childhood and puberty symptoms of early menarche play a crucial role in increasing the risk of malignant
breast
neoplasms
.
In women who experienced one or more miscarriages the risk of malignant
breast
neoplasms
is significantly increased.
On the basis of our study we calculated the odds ratio (OR) of malignant
breast
neoplasms
among women who during lactation experienced problems needing medical intervention (OR = 2.25; 95% CI, 1.20-4.19) in comparison to women who experienced no problems).
[MeSH-major]
Breast
Neoplasms
/ epidemiology. Reproductive History
[MeSH-minor]
Adult. Aged.
Breast
Diseases. Case-Control Studies. Confidence Intervals. Estrogens. Female. Humans. Middle Aged. Odds Ratio. Poland / epidemiology. Risk Factors
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18714573.001).
[ISSN]
0392-2936
[Journal-full-title]
European journal of gynaecological oncology
[ISO-abbreviation]
Eur. J. Gynaecol. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Italy
[Chemical-registry-number]
0 / Estrogens
87.
Bratthauer GL, Saenger JS, Strauss BL:
Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation.
Histopathology
; 2005 Dec;47(6):611-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Antibodies targeting p63 react specifically in the cytoplasm
of breast
epithelial cells exhibiting secretory differentiation.
AIMS: The nuclear detection of p63 in myoepithelial cells of the
breast
has been useful in identifying possibly invasive carcinomas.
The aim was to determine whether this reaction is specific for p63 and indicative of all
breast
secretory cells.
METHODS: Thirty
breast
specimens were tested immunohistochemically for p63 protein.
These included seven with
benign
secretory changes, 10 secretory carcinomas (nine invasive), one microglandular adenosis, three lobular neoplasias, four invasive ductal carcinomas, three clear cell carcinomas, one squamous cell carcinoma and one mucinous carcinoma.
The detection of p63 protein continues to have considerable value for the identification of myoepithelial cells and thus the determination of invasion, but will also have value in the determination of secretory carcinomas of the
breast
and in understanding their development.
[MeSH-major]
Antibodies / metabolism.
Breast
/ cytology.
Breast
/ metabolism. Cell Differentiation. Genes,
Tumor
Suppressor. Phosphoproteins. Trans-Activators
[MeSH-minor]
Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology.
Breast
Neoplasms
/ metabolism.
Breast
Neoplasms
/ pathology. Carcinoma / chemistry. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cytoplasm / metabolism. DNA-Binding Proteins. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Fibrocystic
Breast
Disease / metabolism. Fibrocystic
Breast
Disease / pathology. Humans. Immunohistochemistry.
Neoplasm
Invasiveness. Transcription Factors.
Tumor
Suppressor Proteins
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16324199.001).
[ISSN]
0309-0167
[Journal-full-title]
Histopathology
[ISO-abbreviation]
Histopathology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
88.
Goyal S, Puri T, Gupta R, Julka PK, Rath GK:
Accessory breast tissue in axilla masquerading as breast cancer recurrence.
J Cancer Res Ther
; 2008 Apr-Jun;4(2):95-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Accessory
breast
tissue in axilla masquerading as
breast
cancer recurrence.
Ectopic or accessory
breast
tissue is most commonly located in the axilla, though it may be present anywhere along the milk line.
Development is hormone dependent, similar to normal
breast
tissue.
These lesions do not warrant any intervention unless they produce discomfort, thus their identification and distinction from other
breast
pathologies, both
benign
and malignant, is essential.
We report a case with locally advanced
breast
cancer who presented with an ipsilateral axillary mass following surgery, radiotherapy, and chemotherapy.
Subsequent evaluation with excision biopsy showed duct ectasia in axillary
breast
tissue and the patient was continued on hormone therapy with tamoxifen.
[MeSH-major]
Breast
Neoplasms
/ pathology. Carcinoma, Ductal,
Breast
/ pathology
[MeSH-minor]
Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Axilla. Biopsy. Chemotherapy, Adjuvant. Epirubicin / therapeutic use. Female. Follow-Up Studies. Humans. Mastectomy, Modified Radical.
Neoplasm
Staging. Parity. Pregnancy. Premenopause. Radiotherapy, Adjuvant. Recurrence. Tamoxifen / therapeutic use. Taxoids / therapeutic use. Time Factors. Treatment Outcome
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Hazardous Substances Data Bank.
TAMOXIFEN
.
Hazardous Substances Data Bank.
DOCETAXEL
.
Hazardous Substances Data Bank.
EPIRUBICIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18688128.001).
[ISSN]
1998-4138
[Journal-full-title]
Journal of cancer research and therapeutics
[ISO-abbreviation]
J Cancer Res Ther
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
India
[Chemical-registry-number]
0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin
89.
Kooistra B, Wauters C, Strobbe L:
Indeterminate breast fine-needle aspiration: repeat aspiration or core needle biopsy?
Ann Surg Oncol
; 2009 Feb;16(2):281-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Indeterminate
breast
fine-needle aspiration: repeat aspiration or core needle biopsy?
Fine-needle aspiration (FNA)
of breast
lesions provides indeterminate (C1, C3, and C4) diagnoses in a high proportion of cases.
The aim of the present study was to retrospectively determine whether repeat FNA or core needle biopsy (CNB) most frequently provides a correct and more conclusive
diagnosis
.
Improvement in preoperative
diagnosis
by repeat FNA or CNB was defined as C2/B2 in
benign
lesions, C3/B3 in premalignant lesions, C4/B4 or C5/B5 in malignant lesions where primary FNA was C1, and C5/B5 in malignant lesions where primary FNA was C3 or C4.
Among 255 eligible cases, CNB improved the preoperative
diagnosis
more often than did repeat FNA (78.0% vs. 54.8%, odds ratio = 2.9, P < .001).
When corrected for patient age, appearance on mammogram (mass or not), clinical findings (palpable or not),
tumor
size, and aspiration mode (freehand vs. image guided), this difference slightly increased (odds ratio = 3.0, P = .001).
CNB should be performed after an indeterminate FNA of a
breast
lesion to obtain a reliable and clear preoperative
diagnosis
.
[MeSH-major]
Breast
Neoplasms
/ pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal,
Breast
/ pathology. Carcinoma, Lobular / pathology
[MeSH-minor]
Biopsy, Fine-Needle. Biopsy, Needle.
Diagnosis
, Differential. Female. Follow-Up Studies. Humans. Middle Aged.
Neoplasm
Staging. Prognosis. Retrospective Studies
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19050965.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
90.
Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kao TC, Ponniah S, Peoples GE, Moroni M:
HYOU1/Orp150 expression in breast cancer.
Med Sci Monit
; 2007 Nov;13(11):BR231-239
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HYOU1/Orp150 expression in
breast
cancer.
Preliminary studies demonstrated increased HYOU1/Orp150 expression in prostate, bladder and invasive
breast
cancer.
This study further evaluates HYOU1/Orp150 expression in different stages
of breast
cancer such as
benign
, pre-malignant and malignant lesions, and correlates it with clinical and pathological data.
MATERIAL/METHODS: Sixty-six paraffin-embedded
breast
tissue sections were stained by immunohistochemistry using HYOU1/Orp150 antibody.
RESULTS: There was a small but significant increase (P<0.01) in HYOU1/Orp150 expression as the
tumor
transformed from
benign
(mean 1.52+/-0.12) to ductal carcinoma in situ (mean 2.05+/-0.14) and invasive carcinoma (mean 2.1+/-0.17).
HYOU1/Orp150 was partially lost in
the benign
tissue adjacent to purely invasive cancer (0.88+/-0.22) and it was less (P=0.046) than what was found in
benign
only lesions (1.52+/-0.12) or in
benign
components adjacent to DCIS (1.47+/-0.16).
Overexpression of HYOU1/Orp150 was associated with
tumor
lymph node involvement, presence of lymphovascular invasion, and absence of estrogen receptor expression (P<0.01).
CONCLUSIONS: HYOU1/Orp150 is overexpressed in some invasive
breast
cancers and its overexpression appears to be associated with indicators of poor prognosis.
[MeSH-major]
Breast
Neoplasms
/ metabolism. Proteins / metabolism
[MeSH-minor]
Breast
Diseases / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Female. HSP70 Heat-Shock Proteins. Humans. Immunohistochemistry. Middle Aged.
Neoplasm
Invasiveness.
Neoplasm
Staging. Prognosis. Retrospective Studies
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17968289.001).
[ISSN]
1234-1010
[Journal-full-title]
Medical science monitor : international medical journal of experimental and clinical research
[ISO-abbreviation]
Med. Sci. Monit.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Poland
[Chemical-registry-number]
0 / HSP70 Heat-Shock Proteins; 0 / Proteins; 0 / oxygen-regulated proteins
91.
El-Attar NI, Gaefar HA:
Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
Egypt J Immunol
; 2007;14(2):111-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Plasma mammaglobin messenger RNA in
breast
cancer patients as an addition to serum
tumor
.
Breast
cancer (BC) is the most frequent malignant
tumor
in women worldwide; its recurrence is a result of undetected metastasis present at the time of primary patient treatment.
The detection of cell-free RNA in plasma and serum of human subjects has found increasing applications in the field of medical diagnostics.This study aimed at evaluating plasma mammaglobin mRNA as a useful
tumor
marker for the
diagnosis
and the detection of metastasis in
breast
cancer at the time of
diagnosis
either alone or in combination with conventional serum
tumor
markers CA15.3 and/or CEA.
This study included 40 Egyptian females with primary
breast
cancer and 25 with different
benign breast
diseases.
There was a significance increase in plasma mammaglobin mRNA expression, CA15.3 and CEA levels in BC group as compared to
benign
group (p < 0.001).
No significant difference was observed between levels of plasma mammaglobin mRNA expression in patients with
tumor
's size or grade.
No correlation was observed with plasma mammaglobulin mRNA levels and
tumor
size or grading, CEA and CA15.3.
There was a significant difference (p < 0.05) and a positive correlation between CA 15.3 and CEA levels in patients with
tumor
size and grading.
In conclusion, plasma mammaglobin mRNA alone or in combination with CA15.3 may be used as a valuable noninvasive approach for the
diagnosis
and the detection of metastasis in
breast
cancer at the time of
diagnosis
.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20306663.001).
[ISSN]
1110-4902
[Journal-full-title]
The Egyptian journal of immunology
[ISO-abbreviation]
Egypt J Immunol
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
Egypt
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mammaglobin A; 0 / Mucin-1; 0 / Myelin Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / RNA, Messenger; 0 / SCGB2A2 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
92.
Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C:
Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
Clin Cancer Res
; 2005 Oct 1;11(19 Pt 1):6862-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evaluation of a panel of molecular markers for the
diagnosis
of malignant serous effusions.
EXPERIMENTAL DESIGN: One hundred fourteen serous effusions from 71 patients with
tumors
and 43 patients with
benign
diseases were subjected to RT-PCR for expression of carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (Ep-CAM), E-cadherin, mammaglobin, mucin 1 (MUC1) isoforms MUC1/REP, MUC1/Y, and MUC1/Z, calretinin, and Wilms'
tumor
1 susceptibility gene.
Moreover, CEA and mammaglobin were specifically expressed in epithelial malignancies, and mammaglobin was mainly expressed in effusions from
breast
carcinoma (97.3% of specificity).
CONCLUSIONS: A combination of cytology and RT-PCR analysis of CEA and Ep-CAM significantly improved the detection sensitivity of
tumor
cells in serous effusions.
RT-PCR analysis of CEA, Ep-CAM, and mammaglobin in serous effusions could be a beneficial adjunct to cytology for the
diagnosis
of malignancy.
[MeSH-major]
Biomarkers,
Tumor
. Genetic Predisposition to Disease. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / metabolism
[MeSH-minor]
Aged. Antigens / biosynthesis. Antigens,
Neoplasm
/ biosynthesis. Ascites / metabolism. Cadherins / biosynthesis. Calbindin 2. Carcinoembryonic Antigen / biosynthesis. Carcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Cell Line,
Tumor
. DNA Primers / chemistry. Female. Genes, Wilms
Tumor
. Glycoproteins / biosynthesis. Humans. Male. Mammaglobin A. Middle Aged. Mucin-1. Mucins / biosynthesis.
Neoplasm
Proteins / biosynthesis. Oligonucleotides, Antisense / chemistry. Pleural Effusion. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. S100 Calcium Binding Protein G / biosynthesis. Sensitivity and Specificity. Uteroglobin / biosynthesis. WT1 Proteins / biosynthesis
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16203775.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Cadherins; 0 / Calbindin 2; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / EPCAM protein, human; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mammaglobin A; 0 / Mucin-1; 0 / Mucins; 0 / Neoplasm Proteins; 0 / Oligonucleotides, Antisense; 0 / S100 Calcium Binding Protein G; 0 / SCGB2A2 protein, human; 0 / WT1 Proteins; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
93.
Chung LW, Baseman A, Assikis V, Zhau HE:
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
J Urol
; 2005 Jan;173(1):10-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Molecular insights into prostate cancer progression: the missing link of
tumor
microenvironment.
PURPOSE:
Tumor
cell genotype and phenotype have been considered the only determinants supporting cancer growth and metastasis.
This review focuses on the published literature that suggests that
tumor
-microenvironment interaction has a decisive role in controlling local cancer growth, invasion and distant metastasis.
As this review shows, genetic alterations in prostate cancer cells alone are not enough to confer metastatic status without a supporting
tumor
microenvironment.
Effective therapeutic targeting requires a deeper understanding of the interplay between
tumor
and stroma.
Approaches co-targeting
tumor
and stroma already show promise over the conventional targeting of
tumor
cells alone in preventing prostate cancer progression and eradicating preexisting or newly developed prostate cancers in bone and visceral organs.
MATERIALS AND METHODS: A literature survey using the MEDLINE database was performed in basic and clinical publications relevant to
tumor
-host microenvironment interaction.
RESULTS:
Tumor
associated stroma actively fuel the progression of prostate cancer from localized growth to the invasion of surrounding tissues, and the development of distant bone and visceral organ metastasis.
In concert with this progression
tumor
cells recovered from metastatic sites could represent a subpopulation of preexisting
tumor
cells or could be a newly acquired variant subsequent to
tumor
-stromal interaction.
This presents a new opportunity for therapeutic targeting for the treatment
of benign
and malignant growth of the prostate glands.
This review summarizes specific research implicating
tumor
-microenvironment interaction as the molecular basis of cancer progression, providing a rationale for targeting
tumor
and the
tumor
associated microenvironment in the management of androgen independent and bone metastatic prostate cancer progression in patients.
Further elucidation of the molecular mechanisms underlying
tumor
-stromal interaction may yield improved medical treatments for prostate cancer growth and metastasis.
[MeSH-major]
Prostatic
Neoplasms
/ physiopathology
[MeSH-minor]
Bone
Neoplasms
/ physiopathology. Bone
Neoplasms
/ secondary.
Breast
Neoplasms
/ physiopathology. Cell Differentiation. Cell Line,
Tumor
. Cell Transformation, Neoplastic. Disease Progression. Extracellular Matrix / physiology. Fibroblasts / physiology. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Molecular Mimicry.
Neoplasm
Invasiveness. Signal Transduction / physiology. Vascular Endothelial Growth Factor A / physiology
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15592017.001).
[ISSN]
0022-5347
[Journal-full-title]
The Journal of urology
[ISO-abbreviation]
J. Urol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA 098912; United States / NCI NIH HHS / CA / CA 76620
[Publication-type]
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Vascular Endothelial Growth Factor A
[Number-of-references]
73
94.
Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, Scolyer RA, Lee CS:
p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours.
Histopathology
; 2010 Jun;56(7):868-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
p16 and pRb immunohistochemical expression increases with increasing
tumour
grade in mammary phyllodes
tumours
.
AIMS: Control of cell cycling and proliferation is critical to the development of
neoplasia
and may play a role in the pathogenesis of phyllodes
tumours
(PTs).
This study aimed to evaluate the immunohistochemical expression of certain proteins from the G(1)/S transition of the cell cycle in a cohort of PTs, to determine their role in
tumour
pathogenesis and to identify any associations with patient outcome.
METHODS AND RESULTS: Sixty-five PTs (34
benign
, 23 borderline and eight malignant) diagnosed at a single institution between 1990 and 2006 were analysed.
Expression of the following markers increased significantly with
tumour
grade: stromal nuclear and cytoplasmic p16 (P = 0.01 and 0.002, respectively), stromal and epithelial pRb (P = 0.000,000,06 and 0.004, respectively), and stromal and epithelial Ki67 (P = 0.03 and 0.04, respectively).
[MeSH-major]
Breast
Neoplasms
/ metabolism.
Neoplasm
Proteins / metabolism. Phyllodes
Tumor
/ metabolism. Retinoblastoma Protein / metabolism
[MeSH-minor]
Biomarkers,
Tumor
/ metabolism. Blotting, Western. Cyclin D1 / metabolism. Disease-Free Survival. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Tissue Array Analysis
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20497245.001).
[ISSN]
1365-2559
[Journal-full-title]
Histopathology
[ISO-abbreviation]
Histopathology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Retinoblastoma Protein; 136601-57-5 / Cyclin D1
95.
Tse GM, Tan PH, Ma TK, Gilks CB, Poon CS, Law BK:
CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.
J Clin Pathol
; 2005 Nov;58(11):1185-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CD44s is useful in the differentiation
of benign
and malignant papillary lesions of the
breast
.
BACKGROUND/AIMS: CD44s, the standard form of CD44, has been shown to be downregulated during malignant transformation
of breast
cancers.
It has also been reported recently to be a useful marker in differentiating between
benign
and malignant papillary lesions of the
breast
, with high expression in the former.
CD44s expression in
benign
and malignant papillary lesions was evaluated.
METHODS: CD44s expression was assessed by immunohistochemistry in 101
benign
papillomas and 59 papillary carcinomas (seven invasive papillary carcinomas, 41 papillary ductal carcinomas in situ, and 11 ductal carcinomas involving papillomas).
RESULTS: Patients' age and
tumour
size were significantly different between the papilloma and papillary carcinoma groups (p < 0.0001).
Using CD44s positive staining to differentiate between
benign
and malignant papillary lesions gives a sensitivity, specificity, and accuracy of 45%, 92%, and 62%, respectively.
CONCLUSIONS: CD44s may be useful as an adjunct in the evaluation of morphologically problematic cases of papillary lesion of the
breast
.
[MeSH-major]
Antigens, CD44 / metabolism. Biomarkers,
Tumor
/ metabolism.
Breast
Neoplasms
/
diagnosis
. Carcinoma, Papillary /
diagnosis
. Papilloma, Intraductal /
diagnosis
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Antigens,
Neoplasm
/ metabolism. Carcinoma, Ductal,
Breast
/
diagnosis
. Carcinoma, Ductal,
Breast
/ pathology.
Diagnosis
, Differential. Female. Humans. Middle Aged. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Histol Histopathol. 2004 Apr;19(2):465-71
[
15024707.001
]
[Cites]
Anticancer Res. 2004 May-Jun;24(3a):1665-70
[
15274338.001
]
[Cites]
Cancer Res. 2004 Aug 15;64(16):5702-11
[
15313910.001
]
[Cites]
J Mol Histol. 2004 Mar;35(3):211-31
[
15339042.001
]
[Cites]
Gynecol Oncol. 2004 Oct;95(1):23-31
[
15385106.001
]
[Cites]
Hum Pathol. 1988 Mar;19(3):276-89
[
2450059.001
]
[Cites]
Am J Surg Pathol. 1990 Oct;14(10):939-47
[
1698341.001
]
[Cites]
Cancer Cells. 1991 Sep;3(9):347-50
[
1721518.001
]
[Cites]
J Cell Biol. 1992 Aug;118(4):971-7
[
1380003.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1992;421(4):315-22
[
1384226.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1992;421(4):323-30
[